

CORRECTED VERSION(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 December 2005 (22.12.2005)

PCT

(10) International Publication Number
WO 2005/121331 A2(51) International Patent Classification:
CI2N 9/10 (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2005/019442

(22) International Filing Date: 3 June 2005 (03.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/576,530 3 June 2004 (03.06.2004) US
60/598,584 3 August 2004 (03.08.2004) US(71) Applicant (for all designated States except US): **NEOSE TECHNOLOGIES, INC.** [US/US]; 102 Witmer Road, Horsham, PA 19044 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHNSON, Karl**, F. [US/US]; 2941 Windsor Ave., Willow Grove, PA 19090 (US). **CHEN, Xi** [CN/US]; 997 Hunter Lane, Woodland, CA (US). **TAUDTE, Susann** [DE/US]; Pennsbury, PA (US). **SARIBAS, Sami** [TR/US]; 424 East Church Lane, Philadelphia, PA 19144 (US).(74) Agents: **KELLY, Beth L.** et al.; Townsend and Townsend and Crew LLP, 2 Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GII, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CII, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— without international search report and to be republished upon receipt of that report

(48) Date of publication of this corrected version:

1 June 2006

[Continued on next page]

(54) Title: TRUNCATED GALNACT2 POLYPEPTIDES AND NUCLEIC ACIDS

BamH

1 CTTATGCGAT CGGGGAGA CGCTTCTTCG CCGGAACTG TCACTGAGT CGGAGCTAT
CTTAACTCC GCGCCGCTT CGGATCCG CGCTTCTTCG ATGCTGCTCA CGCTCTCTA

61 AGCTCTGA TGGGGGAGC CTCCTCTGA AGCGGAACT AGCTGCTCA CGCTCTCTA CGCTCTCTA
TGGGGGAGC TGGGGGAGC TGGGGGAGC TGGGGGAGC TGGGGGAGC TGGGGGAGC

121 ATGGGGGG ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
ACCGGGGG TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

181 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

241 ATGGGGGG ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

301 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CTTCTTCC CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

361 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CCCGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

421 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CTGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

481 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CGCTTCTTC CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

541 ATGGGGGG ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

601 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

661 ATGGGGGG ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

721 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
ACCGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

781 ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

841 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

901 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CTTATGCTT CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

961 ATGGGGGG ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

1021 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CTTCTTCA CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

1081 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CTGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

Xba

1141 TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

1201 AGCTGCTC ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

1261 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CTGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

1321 CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

1381 AGCTGCTC ATGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG
TGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

EcoRI

1441 CAGTGGCTG AGCTGCTC CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG CGGGGGGG

A

B

WO 2005/121331 A2

(57) Abstract: The present invention features compositions and methods related to truncated mutants of GalNAcT2. In particular, the invention features truncated human GalNAcT2 polypeptides. The invention also features nucleic acids encoding such truncated polypeptides, as well as vectors, host cells, expression systems, and methods of expressing and using such polypeptides.



(15) Information about Corrections:

see PCT Gazette No. 22/2006 of 1 June 2006

Previous Correction:

see PCT Gazette No. 10/2006 of 9 March 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TRUNCATED GALNACT2 POLYPEPTIDES AND NUCLEIC ACIDS

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 60/576,530, filed June 3, 2004 and U.S. Provisional Application No. 60/598,584, filed August 3, 2004; both of which are herein incorporated by reference for all purposes.

FIELD OF THE INVENTION

[0002] The present invention features compositions and methods related to truncated mutants of GalNAcT2. In particular, the invention features truncated human GalNAcT2 polypeptides. The invention also features nucleic acids encoding such truncated polypeptides, as well as vectors, host cells, expression systems, and methods of expressing and using such polypeptides.

BACKGROUND OF THE INVENTION

[0003] A great diversity of oligosaccharide structures and many types of glycopeptides are found in nature, and these are synthesized, in part, by a large number of glycosyltransferases. Glycosyltransferases catalyze the synthesis of glycolipids, glycopeptides, and polysaccharides, by transferring an activated mono- or oligosaccharide residue to an existing acceptor molecule for the initiation or elongation of the carbohydrate chain. A catalytic reaction is believed to involve the recognition of both the donor and acceptor by suitable domains, as well as the catalytic site of the enzyme.

[0004] Many peptide therapeutics, and many potential peptide therapeutics, are glycosylated peptides. The production of a recombinant glycopeptide, as opposed to a recombinant non-glycosylated peptide, requires that a recombinantly-produced peptide is subjected to additional processing steps, either within the cell or after the peptide is produced by the cell, where the processing steps are performed *in vitro*. The peptide can be treated enzymatically to introduce one or more glycosyl groups onto the peptide, using a glycosyltransferase. Specifically, the glycosyltransferase covalently attaches the glycosyl group or groups to the peptide.

[0005] The extra *in vitro* steps of peptide processing to produce a glycopeptide can be time consuming and costly. This is due, in part, to the burden and cost of producing recombinant glycosyltransferases for the *in vitro* glycosylation of peptides and glycopeptides to produce

glycopeptide therapeutics. As the demand and usefulness of recombinant glycotherapeutics increases, new methods are required in order to more efficiently prepare glycopeptides.

Moreover, as more and more glycopeptides are discovered to be useful for the treatment of a variety of diseases, there is a need for methods that lower the cost of their production.

5 Further, there is also a need in the art to develop methods of more efficiently producing recombinant glycopeptides for use in developing and improving glycopeptide therapeutics.

[0006] Glycosyltransferases are reviewed in general in International (PCT) Patent Application No. WO03/031464 (PCT/US02/32263), which is incorporated herein by reference in its entirety. One such particular glycosyltransferase that has utility in the 10 development and production of therapeutic glycopeptides is GalNAcT2. GalNAcT2, or N-acetyl-D-galactosamine transferase, catalyzes the transfer of GalNAc from a GalNAc donor to a GalNAc acceptor. Full length human GalNAcT2 enzyme is disclosed by Bennett et al. (1996, *J Biol Chem.* 271:17006-17012). However, the identification of useful mutants of this 15 enzyme, having enhanced biological activity such as enhanced catalytic activity or enhanced stability, has not heretofore been reported.

[0007] In the past, there have been efforts to increase the availability of recombinant glycosyltransferases for the in vitro production of glycopeptides. A limited amount of work has been done with respect to recombinant glycosyltransferases that may sometimes be suitable for small-scale production of oligosaccharides or glycopeptides. For example, White 20 et al. have disclosed a soluble form of human GalNAcT2 (1995, *J. Biol. Chem.*, 270:24156-24165). Additionally, Kurosawa et al. (1994, *J Biol Chem.* 269:1402-1409) describe a truncation mutant of chicken GalNAc α 2,6-sialyltransferase (ST6GalNAcI) lacking amino acid residues 1-232 from the full-length enzyme. However, the truncated enzyme described by Kurosawa et al. lacks the substrate specificity of other ST6GalNAcI enzymes. Therefore, 25 a need still exists for recombinant glycosyltransferases having activity that is suitable for “pharmaceutical-scale” processes and reactions, including the production of glycopeptide therapeutics. In particular, there is a need for recombinant glycosyltransferases having favorable functional and structural characteristics. Further, a need exists for efficient methods of identification and characterization of recombinant glycosyltransferases, as well as 30 for the production of such glycosyltransferases. The present invention addresses and meets these needs.

BRIEF SUMMARY OF THE INVENTION

[0008] In one aspect, the present invention provides an isolated nucleic acid comprising a nucleic acid sequence that encodes a truncated human GalNAcT2 polypeptide. The truncated human GalNAcT2 polypeptide lacks all or a portion of the GalNAcT2 signal domain, or in addition lacks all or a portion the GalNAcT2 transmembrane domain, or in addition lacks all or a portion the GalNAcT2 stem domain; with the proviso that the encoded polypeptide is not a human GalNAcT2 truncation mutant polypeptide lacking amino acid residues 1-51.

[0009] In one embodiment, the isolated nucleic acid comprises a nucleic acid sequence having at least 90% identity with a nucleic acid selected from the group consisting of SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:9. In another embodiment, the isolated nucleic acid comprises a nucleic acid sequence having at least 95% identity with a nucleic acid selected from the group consisting of SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:9. In a further embodiment, the isolated nucleic acid comprises a nucleic acid sequence selected from SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:9.

[0010] In some embodiments, the isolated nucleic acid is an isolated chimeric nucleic acid encoding a fusion polypeptide. The fusion polypeptide can include a tag polypeptide covalently linked to a truncated human GalNAcT2 polypeptide, as described herein. Examples of tag polypeptides include a maltose binding protein, a histidine tag, a Factor IX tag, a glutathione-S-transferase tag, a FLAG-tag, and a starch binding domain tag.

[0011] In another aspect, the invention provides an isolated truncated human GalNAcT2 polypeptide, that lacks all or a portion of the GalNAcT2 signal domain, or in addition lacks all or a portion the GalNAcT2 transmembrane domain, or in addition lacks all or a portion the GalNAcT2 stem domain; with the proviso that the encoded polypeptide is not a human GalNAcT2 truncation mutant polypeptide lacking amino acid residues 1-51. In one embodiment, the isolated truncated human GalNAcT2 polypeptide has at least 90% or 95% identity with a polypeptide selected from the group consisting of SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:10. In a further aspect, isolated truncated human GalNAcT2 polypeptide comprises an amino acid sequence selected from SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:10.

[0012] In some embodiments, the isolated truncated GalNAcT2 polypeptide isolated chimeric polypeptide comprising a tag polypeptide covalently linked to the isolated truncated GalNAcT2. Examples of tag polypeptides include a maltose binding protein, a histidine tag,

a Factor IX tag, a glutathione-S-transferase tag, a FLAG-tag, and a starch binding domain tag.

[0013] The isolated nucleic acid encoding a truncated GalNAcT2 polypeptide can also be operably linked to a promoter/regulatory sequence, within *e.g.*, an expression vector. The 5 invention also includes host cells that comprise such expression vectors. Host cells can be *e.g.*, eukaryotic or a prokaryotic cells. Eukaryotic cells include, *e.g.*, mammalian cells, an insect cells, and a fungal cells. Some preferred mammalian host cells are SF9 cells, an SF9+ cells, an Sf21 cells, a HIGH FIVE cells or Drosophila Schneider S2 cells. Prokaryotic host cells include, *e.g.*, *E. coli* cells and *B. subtilis* cells.

10 [0014] The host cells can be used to producing a truncated human GalNAcT2 polypeptide, by growing the recombinant host cells of under conditions suitable for expression of the truncated human GalNAcT2 polypeptide. In preferred embodiments, sufficient truncated human GalNAcT2 polypeptide is made to allow commercial scale production of a glycoprotein or glycopeptide.

15 [0015] In a further aspect the invention includes a method of catalyzing the transfer of a GalNAc moiety to an acceptor moiety comprising incubating the truncated human GalNAcT2 polypeptide with a GalNAc moiety and an acceptor moiety, wherein said polypeptide mediates the covalent linkage of said GalNAc moiety to said acceptor moiety, thereby catalyzing the transfer of a GalNAc moiety to an acceptor moiety to produce a product 20 saccharide, or a product glycoprotein, or a product glycopeptide. In one embodiment, the acceptor moiety is a granulocyte colony stimulating factor (G-CSF) protein. In another embodiment, the acceptor moiety is selected from erythropoietin, human growth hormone, granulocyte colony stimulating factor, interferons alpha, -beta, and -gamma, Factor IX, follicle stimulating hormone, interleukin-2, erythropoietin, anti-TNF-alpha, and a lysosomal 25 hydrolase. In a further embodiment, the polypeptide acceptor is a glycopeptide. In some embodiments, the GalNAc moiety comprises a polyethylene glycol moiety. In another embodiment, the product saccharide, product glycoprotein, or product glycopeptide is produced on a commercial scale.

BRIEF DESCRIPTION OF THE DRAWINGS

30 [0016] For purpose of illustrating the invention, there are depicted in the drawings certain embodiments of the invention. However, the invention is not limited to the precise arrangements and instrumentalities of the embodiments depicted in the drawings.

[0017] Figure 1 is an image of an electrophoretic gel illustrating the PCR amplification of ppGalNAcT2 genes. M, 1 kb DNA ladder; PCR1, PCR product for ppGalNAcT2-N41R (1596 bp); PCR2, PCR product for ppGalNAcT2-N52K (1563 bp); PCR3, PCR product for ppGalNAcT2-N74G (1497 bp); PCR4, PCR product for ppGalNAcT2-N95G (1434 bp).

5 [0018] Figure 2A is a plasmid restriction map for the pCWin2MBP vector.

[0019] Figure 2B is an image of an electrophoretic gel illustrating the fragments resulting from multiple samples of the pCWin2MBP vector digested by both BamHI and XhoI restriction enzymes.

10 [0020] Figure 3 is an image of an electrophoretic gel illustrating the screening of DH5 α (pCWin2MBP-ppGalNAcT2) colonies by restriction mapping (BamHI and XhoI digestion) for plasmid purified from twelve colonies. Lane M, bp ladder. Lanes 1-3, N41R; lanes 4-6, N52K; lanes 8-10, N74G; lanes 11-13, N95G.

15 [0021] Figure 4 is an image of an electrophoretic protein gel illustrating SDS-PAGE for JM109 (pCWin2MBP-ppGalNAcT2) whole cell lysates after IPTG induction as described elsewhere herein. M, Pre-Stained MW Standard; Lane 13, IPTG-induced JM109 (pCWin2MBP); Lanes 1-12, protein in whole cells for colonies 1-12; Lanes 1-3, JM109 (pCWin2MBP-ppGalNAcT2N41R); Lanes 4-6, JM109 (pCWin2MBP-ppGalNAcT2N52K); Lanes 7-9, JM109 (pCWin2MBP-ppGalNAcT2N74G); Lanes 10-12, JM109 (pCWin2MBP-ppGalNAcT2N95G).

20 [0022] Figure 5 is an image of an electrophoretic protein gel illustrating SDS-PAGE for JM109 (pCWin2MBP-ppGalNAcT2) cell lysates. M, Pre-Stained MW Standard; Lane 13, lysate from JM109 (pCWin2MBP); Lanes 1-12, lysates from colonies 1-12; Lanes 1-3, JM109 (pCWin2MBP-ppGalNAcT2N41R); Lanes 4-6, JM109 (pCWin2MBP-ppGalNAcT2N52K); Lanes 7-9, JM109 (pCWin2MBP-ppGalNAcT2N74G); Lanes 10-12, JM109 (pCWin2MBP-ppGalNAcT2N95G).

25 [0023] Figure 6 is an image of an electrophoretic protein gel illustrating SDS-PAGE for inclusion bodies isolated from JM109 (pCWin2MBP-ppGalNAcT2) cells. M, Pre-Stained MW Standard; Lane 13, inclusion bodies from JM109 (pCWin2MBP); Lanes 1-12, inclusion bodies from colonies 1-12; Lanes 1-3, JM109 (pCWin2MBP-ppGalNAcT2N41R); Lanes 4-6, JM109 (pCWin2MBP-ppGalNAcT2N52K); Lanes 7-9, JM109 (pCWin2MBP-ppGalNAcT2N74G); Lanes 10-12, JM109 (pCWin2MBP-ppGalNAcT2N95G).

[0024] Figure 7 is an image of an electrophoretic gel illustrating the protein expression pattern in lysates of cells containing human GalNAcT2 constructs. Lane 1, molecular weight marker; lane 2, construct 1 culture before induction; lane 3, construct 1 culture after induction; lane 4, construct 2 culture before induction; lane 5, construct 2 culture after induction; lane 6, construct 3 culture before induction; lane 7, construct 3 culture after induction; lane 8, construct 4 culture before induction; lane 9, construct 4 culture after induction; lane 10, empty.

[0025] Figure 8 is an image of an electrophoretic protein gel illustrating the protein content of inclusion bodies from JM109 pCWin2 MBP-GalNAcT2 constructs. Lane 1, MW marker; lane 2, JM109 pCWin2 MBP-GalNAcT2 construct 1 inclusion bodies; lane 3, JM109 pCWin2 MBP-GalNAcT2 construct 2 inclusion bodies.

[0026] Figure 9 is an image of an electrophoretic protein gel illustrating the glycoPEGylation of G-CSF by Δ 51 GalNAcT2-MBP. Lane 1, glycoPEGylation in the presence of 1 mg/ml G-CSF; lane 2, glycoPEGylation in the presence of 0.7 mg/ml G-CSF; lane 3, glycoPEGylation in the presence of 0.4 mg/ml G-CSF; lane 4, glycoPEGylation in the presence of 0.2 mg/ml G-CSF. The glycoPEGylated G-CSF is visible around 60 kDa.

[0027] Figures 10A and 10B depict a nucleic acid sequence encoding a Δ 40 GalNAcT2 polypeptide.

[0028] Figures 11A and 11B depict a nucleic acid sequence encoding a Δ 51 GalNAcT2 polypeptide.

[0029] Figures 12A and 12B depict a nucleic acid sequence encoding a Δ 73 GalNAcT2 polypeptide.

[0030] Figures 13A and 13B depict a nucleic acid sequence encoding a Δ 94 GalNAcT2 polypeptide.

[0031] Figure 14A is an image of a chromatogram illustrating the elution of Δ 51 GalNAcT2-MBP that was refolded at pH 5.5 and subsequently eluted from a Q-sepharose fast flow column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

[0032] Figure 14B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 14A. The contents of each lane on the gel are described in the

figure. Figure 14C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 14A.

[0033] Figure 15A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP that was refolded at pH 6.5 and subsequently eluted from a Q-sepharose fast flow column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

[0034] Figure 15B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 15A. The contents of each lane on the gel are described in the figure.

10 [0035] Figure 15C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 15A.

[0036] Figure 16A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP that was refolded at pH 8.0 and subsequently eluted from a Q-sepharose fast flow column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

[0037] Figure 16B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 16A. The contents of each lane on the gel are described in the figure.

20 [0038] Figure 16C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 16A.

[0039] Figure 17A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP that was refolded at pH 8.5 and subsequently eluted from a Q-sepharose fast flow column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

25 [0040] Figure 17B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 17A. The contents of each lane on the gel are described in the figure.

[0041] Figure 17C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 17A.

[0042] Figure 18A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP that was refolded at pH 8.0 and subsequently eluted from a Q-sepharose fast flow column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

5 [0043] Figure 18B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 18A. The contents of each lane on the gel are described in the figure.

[0044] Figure 18C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 18A.

10 [0045] Figure 19A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP from a Q-sepharose fast flow column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

15 [0046] Figure 19B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 19A. The contents of each lane on the gel are described in the figure and correspond to the chromatogram of Figure 19A.

[0047] Figure 19C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 19A.

20 [0048] Figure 20A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP from a Q-sepharose XL column, using 5 mM NaCl. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

[0049] Figure 20B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 20A. The contents of each lane on the gel are described in the figure and correspond to the chromatogram of Figure 20A.

25 [0050] Figure 20C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 20A.

[0051] Figure 21A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP from a Q-sepharose XL column, using 50 mM NaCl. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

30

[0052] Figure 21B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 21A. The contents of each lane on the gel are described in the figure and correspond to the chromatogram of Figure 21A.

5 [0053] Figure 21C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 21A.

[0054] Figure 22A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP from a Q-sepharose XL column, using 100 mM NaCl. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

10 [0055] Figure 22B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 22A. The contents of each lane on the gel are described in the figure and correspond to the chromatogram of Figure 22A.

[0056] Figure 22C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 22A.

15 [0057] Figure 23A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP from a Q-sepharose XL column, using 200 mM NaCl. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

20 [0058] Figure 23B is an image of two electrophoretic gels used to visualize the eluted fractions set forth in Figure 23A. The contents of each lane on the gel are described in the figure and correspond to the chromatogram of Figure 23A.

[0059] Figure 23C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 23A.

25 [0060] Figure 24A is an image of a chromatogram illustrating the elution of $\Delta 51$ GalNAcT2-MBP from a Hydroxyapatite Type I column. Fraction numbers are indicated on the X-axis and the relative absorbance of each fraction is indicated on the Y-axis.

[0061] Figure 24B is an image of an electrophoretic gel used to visualize the eluted fractions set forth in Figure 24A. The contents of each lane on the gel are described in the figure and correspond to the chromatogram of Figure 24A.

[0062] Figure 24C is a table illustrating the relative GalNAc transferase activity of the fractions set forth in Figure 24A.

[0063] Figure 25 is a graph illustrating the relative GalNAc transferase activity of various preparations of refolded $\Delta 51$ GalNAcT2-MBP. The refolding conditions of each preparation 5 is indicated on the x-axis, and the relative GalNAc transferase activity is illustrated on the Y-axis.

[0064] Figure 26 is a graph illustrating the relative GalNAc transferase activity of various preparations of refolded $\Delta 51$ GalNAcT2-MBP. The refolding conditions of each preparation 10 is indicated on the x-axis, and the relative GalNAc transferase activity is illustrated on the Y-axis.

[0065] Figure 27 is an image of three MALDI-TOF spectra demonstrating GalNAc transfer to GCSF mediated by $\Delta 51$ GalNAcT2-MBP that has been refolded and purified according to the present invention.

[0066] Figure 28 is an image of three MALDI-TOF spectra demonstrating GalNAc transfer 15 to GCSF mediated by $\Delta 51$ GalNAcT2-MBP that has been refolded and purified according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[0067] The compositions and methods of the present invention encompass truncation 20 mutants of human GalNAcT2 polypeptides, isolated nucleic acids encoding these proteins, and methods of their use. GalNAcT2 polypeptides catalyze the transfer of a GalNAc from a GalNAc donor to a GalNAc acceptor.

[0068] The glycosyltransferase GalNAcT2 is an essential reagent for glycosylation of therapeutic glycopeptides. Additionally, GalNAcT2 is an important reagent for research and 25 development of therapeutically important glycopeptides and oligosaccharide therapeutics. GalNAcT2 enzymes are typically isolated and purified from natural sources, or from tedious and costly in vitro and recombinant sources. The present invention provides compositions and methods relating to simplified and more cost-effective methods of production of GalNAcT2 enzymes. In particular, the present invention provides compositions and methods 30 relating to truncated GalNAcT2 enzymes that have improved and useful properties in comparison to their full-length enzyme counterparts.

[0069] Truncated glycosyltransferase enzymes of the present invention are useful for in vivo and in vitro preparation of glycosylated peptides, as well as for the production of oligosaccharides containing the specific glycosyl residues that can be transferred by the truncated glycosyltransferase enzymes of the present invention. This is because it is shown 5 for the first time herein that truncated forms of GalNAcT2 polypeptides possess biological activities comparable to, and in some instances, in excess of their full-length polypeptide counterparts. The present application also discloses that such truncation mutants not only possess biological activity, but also that the truncation mutants may have enhanced properties of solubility, stability and resistance to proteolytic degradation.

10 Definitions

[0070] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred 15 methods and materials are described herein.

[0071] Certain abbreviations are used herein as are common in the art, such as: "Ac" for acetyl; "Glc" for glucose; "Glc" for glucosamine; "GlcA" for glucuronic acid; "IdoA" for iduronic acid; "GlcNAc" for N-acetylglucosamine; "NAN" or "sialic acid" or "SA" for N-acetyl neuraminic acid; "UDP" for uridine diphosphate; "CMP" for cytidine monophosphate.

20 [0072] As used herein, each of the following terms has the meaning associated with it in this section.

[0073] The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

25 [0074] "Encoding" refers to the inherent property of specific sequences of nucleotides in a nucleic acid, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and 30 translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand,

used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.

[0075] A “coding region” of a gene consists of the nucleotide residues of the coding strand of the gene and the nucleotides of the non-coding strand of the gene which are homologous 5 with or complementary to, respectively, the coding region of an mRNA molecule which is produced by transcription of the gene.

[0076] A “coding region” of an mRNA molecule also consists of the nucleotide residues of the mRNA molecule which are matched with an anticodon region of a transfer RNA molecule during translation of the mRNA molecule or which encode a stop codon. The 10 coding region may thus include nucleotide residues corresponding to amino acid residues which are not present in the mature protein encoded by the mRNA molecule (e.g., amino acid residues in a protein export signal sequence).

[0077] An “affinity tag” is a peptide or polypeptide that may be genetically or chemically fused to a second polypeptide for the purposes of purification, isolation, targeting, trafficking, 15 or identification of the second polypeptide. The “genetic” attachment of an affinity tag to a second protein may be effected by cloning a nucleic acid encoding the affinity tag adjacent to a nucleic acid encoding a second protein in a nucleic acid vector.

[0078] As used herein, the term “glycosyltransferase,” refers to any enzyme/protein that has the ability to transfer a donor sugar to an acceptor moiety.

20 [0079] A “sugar nucleotide-generating enzyme” is an enzyme that has the ability to produce a sugar nucleotide. Sugar nucleotides are known in the art, and include, but are not limited to, such moieties as UDP-Gal, UDP-GalNAc, and CMP-NAN.

[0080] An “isolated nucleic acid” refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, e.g., a DNA 25 fragment which has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in a genome in which it naturally occurs. The term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, e.g., RNA or DNA or proteins, which naturally accompany it in the cell. The term therefore includes, for example, 30 a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a

separate molecule (e.g., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

[0081] In the context of the present invention, the following abbreviations for the 5 commonly occurring nucleic acid bases are used. "A" refers to adenosine, "C" refers to cytidine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.

[0082] A "polynucleotide" means a single strand or parallel and anti-parallel strands of a nucleic acid. Thus, a polynucleotide may be either a single-stranded or a double-stranded nucleic acid.

10 **[0083]** The term "nucleic acid" typically refers to large polynucleotides. However, the terms "nucleic acid" and "polynucleotide" are used interchangeably herein.

15 **[0084]** The term "oligonucleotide" typically refers to short polynucleotides, generally no greater than about 50 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which "U" replaces "T."

[0085] Conventional notation is used herein to describe nucleic acid sequences: the left-hand end of a single-stranded nucleic acid sequence is the 5' end; the left-hand direction of a double-stranded nucleic acid sequence is referred to as the 5'-direction.

20 **[0086]** A first defined nucleic acid sequence is said to be "immediately adjacent to" a second defined nucleic acid sequence when, for example, the last nucleotide of the first nucleic acid sequence is chemically bonded to the first nucleotide of the second nucleic acid sequence through a phosphodiester bond. Conversely, a first defined nucleic acid sequence is also said to be "immediately adjacent to" a second defined nucleic acid sequence when, for example, the first nucleotide of the first nucleic acid sequence is chemically bonded to the 25 last nucleotide of the second nucleic acid sequence through a phosphodiester bond.

30 **[0087]** A first defined polypeptide sequence is said to be "immediately adjacent to" a second defined polypeptide sequence when, for example, the last amino acid of the first polypeptide sequence is chemically bonded to the first amino acid of the second polypeptide sequence through a peptide bond. Conversely, a first defined polypeptide sequence is said to be "immediately adjacent to" a second defined polypeptide sequence when, for example, the

first amino acid of the first polypeptide sequence is chemically bonded to the last amino acid of the second polypeptide sequence through a peptide bond.

[0088] The direction of 5' to 3' addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction. The DNA strand having the same sequence as an 5 mRNA is referred to as the "coding strand"; sequences on the DNA strand which are located 5' to a reference point on the DNA are referred to as "upstream sequences"; sequences on the DNA strand which are 3' to a reference point on the DNA are referred to as "downstream sequences."

[0089] Unless otherwise specified, a "nucleotide sequence encoding an amino acid 10 sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.

[0090] "Homology" as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid 15 strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same 20 nucleotide residue. By way of example, a region having the nucleotide sequence 5'- ATTGCC-3' and a region having the nucleotide sequence 5'-TATGGC-3' share 50% homology. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the 25 portions are occupied by the same nucleotide residue. More preferably, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

[0091] As used herein, "percent identity" is used synonymously with "homology." The determination of percent identity between two nucleotide or amino acid sequences can be accomplished using a mathematical algorithm. For example, a mathematical algorithm useful 30 for comparing two sequences is the algorithm of Karlin and Altschul (1990, Proc. Natl. Acad. Sci. USA 87:2264-2268), modified as in Karlin and Altschul (1993, Proc. Natl. Acad. Sci. USA 90:5873-5877). This algorithm is incorporated into the NBLAST and XBLAST

programs of Altschul et al. (1990, J. Mol. Biol. 215:403-410), and can be accessed, for example, at the BLAST site of the National Center for Biotechnology Information (NCBI) world wide web site at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). BLAST nucleotide searches can be performed with the NBLAST program 5 (designated "blastn" at the NCBI web site), using the following parameters: gap penalty = 5; gap extension penalty = 2; mismatch penalty = 3; match reward = 1; expectation value 10.0; and word size = 11 to obtain nucleotide sequences homologous to a nucleic acid described herein. BLAST protein searches can be performed with the XBLAST program (designated "blastn" at the NCBI web site) or the NCBI "blastp" program, using the following 10 parameters: expectation value 10.0, BLOSUM62 scoring matrix to obtain amino acid sequences homologous to a protein molecule described herein.

[0092] To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997, Nucleic Acids Res. 25:3389-3402). Alternatively, PSI-Blast or PHI-Blast can be used to perform an iterated search which detects 15 distant relationships between molecules (*id.*) and relationships between molecules which share a common pattern. When utilizing BLAST, Gapped BLAST, PSI-Blast, and PHI-Blast programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used as available on the website of the National Center for Biotechnology Information of the National Library of Medicine at the National Institutes of Health.

20 [0093] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically exact matches are counted.

[0094] "Polypeptide" refers to a polymer composed of amino acid residues, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof 25 linked via peptide bonds, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer. A "polypeptide," as the term is used herein, therefore refers to any size polymer of amino acid residues, provided that the polymer contains at least two amino acid residues.

30 [0095] The term "protein" typically refers to large peptides, also referred to herein as "polypeptides." The term "peptide" typically refers to short polypeptides. However, the terms "peptide," "protein" and "polypeptide" are used interchangeably herein. For example,

the term “peptide” may refer to an amino acid polymer of three amino acids, as well as an amino acid polymer of several hundred amino acids.

[0096] As used herein, amino acids are represented by the full name thereof, by the three letter code corresponding thereto, or by the one-letter code corresponding thereto, as

5 indicated in the following table:

| | <u>Full Name</u> | <u>Three-Letter Code</u> | <u>One-Letter Code</u> |
|----|------------------|--------------------------|------------------------|
| | Aspartic Acid | Asp | D |
| | Glutamic Acid | Glu | E |
| | Lysine | Lys | K |
| 10 | Arginine | Arg | R |
| | Histidine | His | H |
| | Tyrosine | Tyr | Y |
| | Cysteine | Cys | C |
| | Asparagine | Asn | N |
| 15 | Glutamine | Gln | Q |
| | Serine | Ser | S |
| | Threonine | Thr | T |
| | Glycine | Gly | G |
| | Alanine | Ala | A |
| 20 | Valine | Val | V |
| | Leucine | Leu | L |
| | Isoleucine | Ile | I |
| | Methionine | Met | M |
| | Proline | Pro | P |
| 25 | Phenylalanine | Phe | F |
| | Tryptophan | Trp | W |

[0097] Conventional notation is used herein to portray polypeptide sequences: the left-hand end of a polypeptide sequence is the amino-terminus; the right-hand end of a polypeptide sequence is the carboxyl-terminus.

[0098] A “therapeutic peptide” as the term is used herein refers to any peptide that is useful to treat a disease state or to improve the overall health of a living organism. A therapeutic

peptide may effect such changes in a living organism when administered alone, or when used to improve the therapeutic capacity of another substance. The term "therapeutic peptide" is used interchangeably herein with the terms "therapeutic polypeptide" and "therapeutic protein."

5 [0099] A "reagent peptide" as the term is used herein refers to any peptide that is useful in food biochemistry, bioremediation, production of small molecule therapeutics, and even in the production of therapeutic peptides. Typically, reagent peptides are enzymes capable of catalyzing a reaction to produce a product useful in any of the aforementioned areas. The term "reagent peptide" is used interchangeably herein with the terms "reagent polypeptide" and "reagent protein."

10 [0100] A "glycopeptide" as the term is used herein refers to a peptide having at least one carbohydrate moiety covalently linked thereto. It will be understood that a glycopeptide may be a "therapeutic glycopeptide," as described above. The term "glycopeptide" is used interchangeably herein with the terms "glycopolypeptide" and "glycoprotein."

15 [0101] A "vector" is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear nucleic acids, nucleic acids associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes an autonomously replicating plasmid or a virus. The term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, and the like.

20 [0102] "Expression vector" refers to a vector comprising a recombinant nucleic acid comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses that incorporate the recombinant nucleic acid.

[0103] A “multiple cloning site” as the term is used herein is a region of a nucleic acid vector that contains more than one sequence of nucleotides that is recognized by at least one restriction enzyme.

[0104] An “antibiotic resistance marker” as the term is used herein refers to a sequence of 5 nucleotides that encodes a protein which, when expressed in a living cell, confers to that cell the ability to live and grow in the presence of an antibiotic.

[0105] As used herein, the term “GalNAcT2” refers to N-acetyl-D-galactosamine transferase 2.

[0106] As the term is used herein, a “truncated” form of a peptide refers to a peptide that is 10 lacking one or more amino acid residues as compared to the full-length amino acid sequence of the peptide. For example, the peptide “NH₂-Ala-Glu-Lys-Leu-COOH” is an N-terminally truncated form of the full-length peptide “NH₂-Gly-Ala-Glu-Lys-Leu-COOH.” The terms “truncated form” and “truncation mutant” are used interchangeably herein. By way of a non-limiting example, a truncated peptide is a GalNAcT2 polypeptide comprising an active 15 domain, a stem domain, a transmembrane domain, and a signal domain, wherein the signal domain is lacking a single N-terminal amino acid residue as compared to the full length GalNAcT2.

[0107] The term “saccharide” refers in general to any carbohydrate, a chemical entity with the most basic structure of (CH₂O)_n. Saccharides vary in complexity, and may also include 20 nucleic acid, amino acid, or virtually any other chemical moiety existing in biological systems.

[0108] “Monosaccharide” refers to a single unit of carbohydrate of a defined identity.

[0109] “Oligosaccharide” refers to a molecule consisting of several units of carbohydrates of defined identity. Typically, saccharide sequences between 2-20 units may be referred to as 25 oligosaccharides.

[0110] “Polysaccharide” refers to a molecule consisting of many units of carbohydrates of defined identity. However, any saccharide of two or more units may correctly be considered a polysaccharide.

[0111] As used herein, a saccharide “donor” is a moiety that can provide a saccharide to a glycosyltransferase so that the glycosyltransferase may transfer the saccharide to a saccharide acceptor. By way of a non-limiting example, a GalNAc donor may be UDP-GalNAc.

[0112] As used herein, a saccharide “acceptor” is a moiety that can accept a saccharide from a saccharide donor. A glycosyltransferase can covalently couple a saccharide to a saccharide acceptor. By way of a non-limiting example, G-CSF may be a GalNAc acceptor, and a GalNAc moiety may be covalently coupled to a GalNAc acceptor by way of a GalNAc-transferase. In some embodiments, a saccharide acceptor is a protein or peptide comprising an O glycosylation site. In further embodiments, saccharide acceptors include, *e.g.*, erythropoietin, human growth hormone, granulocyte colony stimulating factor, interferons alpha, -beta, and -gamma, Factor IX, follicle stimulating hormone, interleukin-2, erythropoietin, anti-TNF-alpha, and a lysosomal hydrolase

[0113] An oligosaccharide with a “defined size” is one which consists of an identifiable number of monosaccharide units. For example, an oligosaccharide consisting of 10 monosaccharide units is one which may consist of 10 identical monosaccharide units or 5 monosaccharide units of a first identity and 5 monosaccharide units of a second identity. Further, an oligosaccharide of defined size that consists of monosaccharide units of heterogeneous identity may have the monosaccharide units in any order from beginning to end of the oligosaccharide.

[0114] An oligosaccharide of “random size” is one which may be synthesized using methods that do not provide oligosaccharide products of defined size. For example, a method of oligosaccharide synthesis may provide oligosaccharides that range from two monosaccharide units to twenty-two saccharide units, including any or all lengths in between.

[0115] “Commercial scale” refers to gram scale production of a product saccharide, or glycoprotein, or glycopeptide in a single reaction. In preferred embodiments, commercial scale refers to production of greater than about 50, 75, 80, 90 or 100, 125, 150, 175, or 200 grams.

[0116] The term “sialic acid” refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N-acetyl-neuraminic acid (2-keto-5-acetamido-3,5-dideoxy-D-glycero-D-galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA). A second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group of NeuAc is hydroxylated.

A third sialic acid family member is 2-keto-3-deoxy-nonulosonic acid (KDN) (Nadano *et al.* (1986) *J. Biol. Chem.* **261**: 11550-11557; Kanamori *et al.*, *J. Biol. Chem.* **265**: 21811-21819 (1990)). Also included are 9-substituted sialic acids such as a 9-O-C₁-C₆ acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetyl-Neu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-
5 Neu5Ac. For review of the sialic acid family, *see, e.g.*, Varki, *Glycobiology* **2**: 25-40 (1992); *Sialic Acids: Chemistry, Metabolism and Function*, R. Schauer, Ed. (Springer-Verlag, New York (1992)). The synthesis and use of sialic acid compounds in a sialylation procedure is disclosed in international application WO 92/16640, published October 1, 1992.

[0117] A "method of remodeling a protein, a peptide, a glycoprotein, or a glycopeptide" as used herein, refers to addition of a sugar residue to a protein, a peptide, a glycoprotein, or a glycopeptide using a glycosyltransferase. In a preferred embodiment, the sugar residue is covalently attached to a PEG molecule.
10

[0118] An "unpaired cysteine residue" as used herein, refers to a cysteine residue, which in a correctly folded protein (*i.e.*, a protein with biological activity), does not form a disulfide bind with another cysteine residue.
15

[0119] An "insoluble glycosyltransferase" refers to a glycosyltransferase that is expressed in bacterial inclusion bodies. Insoluble glycosyltransferases are typically solubilized or denatured using *e.g.*, detergents or chaotropic agents or some combination. "Refolding" refers to a process of restoring the structure of a biologically active glycosyltransferase to a glycosyltransferase that has been solubilized or denatured. Thus, a refolding buffer, refers to a buffer that enhances or accelerates refolding of a glycosyltransferase.
20

[0120] A "redox couple" refers to mixtures of reduced and oxidized thiol reagents and include reduced and oxidized glutathione (GSH/GSSG), cysteine/cystine, cysteamine/cystamine, DTT/GSSG, and DTE/GSSG. (*See, e.g.*, Clark, *Cur. Op. Biotech.* 25 12:202-207 (2001)).

[0121] The term "contacting" is used herein interchangeably with the following: combined with, added to, mixed with, passed over, incubated with, flowed over, etc.

[0122] The term "PEG" refers to poly(ethylene glycol). PEG is an exemplary polymer that has been conjugated to peptides. The use of PEG to derivatize peptide therapeutics has been demonstrated to reduce the immunogenicity of the peptides and prolong the clearance time from the circulation. For example, U.S. Pat. No. 4,179,337 (Davis *et al.*) concerns non-
30

immunogenic peptides, such as enzymes and peptide hormones coupled to polyethylene glycol (PEG) or polypropylene glycol. Between 10 and 100 moles of polymer are used per mole peptide and at least 15% of the physiological activity is maintained.

[0123] The term "specific activity" as used herein refers to the catalytic activity of an enzyme, *e.g.*, a recombinant glycosyltransferase fusion protein of the present invention, and may be expressed in activity units. As used herein, one activity unit catalyzes the formation of 1 μ mol of product per minute at a given temperature (*e.g.*, at 37°C) and pH value (*e.g.*, at pH 7.5). Thus, 10 units of an enzyme is a catalytic amount of that enzyme where 10 μ mol of substrate are converted to 10 μ mol of product in one minute at a temperature of, *e.g.*, 37 °C and a pH value of, *e.g.*, 7.5.

[0124] "N-linked" oligosaccharides are those oligosaccharides that are linked to a peptide backbone through asparagine, by way of an asparagine-N-acetylglucosamine linkage. N-linked oligosaccharides are also called "N-glycans." All N-linked oligosaccharides have a common pentasaccharide core of $\text{Man}_3\text{GlcNAc}_2$. They differ in the presence of, and in the number of branches (also called antennae) of peripheral sugars such as N-acetylglucosamine, galactose, N-acetylgalactosamine, fucose and sialic acid. Optionally, this structure may also contain a core fucose molecule and/or a xylose molecule.

[0125] "O-linked" oligosaccharides are those oligosaccharides that are linked to a peptide backbone through threonine, serine, hydroxyproline, tyrosine, or other hydroxy-containing amino acids.

[0126] The term "substantially" in the above definitions of "substantially uniform" generally means at least about 60%, at least about 70%, at least about 80%, or more preferably at least about 90%, and still more preferably at least about 95% of the acceptor substrates for a particular glycosyltransferase are glycosylated.

[0127] A "fusion protein" refers to a protein comprising amino acid sequences that are in addition to, in place of, less than, and/or different from the amino acid sequences encoding the original or native full-length protein or subsequences thereof.

[0128] A "stem region" with reference to glycosyltransferases refers to a protein domain, or a subsequence thereof, which in the native glycosyltransferases is located adjacent to the trans-membrane domain, and has been reported to function as a retention signal to maintain the glycosyltransferase in the Golgi apparatus and as a site of proteolytic cleavage. Stem

regions generally start with the first hydrophilic amino acid following the hydrophobic transmembrane domain and end at the catalytic domain, or in some cases the first cysteine residue following the transmembrane domain. Exemplary stem regions include, but is not limited to, the stem region of eukaryotic ST6GalNAcI, amino acid residues from about 30 to 5 about 207 (see *e.g.*, the murine enzyme), amino acids 35-278 for the human enzyme or amino acids 37-253 for the chicken enzyme; the stem region of mammalian GalNAcT2, amino acid residues from about 71 to about 129 (see *e.g.*, the rat enzyme).

[0129] A “catalytic domain” refers to a protein domain, or a subsequence thereof, that catalyzes an enzymatic reaction performed by the enzyme. For example, a catalytic domain 10 of a sialyltransferase will include a subsequence of the sialyltransferase sufficient to transfer a sialic acid residue from a donor to an acceptor saccharide. A catalytic domain can include an entire enzyme, a subsequence thereof, or can include additional amino acid sequences that are not attached to the enzyme, or a subsequence thereof, as found in nature.

[0130] The term “isolated” refers to material that is substantially or essentially free from 15 components which interfere with the activity of an enzyme. For a saccharide, protein, or nucleic acid of the invention, the term “isolated” refers to material that is substantially or essentially free from components which normally accompany the material as found in its native state. Typically, an isolated saccharide, protein, or nucleic acid of the invention is at least about 80% pure, usually at least about 90%, and preferably at least about 95% pure as 20 measured by band intensity on a silver stained gel or other method for determining purity. Purity or homogeneity can be indicated by a number of means well known in the art. For example, a protein or nucleic acid in a sample can be resolved by polyacrylamide gel electrophoresis, and then the protein or nucleic acid can be visualized by staining. For certain purposes high resolution of the protein or nucleic acid may be desirable and HPLC or a 25 similar means for purification, for example, may be utilized.

Description

I. Isolated nucleic acids

A. Generally

[0131] Exemplified herein are various truncation mutants of human GalNAcT2. However, 30 the present invention should not be construed to cover a human GalNAcT2 truncation mutant polypeptide lacking amino acid residues 1-51.

[0132] Full-length GalNAcT2 nucleic acids encode polypeptides that have a domain structure similar to other glycosyltransferases, including an N-terminal signal domain, a transmembrane domain, a stem domain, and an active domain, wherein the active domain may comprise the majority of the amino acid sequence of such polypeptides. As will be understood by one of skill in the art, the presence of domain structure(s) extraneous to the active domain of recombinant GalNAcT2 polypeptides may have a negative effect on the solubility, stability and activity of the polypeptide in an aqueous or in vitro environment. For example, while not wishing to be bound by any particular theory, the presence of a hydrophobic transmembrane domain on a recombinant GalNAcT2 polypeptide used in an in vitro reaction mixture may render the polypeptide less soluble than a recombinant GalNAcT2 polypeptide without a hydrophobic transmembrane domain, and further, may even decrease the enzymatic activity of the polypeptide by affecting or destabilizing the folded structure.

[0133] Therefore, it is desirable to produce recombinant GalNAcT2 nucleic acids that encode GalNAcT2 that is shorter than full-length GalNAcT2, for the purpose of enhancing the activity, stability and/or utility of GalNAcT2 polypeptides. The present invention provides such modified forms of GalNAcT2. More particularly, the present invention provides isolated nucleic acids encoding such truncated polypeptides.

[0134] Nucleic acids of the present invention encode truncated forms of GalNAcT2 polypeptides, as described in greater detail elsewhere herein. A truncated GalNAcT2 polypeptide encoded by a nucleic acid of the present invention, also referred to herein as a “truncation mutant,” may be truncated in various ways, as would be understood by the skilled artisan. Examples of truncated polypeptides encoded by a nucleic acid of the present invention include, but are not limited to, a polypeptide lacking a single N-terminal residue, a polypeptide lacking a single C-terminal residue, a polypeptide lacking both a single N-terminal residue and a single C-terminal residue, a polypeptide lacking a contiguous sequence of residues from the N-terminus, a polypeptide lacking a contiguous sequence of residues from the C-terminus, and any combinations thereof.

[0135] Therefore, it will be understood, based on the disclosure set forth herein, that truncations of nucleic acids encoding GalNAcT2 polypeptides may be made for numerous reasons. In one embodiment of the invention, a truncation may be made in order to remove part or all of the nucleic acid sequence encoding the signal peptide domain of an GalNAcT2.

[0136] In another embodiment of the invention, a truncation may be made in order to remove part or all of a nucleic acid sequence encoding a transmembrane domain of an GalNAcT2. By way of a non-limiting example, removal of a part or all of a nucleic acid sequence encoding a transmembrane domain may increase the solubility or stability of the 5 encoded GalNAcT2 polypeptide and/or may increase the level of expression of the encoded polypeptide.

[0137] In yet another embodiment of the invention, a truncation may be made in order to remove part or all of a nucleic acid sequence encoding a stem domain of an GalNAcT2. By way of a non-limiting example, removal of a part or all of a nucleic acid sequence encoding a 10 stem domain may increase the solubility or stability of the encoded GalNAcT2 polypeptide and/or may increase the level of expression of the encoded polypeptide.

[0138] The skilled artisan, when armed with the disclosure set forth herein, will understand how to design and create a truncation mutant of GalNAcT2 as set forth in detail elsewhere herein. In one aspect of the invention, the nucleic acid residue at which a truncation is made 15 may be a highly-conserved residue. In another aspect of the invention, the nucleic acid residue at which a truncation is made may be selected such that the encoded polypeptide has a new N-terminal amino acid residue that will aid in the purification of the expressed polypeptide. In yet another aspect, the nucleic acid residue at which a truncation is made may be selected such that the encoded truncated polypeptide does not contain a specific 20 secondary and/or tertiary structure.

B. GalNAcT2 Isolated Nucleic Acids

[0139] The present invention features nucleic acids encoding smaller than full-length GalNAcT2. That is, the present invention features a nucleic acid encoding a truncated GalNAcT2 polypeptide, provided the polypeptide expressed by the nucleic acid retains the 25 biological activity of the full-length protein. In one aspect of the invention, a truncated polypeptide is a human truncated GalNAcT2 polypeptide.

[0140] As would be understood by the skilled artisan, a nucleic acid encoding a full-length human GalNAcT2 may contain a nucleic acid sequence encoding one or more identifiable polypeptide domains in addition to the “active domain,” the domain primarily responsible for 30 the catalytic activity, of GalNAcT2. This is because it is known in that art that a full-length GalNAcT2 polypeptide, and in particular, a full-length human GalNAcT2 polypeptide, contains a signal domain, a transmembrane domain, and a stem domain, in addition to an

active domain. Accordingly, a nucleic acid encoding a full-length human GalNAcT2 may encode a polypeptide that has a signal domain at the amino-terminus of the polypeptide, followed by a transmembrane domain immediately adjacent to the signal domain, followed by a stem domain that is immediately adjacent to the transmembrane domain, followed by an active domain that extends to the carboxy-terminus of the polypeptide and is located immediately adjacent to the stem domain.

[0141] Therefore, in one embodiment, an isolated nucleic acid of the invention may encode a truncated human GalNAcT2 polypeptide, wherein the truncated human GalNAcT2 polypeptide is lacking all or a portion of the GalNAcT2 signal domain. In another embodiment, an isolated nucleic acid of the invention may encode a truncated human GalNAcT2 polypeptide, wherein the truncated human GalNAcT2 polypeptide is lacking the GalNAcT2 signal domain and all or a portion of the GalNAcT2 transmembrane domain. In yet another embodiment, a nucleic acid of the invention may encode a truncated human GalNAcT2 polypeptide, wherein the truncated human GalNAcT2 polypeptide is lacking the GalNAcT2 signal domain, the GalNAcT2 transmembrane domain and all or a portion the GalNAcT2 stem domain.

[0142] When armed with the disclosure of the present invention, the skilled artisan will know how to make and use these and other such truncation mutants of human GalNAcT2.

[0143] The “biological activity of GalNAcT2” is the ability to transfer a GalNAc moiety from a GalNAc donor to an acceptor molecule. Full-length human GalNAcT2, the sequence of which is set forth in SEQ ID NO:1, exhibits such activity. The “biological activity of a GalNAcT2 truncated polypeptide” is similarly the ability to transfer a GalNAc moiety from a GalNAc donor to an acceptor molecule. That is, a truncated GalNAcT2 polypeptide of the present invention can catalyze the same glycosyltransfer reaction as the full-length GalNAcT2. By way of a non-limiting example, a truncated human GalNAcT2 polypeptide encoded by a GalNAcT2 nucleic acid of the invention has the ability to transfer a GalNAc moiety from a UDP-GalNAc donor to a granulocyte-colony stimulating factor (G-CSF) acceptor, wherein such a transfer results in the O-linked covalent coupling of a GalNAc moiety to a threonine residue of G-CSF.

[0144] Therefore, a nucleic acid encoding a smaller than full-length, or “truncated,” GalNAcT2 is included in the present invention provided that the truncated GalNAcT2 has GalNAcT2 biological activity.

[0145] The methods and compositions of the invention should not be construed to be limited solely to a nucleic acid comprising a GalNAcT2 truncation mutant as disclosed herein, but rather, should be construed to encompass any nucleic acid encoding a GalNAcT2 truncated mutant, prepared in accordance with the disclosure herein, either known or 5 unknown, which is capable of catalyzing transfer of a GalNAc to a GalNAc acceptor. Modified nucleic acid sequences, i.e. nucleic acid sequences having sequences that differ from the nucleic acid sequences encoding the naturally-occurring proteins, are also encompassed by methods and compositions of the invention, so long as the modified nucleic acid still encodes a truncated protein having the biological activity of catalyzing the transfer 10 of a GalNAc to a GalNAc acceptor, for example. These modified nucleic acid sequences include modifications caused by point mutations, modifications due to the degeneracy of the genetic code or naturally occurring allelic variants, and further modifications that have been introduced by genetic engineering, i.e., by the hand of man. Thus, the term nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically 15 occurring bases (adenine, guanine, thymine, cytosine and uracil).

[0146] The present invention features an isolated nucleic acid comprising a nucleic acid sequence that is at least about 90%, 95%, 97%, 98%, or 99% identical to a nucleic acid sequence set forth in any one of SEQ ID NO:3, SEQ ID NO:7 or SEQ ID NO:9. The present invention also features an isolated nucleic acid sequence comprising any one of the sequences 20 set forth in SEQ ID NO:3, SEQ ID NO:7 or SEQ ID NO:9, wherein the isolated nucleic acid encodes a truncated GalNAcT2 polypeptide.

[0147] The present invention also encompasses isolated nucleic acid molecules encoding a truncated GalNAcT2 polypeptide that contains changes in amino acid residues that are not essential for activity. Such polypeptides encoded by an isolated nucleic acid of the invention 25 differ in amino acid sequence from any one of the sequences set forth in SEQ ID NO:4, SEQ ID NO:8 or SEQ ID NO:10, yet retain the biological activity of GalNAcT2. By way of a non-limiting example, an isolated nucleic acid of the invention may include a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least about 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:4. Further, by 30 way of another non-limiting example, an isolated nucleic acid of the invention may include a nucleotide sequence encoding a polypeptide that has an amino acid sequence at least about 90%, 95%, 97%, 98%, or 99% identical to an amino acid sequence set forth in any one of SEQ ID NO:8 or SEQ ID NO:10.

[0148] The determination of percent identity between two nucleotide or amino acid sequences can be accomplished using a mathematical algorithm. For example, a mathematical algorithm useful for comparing two sequences is the algorithm of Karlin and Altschul (1990, Proc. Natl. Acad. Sci. USA 87:2264-2268), modified as in Karlin and Altschul (1993, Proc. Natl. Acad. Sci. USA 90:5873-5877). This algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990, J. Mol. Biol. 215:403-410), and can be accessed, for example at the National Center for Biotechnology Information (NCBI) world wide web site. BLAST nucleotide searches can be performed with the NBLAST program (designated "blastn" at the NCBI web site), using the following parameters: gap penalty = 5; gap extension penalty = 2; mismatch penalty = 3; match reward = 1; expectation value 10.0; and word size = 11 to obtain nucleotide sequences homologous to a nucleic acid described herein. BLAST protein searches can be performed with the XBLAST program (designated "blastn" at the NCBI web site) or the NCBI "blastp" program, using the following parameters: expectation value 10.0, BLOSUM62 scoring matrix to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997, Nucleic Acids Res. 25:3389-3402). Alternatively, PSI-Blast or PHI-Blast can be used to perform an iterated search which detects distant relationships between molecules and relationships between molecules which share a common pattern. When utilizing BLAST, Gapped BLAST, PSI-Blast, and PHI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See, generally, the internet website for the National Center for Biotechnology Information, which is maintained by the National Library of Medicine and the National Institutes of Health.

[0149] In another aspect, a nucleic acid useful in the methods and compositions of the present invention and encoding a truncated GalNAcT2 polypeptide may have at least one nucleotide inserted into the nucleic acid sequence of such a truncated mutant. Alternatively, an additional nucleic acid encoding a truncated GalNAcT2 polypeptide may have at least one nucleotide deleted from the nucleic acid sequence. Further, a GalNAcT2 nucleic acid encoding a truncated mutant and useful in the invention may have both a nucleotide insertion and a nucleotide deletion present in a single nucleic acid sequence encoding the truncated polypeptide.

[0150] Techniques for introducing changes in nucleotide sequences that are designed to alter the functional properties of the encoded proteins or polypeptides are well known in the

art. Such modifications include the deletion, insertion, or substitution of bases, and thus, changes in the amino acid sequence. As is known to one of skill in the art, nucleic acid insertions and/or deletions may be designed into the gene for numerous reasons, including, but not limited to modification of nucleic acid stability, modification of nucleic acid expression levels, modification of expressed polypeptide stability or half-life, modification of expressed polypeptide activity, modification of expressed polypeptide properties and characteristics, and changes in glycosylation pattern. All such modifications to the nucleotide sequences encoding such proteins are encompassed by the present invention.

[0151] It is not intended that methods and compositions of the present invention be limited by the nature of the nucleic acid employed. The target nucleic acid encompassed by methods and compositions of the invention may be native or synthesized nucleic acid. The nucleic acid may be DNA or RNA and may exist in a double-stranded, single-stranded or partially double-stranded form. Furthermore, the nucleic acid may be found as part of a virus or other macromolecule. See, e.g., Fasbender et al., 1996, *J. Biol. Chem.* 272:6479-89.

15 II. Vectors and Expression Systems

[0152] In other related aspects, the invention includes an isolated nucleic acid encoding a truncated GalNAcT2 polypeptide operably linked to a nucleic acid comprising a promoter/regulatory sequence such that the nucleic acid is preferably capable of directing expression of the polypeptide encoded by the nucleic acid. Thus, the invention encompasses expression vectors and methods for the introduction of exogenous DNA into cells with concomitant expression of the exogenous DNA in those cells, as described, for example, in 20 Sambrook et al. (Third Edition, 2001, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York).

25 [0153] Expression of a truncated GalNAcT2 polypeptide in a cell may be accomplished by generating a plasmid, viral, or other type of vector comprising a nucleic acid encoding the appropriate nucleic acid, wherein the nucleic acid is operably linked to a promoter/regulatory sequence which serves to drive expression of the encoded polypeptide, with or without tag, in cells in which the vector is introduced. In addition, promoters which are well known in the art which are induced in response to inducing agents such as metals, glucocorticoids, and the like, are also contemplated in the invention. Thus, it will be appreciated that the invention 30 includes the use of any promoter/regulatory sequence, which is either known or unknown,

and which is capable of driving expression of the truncated GalNAcT2 polypeptide operably linked thereto.

[0154] In an expression system useful in the present invention, a nucleic acid encoding a truncated GalNAcT2 polypeptide may be fused to one or more additional nucleic acids 5 encoding a functional polypeptide. By way of a non-limiting example, an affinity tag coding sequence may be inserted into a nucleic acid vector adjacent to, upstream from, or downstream from a truncated GalNAcT2 polypeptide coding sequence. As will be understood by one of skill in the art, an affinity tag will typically be inserted into a multiple cloning site in frame with the truncated GalNAcT2 polypeptide. One of skill in the art will 10 also understand that an affinity tag coding sequence can be used to produce a recombinant fusion protein by concomitantly expressing the affinity tag and truncated GalNAcT2 polypeptide. The expressed fusion protein can then be isolated, purified, or identified by means of the affinity tag.

[0155] Affinity tags useful in the present invention include, but are not limited to, a maltose 15 binding protein, a histidine tag, a Factor IX tag, a glutathione-S-transferase tag, a FLAG-tag, and a starch binding domain tag. Other tags are well known in the art, and the use of such tags in the present invention would be readily understood by the skilled artisan.

[0156] As would be understood by one of skill in the art, a vector comprising a truncated GalNAcT2 polypeptide of the present invention may be used to express the truncated 20 polypeptide as either a non-fusion or as a fusion protein. Selection of any particular plasmid vector or other DNA vector is not a limiting factor in this invention and a wide plethora of vectors are well-known in the art. Further, it is well within the skill of the artisan to choose particular promoter/regulatory sequences and operably link those promoter/regulatory sequences to a DNA sequence encoding a truncated GalNAcT2 polypeptide. Such 25 technology is well known in the art and is described, for example, in Sambrook et al. (Third Edition, 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York). By way of a non-limiting example, a vector useful in one embodiment 30 of the present invention is based on the pcWori+ vector (Muchmore et al., 1987, Meth. Enzymol. 177:44-73).

[0157] The invention thus includes a vector comprising an isolated nucleic acid encoding a truncated GalNAcT2 polypeptide. The incorporation of a nucleic acid into a vector and the

choice of vectors is well-known in the art as described in, for example, Sambrook et al. (Third Edition, 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York), and in Ausubel et al. (1997, Current Protocols in Molecular Biology, John Wiley & Sons, New York).

5 [0158] In an aspect of the invention, an isolated nucleic acid encoding a truncated GalNAcT2 polypeptide is integrated into the genome of a host cell in conjunction with a nucleic acid encoding a truncated GalNAcT2 polypeptide. In another aspect of the invention, a cell is transiently transfected with an isolated nucleic acid encoding a truncated GalNAcT2 polypeptide. In yet another aspect of the invention, a cell is stably transfected with an 10 isolated nucleic acid encoding a truncated GalNAcT2 polypeptide.

15 [0159] For the purpose of inserting an isolated nucleic acid into a cell, one of skill in the art would also understand that the methods available and the methods required to introduce an isolated nucleic acid of the invention into a host cell vary and depend upon the choice of host cell. Suitable methods of introducing an isolated nucleic acid into a host cell are well-known in the art. Other suitable methods for transforming or transfecting host cells may include, but are not limited to, those found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 3rd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001), and other such laboratory manuals.

20 [0160] A nucleic acid encoding a truncated GalNAcT2 polypeptide may be purified by any suitable means, as are well known in the art. For example, the nucleic acids can be purified by reverse phase or ion exchange HPLC, size exclusion chromatography or gel electrophoresis. Of course, the skilled artisan will recognize that the method of purification will depend in part on the size of the DNA to be purified.

25 [0161] The present invention also features a recombinant bacterial host cell comprising, *inter alia*, a nucleic acid vector as described elsewhere herein. In one aspect, the recombinant cell is transformed with a vector of the present invention. The transformed vector need not be integrated into the cell genome nor does it need to be expressed in the cell. However, the transformed vector will be capable of being expressed in the cell. In one aspect of the invention, *E. coli* is used for transformation of a vector of the present invention and 30 expression of protein therefrom. In another aspect of the invention, a K-12 strain of *E. coli* is useful for expression of protein from a vector of the present invention. Strains of *E. coli*

useful in the present invention include, but are not limited to, JM83, JM101, JM103, JM109, W3110, chi1776, and JA221.

[0162] It will be understood that a host cell useful in the present invention will be capable of growth and culture on a small scale, medium scale, or a large scale. For example, a host 5 cell of the invention is useful for testing the expression of a protein from a vector of the invention equally as much as it is useful for large scale production of a reagent or therapeutic protein product. Techniques useful in culturing host cells and expressing protein from a vector contained therein are well known in the art and will therefore not be listed herein.

[0163] A host cell useful in methods of the present invention, as described above, may be 10 prepared according to various methods, as would be understood by the skilled artisan when armend with the disclosure set forth herein. In one aspect, a host cell of the present invention may be transformed with a vector of the present invention to produce a transformed host cell of the invention. Transformation, as known to the skilled artisan, includes the process of inserting a nucleic acid vector into a host cell, such that the host cell containing the nucleic 15 acid vector remains viable. Such transformation of nucleic acid into a bacterial cell is useful for purposes including, but not limited to, creation of a stably-transformed host cell, making a biological deposit, propagating the vector-containing host cell, propagating the vector-containing host cell for the production and isolation of additional vector, expression of target protein encoded by vector, and the like.

[0164] Methods of transforming a cell with a vector are numerous and well-known in the 20 art, and will therefore not be listed here. By way of a non-limiting example, a competent bacterial cell of the invention may be transformed by a vector of the invention using electroporation. Methods of making bacterial cells “competent” are well-known in the art, and typically involve preparation of the bacterial cells so that the cells take up exogenous 25 DNA. Similarly, methods of electroporation are known in the art, and detailed descriptions of such methods may be found, for example, in Sambrook et al. (1989, *supra*). The transformation of a competent cell with vector DNA may be also accomplished using chemical-based methods. One example of a well-known chemical-based method of bacterial transformation is described by Inoue, et al. (1990, Gene 96:23-28). Other methods of 30 transformation will be known to the skilled artisan.

[0165] A transformed host cell of the present invention may be used to express a truncated GalNAcT2 polypeptide of the present invention. In an embodiment of the invention, a

transformed host cell contains a vector of the invention, which contains therein a nucleic acid sequence encoding an truncated polypeptide of the invention. The truncated polypeptide is expressed using any expression method known in the art (for example, IPTG). The expressed truncated polypeptide may be contained within the host cell, or it may be secreted from the host cell into the growth medium.

5 [0166] Methods for isolating an expressed polypeptide are well-known in the art, and the skilled artisan will know how to determine the best method for isolation of an expressed polypeptide based on the characteristics of any given host cell expression system. By way of a non-limiting example, an expressed polypeptide that is secreted from a host cell may be 10 isolated from the growth medium. Isolation of a polypeptide from a growth medium may include removal of bacterial cells and cellular debris. By way of another non-limiting example, an expressed polypeptide that is contained within a host cell may be isolated from the host cell. Isolation of such an "intracellular" expressed polypeptide may include disruption of the host cell and removal of cellular debris from the resultant mixture. These 15 methods are not intended to be exclusive representations of the present invention, but rather, are merely for the purposes of illustration of various applications of the present invention.

20 [0167] Purification of a truncated polypeptide expressed in accordance with the present invention may be effected by any means known in the art. The skilled artisan will know how to determine the best method for the purification of a polypeptide expressed in accordance with the present invention. A purification method will be chosen by the skilled artisan based 25 on factors such as, but not limited to, the expression host, the contents of the crude extract of the polypeptide, the size of the polypeptide, the properties of the polypeptide, the desired end product of the polypeptide purification process, and the subsequent use of the end product of the polypeptide purification process.

25 [0168] In an embodiment of the invention, isolation or purification of a truncated polypeptide expressed in accordance with the present invention may not be desired. In an aspect of the present invention, an expressed polypeptide may be stored or transported inside the bacterial host cell in which the polypeptide was expressed. In another aspect of the invention, an expressed polypeptide may be used in a crude lysate form, which is produced 30 by lysis of a host cell in which the polypeptide was expressed. In yet another embodiment of the invention, an expressed polypeptide may be partially isolated or partially purified according to any of the methods set forth or described herein. The skilled artisan will know

when it is not desirable to isolate or purify a polypeptide of the invention, and will be familiar with the techniques available for the use and preparation of such polypeptides.

[0169] When armed with the disclosure set forth herein, the skilled artisan would also know how to prepare a eukaryotic host cell of the invention. As set forth elsewhere herein, 5 and as would be known to one of skill in the art based on the disclosure provided herein, an isolated nucleic acid encoding a truncated GalNAcT2 polypeptide may be introduced into a eukaryotic host cell, for example, using a lentivirus-based genomic integration or plasmid-based transfection (Sambrook et al., Third Edition, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (2001)). In one embodiment of the 10 invention, a eukaryotic host cell is a fungal cell. In another embodiment, a nucleic acid encoding a truncated polypeptide of the invention is cloned into a lentiviral vector containing a specific promoter sequence for expression of the truncated polypeptide. The truncated polypeptide-containing lentiviral vector is then used to transfect a host cell for expression of the truncated polypeptide. Methods of making and using lentiviral vectors, such as those 15 useful in the present invention, are well-known in the art and are not described further herein.

[0170] In yet another embodiment, a nucleic acid encoding a truncated polypeptide of the invention is introduced into a host cell using a viral expression system. Viral expression systems are well-known in the art, and will not be described in detail herein. In one aspect of the invention, a viral expression system is a mammalian viral expression system. In another 20 aspect of the invention, a viral expression system is a baculovirus expression system. Such viral expression systems are typically commercially available from numerous vendors.

[0171] The skilled artisan will know how to use a host cell-vector expression system for the expression of a truncated polypeptide of the invention. Appropriate cloning and expression vectors for use with eukaryotic hosts are described by Sambrook, et al., in Molecular 25 Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor, N.Y. (2001), the disclosure of which is hereby incorporated in its entirety by reference.

[0172] Insect cells can also be used for expression of a truncated polypeptide of the present invention. In an aspect of the invention, Sf9, SF9⁺, Sf21, High FiveTM or Drosophila Schneider S2 cells can be used. In yet another aspect of the invention, a baculovirus, or a 30 baculovirus/insect cell expression system can be used to express a truncated polypeptide of the invention using a pAcGP67, pFastBac, pMelBac, or pIZ vector and a polyhedrin, p10, or

OpIE3 actin promoter. In another aspect of the invention, a *Drosophila* expression system can be used with a pMT or pAC5 vector and an MT or Ac5 promoter.

[0173] A truncated GalNAcT2 polypeptide of the invention can also be expressed in mammalian cells. In an aspect of the invention, 294, HeLa, HEK, NSO, Chinese hamster ovary (CHO), Jurkat, or COS cells can be used to express a truncated polypeptide of the invention. In the case of a mammalian cell expression of a truncated polypeptide, a suitable vector such as pT-Rex, pSecTag2, pBudCE4.1, or pCDNA/His Max vector can be used, along with, for example, a CMV promoter. As will be understood by the skilled artisan, the choice of promoter, as well as methods and strategies for introducing one or more promoters into a host cell used for expressing a truncated GalNAcT2 polypeptide of the invention are well-known in the art, and will vary depending upon the host cell and expression system used.

[0174] Various mammalian cell culture systems can be employed to express recombinant protein. Non-limiting examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell* 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors may comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

[0175] The methods available and the methods required to introduce any isolated nucleic acid of the invention into a host cell vary and depend upon the choice of the host cell, as would be understood by one of skill in the art. Suitable methods of introducing an isolated nucleic acid into a host cell are well-known in the art. By way of a non-limiting example, vector DNA can be introduced into a eukaryotic cell using conventional transfection techniques. As used herein, the term "transfection" refers to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning*:

A Laboratory Manual. 3nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001), and other such laboratory manuals.

[0176] For example, for stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may 5 integrate the foreign DNA into their genome. In order to identify and select these transformants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on 10 the same vector as that encoding a truncated polypeptide of the invention or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

III. Polypeptides

[0177] A truncated GalNAcT2 polypeptide of the present invention may be truncated in 15 various ways, as would be known and understood by the skilled artisan, when armed with the present disclosure. Examples of truncated polypeptides of the present invention include, but are not limited to, a polypeptide lacking a single N-terminal residue, a polypeptide lacking a single C-terminal residue, a polypeptide lacking both an single N-terminal residue and a 20 single C-terminal residue, a polypeptide lacking a contiguous sequence of residues from the N-terminus, a polypeptide lacking a contiguous sequence of residues from the C-terminus, and any such combinations thereof.

[0178] As would be understood by the skilled artisan, a full-length human GalNAcT2 polypeptide may contain one or more identifiable polypeptide domains in addition to the 25 "active domain," the domain primarily responsible for the catalytic activity, of GalNAcT2. This is because it is known in that art that a full-length GalNAcT2 polypeptide, and in particular, a full-length human GalNAcT2 polypeptide, contains a signal domain, a transmembrane domain, and a stem domain, in addition to an active domain. Accordingly, a full-length human GalNAcT2 may have a signal domain at the amino-terminus of the 30 polypeptide, followed by a transmembrane domain immediately adjacent to the signal domain, followed by a stem domain that is immediately adjacent to the transmembrane

domain, followed by an active domain that extends to the carboxy-terminus of the polypeptide and is located immediately adjacent to the stem domain.

[0179] Therefore, in one embodiment, a GalNAcT2 polypeptide of the invention is a truncated human GalNAcT2 polypeptide lacking all or a portion of the GalNAcT2 signal domain. In another embodiment, a GalNAcT2 polypeptide of the invention is a truncated human GalNAcT2 polypeptide lacking the GalNAcT2 signal domain and all or a portion of the GalNAcT2 transmembrane domain. In yet another embodiment, a GalNAcT2 polypeptide of the invention is a truncated human GalNAcT2 polypeptide lacking the GalNAcT2 signal domain, the GalNAcT2 transmembrane domain and all or a portion of the GalNAcT2 stem domain. When armed with the disclosure of the present invention, the skilled artisan will know how to make and use these and other such truncation mutants of human GalNAcT2.

[0180] The size and identity of a truncated GalNAcT2 mutant of the present invention is based on the point at which the full-length polypeptide is truncated. By way of a non-limiting example, a “Δ40 human truncated GalNAcT2” mutant of the invention refers to a truncated GalNAcT2 polypeptide of the invention in which amino acids 1 through 40, counting from the N-terminus of the full-length polypeptide, are deleted from the polypeptide. Therefore, the N-terminus of the Δ40 human truncated GalNAcT2 mutant begins with the amino acid residue that would be referred to as “amino acid 41” of the full-length polypeptide. This nomenclature applies to all truncated GalNAcT2 polypeptides of the invention, including human GalNAcT2.

[0181] The present invention therefore also includes an isolated polypeptide comprising a truncated GalNAcT2 polypeptide. Preferably, an isolated truncated GalNAcT2 polypeptide of the present invention has at least about 90% identity to a polypeptide having the amino acid sequence of any one of the sequences set forth in SEQ ID NO:4, SEQ ID NO:8 or SEQ ID NO:10. More preferably, the isolated polypeptide is about 95% identical, and even more preferably, about 98% identical, still more preferably, about 99% identical, and most preferably, the isolated polypeptide comprising a truncated GalNAcT2 polypeptide is identical to the polypeptide set forth in one of SEQ ID NO:4, SEQ ID NO:8 or SEQ ID NO:10.

[0182] The present invention also provides for analogs of polypeptides which comprise a truncated GalNAcT2 polypeptide as disclosed herein. Analogs can differ from naturally

occurring proteins or peptides by conservative amino acid sequence differences or by modifications which do not affect sequence, or by both.

[0183] For example, conservative amino acid changes may be made, which although they alter the primary sequence of the protein or peptide, do not normally alter its function.

5 Conservative amino acid substitutions typically include substitutions within the following groups:

glycine, alanine;
valine, isoleucine, leucine;
aspartic acid, glutamic acid;
10 asparagine, glutamine;
serine, threonine;
lysine, arginine;
phenylalanine, tyrosine.

15 [0184] Modifications (which do not normally alter primary sequence) include in vivo, or in vitro chemical derivatization of polypeptides, e.g., acetylation, or carboxylation. Also included are modifications of glycosylation, e.g., those made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps; e.g., by exposing the polypeptide to enzymes which affect glycosylation, e.g., mammalian 20 glycosylating or deglycosylating enzymes. Also embraced are sequences which have phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

[0185] Also included are polypeptides which have been modified using ordinary molecular biological techniques so as to improve their resistance to proteolytic degradation or to 25 optimize solubility properties or to render them more suitable as a therapeutic agent. Analogs of such polypeptides include those containing residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring synthetic amino acids. The peptides of the invention are not limited to products of any of the specific exemplary processes listed herein.

30 [0186] Fragments of a truncated GalNAcT2 polypeptide of the invention are included in the present invention, provided the fragment possesses the biological activity of the full-length polypeptide. That is, a truncated GalNAcT2 polypeptide of the present invention can

catalyze the same glycosyltransfer reaction as the full-length GalNAcT2. By way of a non-limiting example, a truncated human GalNAcT2 polypeptide has the ability to transfer a GalNAc moiety from a UDP-GalNAc donor to a granulocyte-colony stimulating factor (G-CSF) acceptor, wherein such a transfer results in the O-linked covalent coupling of a GalNAc moiety to a threonine residue of G-CSF. Therefore, a smaller than full-length, or “truncated,” GalNAcT2 is included in the present invention provided that the truncated GalNAcT2 has GalNAcT2 biological activity.

[0187] In another aspect of the present invention, compositions comprising an isolated truncated GalNAcT2 polypeptide as described herein may include highly purified truncated GalNAcT2 polypeptides. Alternatively, compositions comprising truncated GalNAcT2 polypeptides may include cell lysates prepared from the cells used to express the particular truncated GalNAcT2 polypeptides. Further, truncated GalNAcT2 polypeptides of the present invention may be expressed in one of any number of cells suitable for expression of polypeptides, such cells being well-known to one of skill in the art, as described in detail elsewhere herein.

[0188] Substantially pure protein isolated and obtained as described herein may be purified by following known procedures for protein purification, wherein an immunological, enzymatic or other assay is used to monitor purification at each stage in the procedure. Protein purification methods are well known in the art, and are described, for example in Deutscher *et al.* (ed., 1990, Guide to Protein Purification, Harcourt Brace Jovanovich, San Diego).

IV. Methods

[0189] The present invention features a method of expressing a truncated polypeptide. Polypeptides which can be expressed according to the methods of the present invention include a truncated GalNAcT2 polypeptide. More preferably, polypeptides which can be expressed according to the methods of the present invention include, but are not limited to, a truncated human GalNAcT2 polypeptide. In a preferred embodiment, a polypeptide which can be expressed according to the methods of the present invention is a polypeptide comprising any one of the polypeptide sequences set forth in SEQ ID NO:4, SEQ ID NO:8 or SEQ ID NO:10.

[0190] In one embodiment, the present invention features a method of expressing a truncated GalNAcT2 polypeptide encoded by an isolated nucleic acid of the invention, as

described elsewhere herein, wherein the expressed truncated GalNAcT2 polypeptide has the property of catalyzing the transfer of a GalNAc moiety to an acceptor moiety. In one aspect of the invention, a method of expressing a truncated GalNAcT2 polypeptide includes the steps of cloning an isolated nucleic acid of the invention into an expression vector, inserting 5 the expression vector construct into a host cell, and expressing a truncated GalNAcT2 polypeptide therefrom.

[0191] Methods of expression of polypeptides, as well as construction of expression systems and recombinant host cells for expression of polypeptides, are discussed in extensive detail elsewhere herein. Methods of expression of a truncated polypeptide of the present 10 invention will be understood to include, but not to be limited to, all such methods as described herein. In some expression systems, the truncated GalNAcT2 polypeptides of the invention are expressed as insoluble proteins, *e.g.*, in an inclusion protein in a bacterial host cell. Methods of refolding insoluble glycosyltransferases, including GalNAcT2 polypeptides, are disclosed in U.S. Provisional Patent Application Serial No. 60/542,210, filed February 4, 15 2004; U.S. Provisional Patent Application Serial No. 60/599,406, filed August 6, 2004; U.S. Provisional Patent Application Serial No. 60/627,406, filed November 12, 2004; and International Patent Application No. PCT/US05/03856, filed February 4, 2005; each of which 20 are herein incorporated by reference for all purposes.

[0192] The present invention also features a method of catalyzing the transfer of a GalNAc 25 moiety to a GalNAc acceptor moiety, wherein the GalNAc-transfer reaction is carried out by incubating a truncated GalNAcT2 polypeptide of the invention with a GalNAc donor moiety and a GalNAc acceptor moiety. In one aspect, a truncated GalNAcT2 polypeptide of the invention mediates the covalent linkage of a GalNAc moiety to a GalNAc acceptor moiety, thereby catalyzing the transfer of a GalNAc moiety to an acceptor moiety.

[0193] In one embodiment of the invention, a truncated GalNAcT2 polypeptide useful in a 30 glycosyltransfer reaction is a truncated human GalNAcT2 polypeptide. In one aspect, the human GalNAcT2 glycosyltransfer reaction involves the transfer of a GalNAc residue from a GalNAc donor to a GalNAc acceptor.

[0194] By way of a non-limiting example, a method of catalyzing the transfer of a GalNAc 35 moiety to an acceptor moiety includes the steps of incubating a truncated GalNAcT2 polypeptide with UDP-GalNAc GalNAc donor and a granulocyte colony stimulating factor

(G-CSF) acceptor moiety, wherein the truncated GalNAcT2 polypeptide mediates the transfer of GalNAc from the UDP-GalNAc donor to the GCSF acceptor.

[0195] Therefore, in one embodiment, the present invention also features a polypeptide acceptor moiety. In one embodiment of the invention, a polypeptide acceptor moiety is a human growth hormone. In another embodiment, a polypeptide acceptor moiety is an erythropoietin. In yet another embodiment, a polypeptide acceptor moiety is an interferon-alpha. In another embodiment, a polypeptide acceptor moiety is an interferon-beta. In another embodiment of the invention, a polypeptide acceptor moiety is an interferon-gamma. In still another embodiment of the invention, a polypeptide acceptor moiety is a lysosomal hydrolase. In another embodiment, a polypeptide acceptor moiety is a blood factor polypeptide. In still another embodiment, a polypeptide acceptor moiety is an anti-tumor necrosis factor-alpha. In another embodiment of the invention, a polypeptide acceptor moiety is follicle stimulating hormone.

[0196] In one embodiment, the present invention also features a method of transferring a GalNAc-polyethyleneglycol conjugate to an acceptor molecule. In one aspect, an acceptor molecule is a polypeptide. In another aspect, an acceptor molecule is a glycopeptide. Compositions and methods useful for designing, producing and transferring a GalNAc-polyethyleneglycol conjugate to an acceptor molecule are discussed at length in International (PCT) Patent Application No. WO03/031464 (PCT/US02/32263) and U.S. Patent Application No. 2004/0063911, each of which is incorporated herein by reference in its entirety. Methods of assaying for glycosyltransferase activity are well-known in the art. Various assays for detecting glycosyltransferases which can be used in accordance with the invention have been published. The following are illustrative, but should not be considered limiting, of those assays useful for detecting glycosyltransferase activity. Furukawa *et al.* (1985, *Biochem. J.*, 227:573-582) describe a borate-impregnated paper electrophoresis assay and a fluorescence assay. Roth *et al.* (1983, *Exp'l Cell Research* 143:217-225) describe application of the borate assay to glucuronyl transferases, previously assayed calorimetrically. Benau *et al.* (1990, *J. Histochem. Cytochem.*, 38:23-30) describe a histochemical assay based on the reduction, by NADH, of diazonium salts. See also U.S. Patent No. 6,284,493 of Roth, incorporated herein by reference.

EXPERIMENTAL EXAMPLES

[0197] The invention is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these examples but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Example 1: Cloning, Expression, and Refolding of Human Polypeptide N-acetylgalactosaminyltransferase II (GalNAcT2) in *E. coli* JM109

[0198] Four constructs were designed and created in order to assess the sialyltransferase activity of truncation mutants of human GalNAcT2. The four mutants created included $\Delta 40$, a truncation mutant which has as its new N-terminal residue an lysine that corresponds to R41 of the full-length human GalNAcT2 set forth in SEQ ID NO:2, $\Delta 51$, a truncation mutant which has as its new N-terminal residue an lysine that corresponds to K52 of the full-length human GalNAcT2 set forth in SEQ ID NO:2, $\Delta 73$, a truncation mutant which has as its new N-terminal residue a glycine that corresponds to G74 of the full-length human GalNAcT2 set forth in SEQ ID NO:2, and $\Delta 94$, a truncation mutant which has as its new N-terminal residue a glycine that corresponds to G95 of the full-length human GalNAcT2 set forth in SEQ ID NO:2.

[0199] Truncated human polypeptide N-acetylgalactosaminyltransferase II (GalNAcT2) was expressed as maltose binding protein (MBP)-fusion proteins in inclusion bodies from *E. coli* JM109 cells. The production of active enzyme was examined by refolding and assaying against two polypeptide acceptors. Therefore, described herein is the generation of several truncated forms of human polypeptide GalNAcT2 as maltose binding protein fusion proteins in *E. coli* JM109 cells. The recombinant proteins are refolded from isolated inclusion bodies using the Hampton FoldIt screen kit (Hampton Research, Aliso Vieja, CA). All four constructs were expressed in JM109 *E. coli* at levels of approximately 2g/L culture media.

[0200] PCR (Polymerase Chain Reaction) amplifications were performed in a final reaction volume of 50 μ l containing 5 μ l of template DNA (11 μ g/ml, 100-fold diluted pBKS-Full ppGalNAcT2), 40 pmol of 5'- primer and 3'- primer, 10 nmol of dNTP mixture, and 5 units of HerculaseTM Enhanced DNA Polymerase under the conditions of 31 cycles of denaturation at 95°C for 45 seconds, annealing at 62°C for 45 seconds, and extension at 74°C for 170 seconds. PCR products were subjected to 1% agarose gel electrophoresis. DNA fragments

were excised and purified by QIAEX II gel extraction kit (Qiagen, Valencia, CA). Table 1 illustrates the primers used in the PCR reactions.

Table 1: Primers used in cloning ppGalNAcT2

Sense Primers:

For N41R (relates to $\Delta 40$):

5' CGCGGATCCAGGAAGGAGGACTGGAATG 3' (SEQ ID NO:11)
BamHI

For N52K (relates to $\Delta 51$):

5' CGCGGATCCAAAAAGAAAGACCTTCATCACAGC 3' (SEQ ID NO:12)
BamHI

For N74G (relates to $\Delta 73$):

5' CGCGGATCCGGAAAGTACGGTGGCCAGAC 3' (SEQ ID NO:13)
BamHI

For N95G (relates to $\Delta 94$):

5' CGCGGATCCGGCAGGACCCTTACGCC 3' (SEQ ID NO:14)
BamHI

Antisense Primer with STOP codon:

5'-CTGCTCGAGCTACTGCTGCAGGTTGAGCG 3' (SEQ ID NO:15)
XhoI Stop

[0201] Gel-purified PCR products were digested with *BamHI* and *XhoI*, gel purified again

5 and ligated into a pCWin2MBP vector previously digested by the same restriction enzymes.

The ligated products were transformed into *E. coli* DH5 α electrocompetent cells. The

transformants were plated on LB Agar plates with 50 μ g/ml Kanamycin and incubated at

37°C overnight. Three colonies were picked for each construct and cultured in LB medium containing 15 μ g/ml kanamycin. Plasmid DNAs were purified by QIAprep Spin Miniprep

10 Kit (Qiagen, Valencia, CA) and screened by restriction mapping with *BamHI* and *XhoI*. The plasmids having the correct digest patterns were transformed into JM109 chemical competent cell.

[0202] JM109 cells were cultured in a 15 ml culture tube containing 6 ml LB medium and

15 μ g/ml of kanamycin overnight at 37°C with rapid shaking (250 rpm). For each culture,

15 two milliliters of starting culture was transferred to a 50 ml centrifuge tube containing 23 ml LB medium with 15 μ g/ml kanamycin and incubated at 37°C with rapid shaking for 3 hours.

Isopropyl-1-thio- β -D-galactopyranoside (IPTG) was added to a final concentration of 0.4

mM to induce the protein expression. After shaking at 37°C (250 rpm) for another 3 hours, cells were harvested by centrifugation at 3,500 x g for 10 minutes. The cell pellets were then

resuspended in 0.6 ml of 20 mM Tris-HCl buffer (pH 8.5) containing 1% Triton X-100. Lysozyme (100 μ g) and DNaseI (2 μ g) were then added. The mixture was shaken at 37°C in an incubator shaker for 45 minutes before being transferred to a 1.5 ml microcentrifuge tube. Lysate was separated from inclusion bodies (IB) by centrifugation at 14,000 rpm for 5

5 minutes.

[0203] Each sample for SDS-PAGE separation was prepared by mixing 5 μ l of whole cells suspension, lysate, or inclusion bodies suspension with 5 μ l of 2 x Tris-Glycine SDS sample buffer and 1.1 μ l of DTT (1 M). The mixture was heated at 98°C for 5 minutes, cooled to room temperature, and loaded to each well of a 1.0 mm x 15 well 4-20% Tris-Glycine gradient gel. The electrophoresis was conducted at 120 V for 100 minutes. The gel was then stained for 2 hours and de-stained with distilled water (see Figures 4-6).

[0204] Inclusion bodies were dissolved at 20 mg/ml (high protein concentration) or 2 mg/ml concentration (low protein concentration) in solubilizing buffer containing 4 M Guanidine-HCl, 100 mM Tris-HCl, pH 9.0, 5 mM EDTA, and 10 mM DTT. Refolding of inclusion bodies by Hampton FoldIt Screen Kit was carried out by following the manufacturer's protocol, except that a 10-fold less volume was used (100 μ l -scale) (Hampton Products, Aliso Viejo, CA).

[0205] Non-radioactive enzyme activity assays for lysates were carried out in a 0.5 μ l microcentrifuge tube at 37°C for overnight in a final volume of 10 μ l containing 50 mM MES buffer, pH 6.0, MnCl₂ (15 mM), MgCl₂ (15 mM), NaCl (0.15 M), UDP-GalNAc (5 mM), 1.5 μ g G-CSF (acceptor), and 2.15 μ l of lysate sample. Enzyme was substituted by H₂O as a negative control. Purified recombinant ppGalNAcT2 (0.5 μ l) from Sf9 baculovirus expression system was used as the positive control. An assay for refolded inclusion bodies was performed in a similar manner as described for the lysates, except that Interferon α 2b (4 μ g) was used as the acceptor for the enzyme and the volume of the sample added to the reaction mixture was 5.65 μ l.

[0206] DNA fragments for ppGalNAcT2 genes (about 1.5 kb) were successfully amplified by PCR as shown in Figure 5. Vector plasmid DNA pCWin2MBP was digested by BamHI and XhoI, and purified on a 1% agarose gel. The gel purified DNA fragment was digested by the same two enzymes and purified. After digestion, the DNA fragments were clean as visualized on an agarose gel (Figure 2B).

[0207] BamHI and XhoI digestion of the plasmids purified from the selected twelve colonies showed predicted correct pattern on a 1% agarose gel. The size of the vector was around 6.2 kb, and the inserts were approximately 1.5 kb. Maltose-binding protein (MBP) expressed in the JM109 transformed with pCWin2MBP vector plasmid showed a band at around 43 kDa. Over 90% of the proteins in the whole cells are MBP. The #2 colony of the construct N41R expressed a shorter protein than expected, indicating the occurrence of mutation. All other eleven colonies showed a band at about 100 kDa for MBP-ppGalNAcT2 fusion proteins, with over 80% of the total proteins were the target fusion proteins.

[0208] Gel electrophoresis showed that most of the MBP was expressed as a soluble form in cell lysate (Figures 1 and 2). The overexpressed protein in the wrong construct (colony #2) for N41R was also observed in the cell lysate. However, most of the MBP-ppGalNAcT2 fusion proteins were in inclusion bodies (Lane 1 and 3 – 12 in Figures 1 and 2). Over 90% of the proteins in the inclusion bodies were the MBP fusion proteins of interest.

[0209] In summary, four truncated forms of human polypeptide GalNAcT2 were successfully cloned into pCWin2MBP vector and expressed in *E. coli* JM109 as MBP fusion proteins in inclusion bodies. The level of expression of enzyme in inclusion bodies was about 2 g/L. As estimated from the SDS-PAGE, over 80% of the inclusion bodies were the target MBP-ppGalNAcT2 fusion proteins.

Example 2: Development of Protein Refolding Conditions for *E. Coli* Expressed MBP-Human GalNAcT2

[0210] Refolding experiments on MBP-GalNAcT2 were carried out on a 1 ml scale, with four different MBP-GalNAcT2 DNA constructs and under 16 different possible refolding conditions. Refolding was performed using the Hampton Research Foldit kit (Hampton Research, Aliso Viejo, CA) and the assays were performed via radioactive detection of [³H] UDP-GalNAc addition to a MuC-2 peptide and via matrix-assisted laser desorption ionization mass spectrometry (MALDI) analysis utilizing addition of GalNAc to Interferon α -2b and G-CSF. The data illustrates that *E. coli*-expressed MBP-GalNAcT2 can be refolded into an active enzyme. It appears that under refolding conditions 8 and 15, found in Hampton Research's Foldit kit (Hampton Research, Aliso Viejo, CA), active conformations of MBP-GalNAcT2, construct 1 and 2, were identified. Success was indicated by the [³H] UDP-GalNAc assay and later confirmed by interferon α -2b (IF α -2b) and granulocyte-colony

stimulating factor (G-CSF) -based glycosyltransferase assays. The specific methods and data of this study are presented herein.

[0211] As described elsewhere herein, GalNAcT2 constructs used in the present invention comprised DNA encoding various amino terminal amino acid truncation mutants of the 5 original human GalNAcT2 protein, including the following constructs, which begin with the N-terminal amino acid as indicated:

Construct 1 – pCWin2 MBP-GalNAcT2 – R41 Arginine (924aa, 103682.5MW),
Construct 2 – pCWin2 MBP-GalNAcT2 – K52 Lysine (913aa, 102286.0MW),
Construct 3 – pCWin2 MBP-GalNAcT2 – G74 Glycine (891aa, 99799.3MW), and
Construct 4 – pCWin2 MBP-GalNAcT2 – G95 Glycine (870aa, 97419.8MW).

[0212] Constructs were first expanded to 2 ml starter cultures by inoculating 2 ml of Martone L-Broth containing 10 μ g/ml Kanamycin sulfate with a pipette tip scraping from the particular glycerol stock culture. This procedure was performed on all four constructs for a total of four starter cultures. Starter cultures were incubated overnight at 37°C, with rotary 15 shaking at 250rpm. From the overnight cultures, four 275 ml Martone L-Broth cultures containing 10 μ g/ml Kanamycin sulfate were prepared. Each of these cultures was inoculated with 275 μ L of one of the 2 ml starter cultures of constructs 1 through 4. These 275 ml cultures were incubated overnight at 37°C, with shaking at 250rpm.

[0213] Lastly, four 1L Martone L-Broth cultures containing 10 μ g/ml Kanamycin sulfate 20 were prepared. Each of these cultures was inoculated with 40 ml of one of the 275 ml cultures of constructs 1 though 4. These 1L cultures were incubated at 37°C, with shaking at 250rpm, until the OD600 measured approximately 1.0. Upon reaching this point, IPTG was added to each of the four 1L cultures to a final concentration of 0.4mM. Cultures were then allowed incubate overnight at 37°C, with shaking at 250rpm.

[0214] One-liter cultures containing JM109 pCWin2 MBP-GalNAcT2 constructs, 25 designated numbers 1 through 4, were transferred to 1L centrifuge bottles. Cultures were then centrifuged at 5000rpm for 30 minutes at 4°C. Supernatants were removed and the pellets were weighed. The pellets from each sample were then washed to isolate the inclusion bodies (IBs). The pellet of each construct was first resuspended in 15 ml of 20mM Tris-HCl pH=8.5, 5mM EDTA and then lysed by two passages through a french press at 12,000psi.

[0215] The lysates for each construct were then centrifuged at 5000rpm, 25°C for 5 minutes in 50 ml disposable tubes. The supernatants were removed and the pellets were resuspended in 25 ml of 20mM Tris-HCl pH=8.5, 1% Triton X-100. The suspensions

incubated at room temperature for 10 minutes. The suspensions were then centrifuged at 5000 rpm, 25°C for 5 minutes. The supernatants were then removed and the samples were resuspended for a second time in 25 ml of 20mM Tris-HCl pH=8.5, 1% Triton X-100 and allowed to incubate at room temperature for 10 minutes. The suspensions were again 5 centrifuged at 5000 rpm, 25°C for 5 minutes. The supernatants were removed and a third wash was performed by resuspending the pellets in 25 ml of 20mM Tris-HCl pH=8.5, 1% Triton X-100. The suspensions sat at room temperature for 10 minutes and then were centrifuged at 5000 rpm, 25°C for 5 minutes. The supernatants from each sample were removed and the pellets were weighed. The pellets were then diluted to 20mg/ml by 10 resuspending them in the appropriate volume of 20mM Tris-HCl pH=8.5, 5mM EDTA. One-ml aliquots were made from these suspensions for each of the four constructs and stored at -20°C. These aliquots represent the triple washed IBs or "TWIBs."

[0216] Solubilization buffer was prepared with the following constituents: 6M Guanidine HCl, 5mM EDTA, 50mM Tris-HCl pH=8 and 10mM DTT. 1 ml of this solution was added 15 to a 20mg aliquot of TWIBs to yield a 20mg/ml solution. The solution was incubated overnight on the bench top to solubilize IBs. This procedure was performed on a TWIB aliquot of each MBP-GalNAcT2 construct to provide protein for refolding experiments.

[0217] To screen refolding conditions that may result in an active form of E.coli expressed MBP-GalNAcT2, a Hampton Foldit Screening kit was utilized (Hampton Products, Aliso 20 Viejo, CA). The composition of each of the refold buffers is found in Table 2.

Table 2: Refold Conditions from Hampton Research Foldit kit (Hampton Research, Aliso Viejo, CA)

| Refold Matrix | | | | | | | | | | | | | | |
|------------------|-----------|----------|-------------------|-------------|-----------------------|--------------|----------------|----------------|----------------|----------------|---------|---------|------------|-----------------------|
| Refold Condition | 55mM Tris | 55mM MES | 264mM NaCl/ NaCl/ | 10.56mM PEG | 0.005% Guanidine EDTA | 550mM NaCl2/ | 1.1mM Sucrose/ | 2.2mM Sucrose/ | 440mM Sucrose/ | 550mM Arginine | 1mM DTT | 1mM GSH | 0.1mM GSSG | Protein Concentration |
| 1 | X | | X | | X | | X | | | X | X | X | | 0.1 |
| 2 | | X | | X | | X | | X | | | X | X | | 0.1 |
| 3 | | X | | X | | X | | X | | | X | X | | 0.1 |
| 4 | X | | X | | X | | X | | X | | X | | | 0.1 |
| 5 | X | | X | | X | | X | | X | | X | | | 1 |
| 6 | X | | X | | X | | X | | X | | X | | | 1 |
| 7 | X | | X | | X | | X | | X | | X | | | 1 |
| 8 | X | | X | | X | | X | | X | | X | X | | 1 |
| 9 | X | | X | | X | | X | | X | | X | X | | 0.1 |
| 10 | X | | X | | X | | X | | X | | X | X | | 0.1 |
| 11 | X | | X | | X | | X | | X | | X | X | | 0.1 |
| 12 | X | | X | | X | | X | | X | | X | X | | 1 |
| 13 | X | | X | | X | | X | | X | | X | X | | 1 |
| 14 | X | | X | | X | | X | | X | | X | X | | 1 |
| 15 | X | | X | | X | | X | | X | | X | X | | 1 |
| 16 | X | | X | | X | | X | | X | | X | X | | 1 |

[0218] For a given refold condition, 950 μ L of refold buffer was combined with 50 μ L of solubilized protein (for high protein concentration conditions) or 995 μ L of refold buffer was combined with 5 μ L of solubilized protein (for low protein concentration conditions).

5 Refolding reactions were placed on a rotary shaker in the cold room (4°C) overnight.

[0219] From results obtained in the screen, it was determined that refold conditions 3, 8, 11, 12, 15 and 16 yielded the most promising results for constructs 1 and 2. Additional refolding reactions were performed with under those conditions using G-50 gel filtration instead of dialysis to yield more concentrated protein refold samples (See Refold Purification 10 section for methods). From those experiments, further refinement was achieved and conditions 8 and 11 were found to be optimal. More specifically, condition 15 was optimal in an overnight incubation rotating and condition 8 was found to be optimal remaining still in a 5 day incubation.

[0220] Protein refold samples were first purified by dialysis against 20mM Tris-HCl, pH=8.5. 100 μ L of each refold sample was dialyzed. Dialysis was conducted in a beaker containing 20mM Tris-HCl pH=8.5 with slow stirring. Samples were placed at 4°C and allowed to dialyze overnight. Resulting retentate was used in a radioactive activity assay, as discussed elsewhere herein. As an alternative method to yield more concentrated protein samples, MBP-GalNAcT2 refold samples were purified by use of G-50 Macro Spin Columns 20 (Harvard Bioscience, Holliston, MA). Caps were removed from the G-50 columns and columns were placed into 2 ml microcentrifuge tubes. H₂O (500 μ l) was added to each column and the columns were allowed to incubate for 15 minutes to hydrate. The columns were then centrifuged at ~2000 x g for 4 minutes after which they were transferred to new 2 ml centrifuge tubes. Each refold solution (150 μ l) was applied to one of the columns. 25 Columns were then centrifuged at 2000 x g for ~2 minutes. Resulting permeates represented the purified refold samples.

[0221] A radiolabeled [³H]-UDP-GalNAc assay was performed to determine the activity of the E.coli-expressed refolded MBP-GalNAcT2 by monitoring the addition of radiolabeled GalNAc to a peptide acceptor. The acceptor was a MuC-2 – like peptide having the sequence 30 MVTPTPTPTC (SEQ ID NO:16). The peptide was dissolved in 1M Tris-HCl pH=8.0. The initial screen was performed on refolded protein samples which had been purified by dialysis. Subsequent refold samples were freshly refolded and purified by G-50 gel filtration. The assay included protein refold samples, GalNAcT2 from Baculovirus as a positive control, a

negative control sample with all the components except enzyme and a maximum input sample which contained all components except enzyme. A total of 19 samples were tested. The assay solution consisted of the components listed in Table 3:

Table 3: GalNAcT2 assay reaction composition.

| Component | Dilution | Volume (μl) | Final Concentration |
|---|----------------|-------------|---------------------|
| 0.25M Tris-HCl | N/A | 5 | 25mM |
| 2.5% Triton X-100 | N/A | 5 | 0.25% |
| 100mM MnCl ₂ | N/A | 5 | 10mM |
| [H ³] UDP-GalNAc 0.1mCi/ml | 0.5μl in 4.5μl | 5 | 50nCi |
| 1mM UDP-GalNAc | N/A | 5 | 0.1mM |
| 10mM MuC2 Peptide | 0.5μl in 4.5μl | 5 | 0.1mM |
| Enzyme | | 20 | |

[0222] For each of the refold samples, 30μL of the reaction mixture were combined with 20μL of the refold sample. For the negative control, 20μL H₂O was combined with 30μL of the reaction mixture. For the positive control, 1μL of GalNAcT2 Baculovirus enzyme was added in addition to 19μL of H₂O to form a 30μL reaction mixture. For the “maximum input” sample, 30μL of the reaction mixture was combined with 20μL of dH₂O. Reactions were incubated at 37°C for 30 minutes. 100 ml DOWEX AG 1X8 (chloride form) was washed by combining 100 ml of resin and 100 ml of H₂O and mixing well. The water was poured off the resin and another 100 ml of H₂O was added, mixed and removed. The resin was resuspended one final time in 100 ml of dH₂O. After the GalNAcT2 assay reaction had incubated for 30 minutes, 1 ml of resuspended resin in H₂O was added to each reaction (except for the maximum input sample). Samples were vortexed briefly and then loaded into filter columns and allowed to drain by gravity into scintillation vials. 5 ml of scintillation solution was added to each of the samples and standards. Samples were shaken briefly and loaded on the scintillation counter and radioactivity measured.

[0223] An IF α -2b assay was performed to determine whether E.coli-expressed refolded MBP-GalNAcT2 could transfer GalNAc to an interferon α -2b acceptor from a UDP-GalNAc donor. From data obtained in the refold screen (see the [³H]UDP-GalNAcT2 assay description elsewhere herein), it was shown that MBP-GalNAc constructs 1 and 2 in refold buffers 8 and 15 yielded the most active enzymes, as determined by the radioactive assay. Therefore, in the IF α -2b assay, constructs 1 and 2 in refold buffers 8 and 15 were assayed for transferase activity. Additionally, as a positive control, GalNAcT2 from a Baculovirus system was assayed as well.

[0224] The assay consisted of reaction buffer (27mM MES, pH=7, 200mM NaCl, 20mM MgCl₂, 20mM MnCl₂, and 0.1% Tween 80), IF α -2b Protein (2mg/ml in 50mM MES pH=6, 150mM NaCl, 0.05% Tween 80, 0.05% NaN₃), and 100mM UDP-GalNAc. The assay solution was prepared as shown in Table 4 for each reaction.

5 Table 4: Parameters for IF α -2b acceptor GalNAcT2 activity assay

| Reaction Buffer | Reaction Components | Reaction Component Volumes | Final Concentration |
|-----------------|--------------------------------|---|---------------------|
| | MES, pH=7 | | 20mM |
| | NaCl | 5 μ l from Rxn Buffer | 150mM |
| | MgCl ₂ | (additional concentration from IF α -2b dilution buffer) | 5mM |
| | MnCl ₂ | | 5mM |
| | Tween 80 | | 0.05% |
| | 2mg/ml IF α -2b Protein | 10 μ l | 1mg/ml |
| | 100mM UDP-GalNAc | 0.6 μ l | 3mM |

[0225] For each refold sample, 4.4 μ L of sample were added to 15 μ L of reaction solution.

10 For the positive control, 1 μ L of standard GalNAcT2 Baculovirus was added along with 3.4 μ L of H₂O to one tube. Reactions were incubated at 32°C on a rotary shaker for several days, during which time an overnight time point and a 5 day time point were assayed by MALDI.

[0226] The above assay was performed to determine whether E.coli-expressed refolded 15 MBP-GalNAcT2 could transfer GalNAc to G-CSF acceptor from a UDP-GalNAc donor. As above, construct 2 in refold buffer 8 was assayed for GalNAcT2 activity. Additionally, as a positive control, GalNAcT2 from Baculovirus was assayed. The assay consisted of reaction buffer (27mM MES, pH=7, 200mM NaCl, 20mM MgCl₂, 20mM MnCl₂, and 0.1% Tween 80), G-CSF Protein (2mg/ml in H₂O), and 100mM UDP-GalNAc. The assay solution was 20 prepared for each reaction as shown in Table 5.

Table 5: Parameters for G-CSF acceptor GalNAcT2 activity assay

| Reaction Buffer | Reaction Components | Reaction Component Volumes | Final Concentration |
|-----------------|---------------------|----------------------------|---------------------|
| | MES, pH=7 | | 20mM |
| | NaCl | | 150mM |
| | MgCl ₂ | 5µl of Rxn Buffer | 5mM |
| | MnCl ₂ | | 5mM |
| | Tween 80 | | 0.05% |
| | 2mg/ml G-CSF | 10µl | 1mg/ml |
| | 100mM UDP-GalNAc | 0.6µl | 3mM |

5 [0227] For the refold sample, 4.4µL of sample were added to 15µL of reaction solution. For the positive control, 1µL of standard GalNAcT2 Baculovirus was added along with 3.4µL of H₂O to one tube. Reactions were incubated at 32°C on a rotary shaker for 4 days, at the end of which a sample was taken and assayed by MALDI.

[0228] Pellet weights and inclusion body weight were determined for each of the four 1L

10 JM109 pCWin2 MBP-GalNAcT2 constructs 1 through 4 cultures, as shown in Table 22.

Table 6: Cell pellet weights versus inclusion body weights

| Pellet and Inclusion Body Weights from 1L JM109 pCWin2 MBP-GalNAcT2 Cultures | | |
|--|------------------------|---------------------------|
| JM109 pCWin2 MBP-GalNAcT2 Construct | Cell Pellet Weight (g) | Inclusion Body Weight (g) |
| 1 | 5.04 | 2.04 |
| 2 | 5.24 | 2.19 |
| 3 | 4.89 | 2.42 |
| 4 | 4.30 | 2.44 |

[0229] The expression of MBP-GalNAcT2 was observed by way of the SDS-Page gel analysis of JM109 pCWin2 MBP-GalNAcT2 whole cell samples before and after induction 15 by IPTG (Figure 7). The protein gel shows a clear increase in protein expression in the induced state compared to the uninduced state. Furthermore there is a distinct band at ~100kDa that substantially increases after induction which correlates to the expected size of the MBP-GalNAcT2 band.

[0230] Protein samples were diluted by combining 950µL of H₂O with 50µL of protein 20 sample. Samples were then analyzed using a UV spectrophotometer. Protein concentration

was calculated from absorption values and the molar extinction coefficients: Construct 1 – 0.65mg/ml per 1 A₂₈₀ unit, Construct 2 – 0.64mg/ml per 1 A₂₈₀ unit, as shown in Table 7.

5 Table 7: Protein concentration of 1L JM109 pCWin2 MBP-GalNAcT2 Cultures after Solubilization and G-50 Purification

| JM109 pCWin2 MBP- GalNAcT2 Construct | A ₂₈₀ After Solubilization | Protein Concentration (mg/ml) | A ₂₈₀ After G-50 Purification | Protein Concentration (mg/ml) |
|---|--|-------------------------------------|---|-------------------------------------|
| 1 | 0.2827 | 2.5 | 0.0100 | 0.156 |
| 2 | 0.2531 | 2.4 | 0.0160 | 0.102 |

10 [0231] Inclusion bodies obtained from JM109 pCWin2 MBP-GalNAcT2 constructs 1 and 2 were analyzed using SDS-PAGE to verify the presence of MBP-GalNAcT2. The protein was clearly observed in both lanes of the gel, running at approximately 100kDa (Figure 8).

15 [0232] All four constructs were tested in a [³H]UDP-GalNAcT2 assay under all 16 refold conditions available in the Hampton Foldit kit (Hampton Research, Aliso Viejo, CA). Refolded truncated enzymes were purified by dialysis and then tested for activity using the radioactive assay, as shown in Table 8.

Table 8: Results of the GalNAcT2 activity assay for refolded proteins

| Refold Condition | Raw CPM | | | | | | | | | | | | | | | |
|------------------------------|---------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| Colony 1 | 112 | 119 | 155 | 150 | 131 | 168 | 167 | 243 | 111 | 144 | 218 | 218 | 166 | 114 | 214 | 194 |
| Colony 2 | 119 | 121 | 251 | 143 | 132 | 156 | 160 | 221 | 121 | 166 | 230 | 184 | 139 | 137 | 224 | 222 |
| Colony 3 | 125 | 113 | 207 | 139 | 96 | 123 | 143 | 170 | 100 | 110 | 134 | 104 | 143 | 114 | 174 | 180 |
| Colony 4 | 122 | 123 | 125 | 150 | 132 | 120 | 119 | 135 | 127 | 121 | 148 | 154 | 121 | 95 | 157 | 165 |
| Average for Refold Condition | 119.5 | 119.0 | 184.5 | 145.5 | 122.8 | 141.8 | 147.3 | 192.3 | 114.8 | 135.3 | 182.5 | 185.0 | 142.3 | 115.0 | 192.3 | 190.3 |
| Negative Control | 102 | | | | | | | | | | | | | | | |
| Positive Control | 1585 | | | | | | | | | | | | | | | |
| Refold Condition | Corrected CPM | | | | | | | | | | | | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| Colony 1 | 10 | 17 | 53 | 48 | 29 | 66 | 65 | 141 | 9 | 42 | 116 | 116 | 64 | 12 | 112 | 92 |
| Colony 2 | 17 | 19 | 149 | 41 | 30 | 54 | 58 | 119 | 19 | 64 | 128 | 82 | 37 | 35 | 122 | 120 |
| Colony 3 | 23 | 11 | 105 | 37 | 6 | 21 | 41 | 68 | -2 | 8 | 32 | 82 | 41 | 12 | 72 | 78 |
| Colony 4 | 20 | 21 | 23 | 48 | 30 | 18 | 17 | 33 | 25 | 19 | 46 | 52 | 19 | -7 | 55 | 63 |
| Average for Refold Condition | 17.5 | 17.0 | 82.5 | 43.5 | 20.8 | 39.8 | 45.3 | 90.3 | 12.8 | 33.3 | 80.5 | 83.0 | 40.3 | 13.0 | 90.3 | 88.3 |

20 [0233] Results from this assay indicated that refold conditions 3, 8, 11, 12, 15 and 16 provided the highest CPM and therefore the greatest potential GalNAcT2 activity. Furthermore it appeared that construct 2 yielded the greatest number of positive hits in this assay, therefore efforts were focused on this construct.

Table 9: Results from focused overnight refold of truncated enzymes

| Refold Condition | Raw CPM3 | | | | | |
|------------------|----------|------|------------------------------------|------|------|------|
| | 3 | 8 | 11 | 12 | 15 | 16 |
| Construct 2 | 924 | 1197 | 689 | 1585 | 1701 | 1561 |
| Negative Control | | 277 | | | | |
| Positive Control | | 4919 | (1 μ l of 200ug/ml STD Enzyme) | | | |

| Refold Condition | Corrected CPM3 | | | | | |
|------------------|----------------|-----|-----|------|------|------|
| | 3 | 8 | 11 | 12 | 15 | 16 |
| Construct 2 | 647 | 920 | 412 | 1308 | 1424 | 1284 |

Activity:

$$U/L = \frac{CPM \times (\text{nmoles Donor}) \times 100\mu\text{l/ml}}{(\text{Input CPM}) \times (0.35/0.55) \times (\text{Assay Incubation Time(minutes)}) \times \text{Volume Enzyme } (\mu\text{l})}$$

| | |
|---------------------------------|-------|
| nmoles Donor (UDP-GalNAc) | 5 |
| Assay Incubation Time (minutes) | 30 |
| Volume Enzyme (μ l) | 20 |
| Maximum Input | 48998 |

| | Activity U/L | | | | | |
|------------------|--------------|------|------|------|------|-------|
| | 3 | 8 | 11 | 12 | 15 | 16 |
| Construct 2 | 0.17 | 0.25 | 0.11 | 0.35 | 0.38 | 0.34 |
| Positive Control | | | | | | 26.29 |

[0234] In this assay, construct 2 was tested under refold conditions 3, 8, 11, 12, 15 and 16 from the Hampton Foldit kit (Hampton Research, Aliso Viejo, CA). These refolded enzymes were purified by G-50 gel filtration and then tested for activity by the radioactive assay. Results indicate that after overnight incubation on a rotator, greatest activity was obtained from refold condition 15.

Table 10: GalNAcT2 activity results from 5 day refolding experiment

| Refold Condition | Raw CPM3 - 5 Day Refold | | | | | |
|------------------|-------------------------|------|-----|-----|-----|-----|
| | 3 | 8 | 11 | 12 | 15 | 16 |
| Construct 2 | 185 | 2288 | 186 | 226 | 496 | 270 |
| Negative Control | | 129 | | | | |
| Positive Control | | 3612 | | | | |

(1μl of 200ug/ml STD Enzyme)

| Refold Condition | Corrected CPM3 - 5 Day Refold | | | | | |
|------------------|-------------------------------|------|----|----|-----|-----|
| | 3 | 8 | 11 | 12 | 15 | 16 |
| Construct 2 | 56 | 2159 | 57 | 97 | 367 | 141 |

Activity:

$$U/L = \frac{CPM \times (\text{nmoles Donor}) \times 100\mu\text{l/ml}}{(\text{Input CPM}) \times (0.35/0.55) \times (\text{Assay Incubation Time(minutes)}) \times \text{Volume Enzyme } (\mu\text{l})}$$

| | |
|---------------------------------|-------|
| nmoles Donor (UDP-GalNAc) | 5 |
| Assay Incubation Time (minutes) | 30 |
| Volume Enzyme (μl) | 20 |
| Maximum Input | 47527 |

| | Activity U/L - 5 Day Refold | | | | | | Positive Control |
|-------------|-----------------------------|------|------|------|------|------|------------------|
| | 3 | 8 | 11 | 12 | 15 | 16 | |
| Construct 2 | 0.02 | 0.59 | 0.02 | 0.03 | 0.10 | 0.04 | 19.90 |

[0235] In this assay, construct 2 was tested under refold conditions 3, 8, 11, 12, 15 and 16 from the Hampton Foldit kit (Hampton Research, Aliso Viejo, CA) after being rotated overnight at 4°C and left resting at 4°C for 5 days. These refolded enzymes were purified by G-50 gel filtration and then tested for activity by the radioactive assay. Results indicated that after 5 days in refold buffer 8, construct 8 displayed the highest activity. Therefore it was determined that conditions 8 and 15 had the greatest potential for producing a properly folded and active MBP-GalNAcT2.

[0236] An IF α -2b assay was performed on overnight refolds of constructs 1 and 2 in refold buffer 15 (1-15 and 2-15, respectively) and was incubated at 32°C for 5 days. Time points were taken of the IF α -2b reaction at 16 hours and 5 days. The results indicate that the parental peak for IF α -2b is at MW ~19267. A successful reaction would be indicated by addition of ~203 molecular weight to that peak. From the 5 day data for refolds 1-15 and 2-15, a developing peak was observed at ~119478 and ~19473 respectively, a difference of approximately 203 MW. This data illustrated that GalNAc was added to IF α -2b by the refolded GalNAcT2 protein, thereby confirming the activity that was reported elsewhere herein by the radioactive assay.

[0237] Additionally, the IF α -2b assay was performed with the 5-day refolded enzymes of constructs 1 and 2 in refold buffer 8 (1-8 and 2-8, respectively). The IF α -2b reactions were again allowed to incubate at 32°C for 3 days. Reactions were analyzed at the 3 day time point. The results indicated that the parental peak for IF α -2b is at MW ~19263. A successful reaction would be indicated by the addition of ~203 molecular weight to that peak. From the 3 day data for refolds 1-8 and 2-8 a developing peak is seen at ~19462 and 19469 respectively, again a difference of approximately 203 MW. This data again indicated that GalNAc was added to IF α -2b by the refolded GalNAcT2 protein and confirmed what was reported by the radioactive assay.

[0238] A G-CSF assay was performed on the 5-day refolded enzymes of construct 2 in refold buffer 8. The G-CSF reaction was allowed to incubate at 32°C for 4 days. The reaction was analyzed at the 4 day time point. The parental peak for G-CSF is expected at MW ~18786. A successful reaction would be indicated by addition of ~203 molecular weight to that peak. From the 3 day data for refolded enzymes 2-8, a developing peak was observed at ~19001, a difference of approximately 203 MW. This data again indicated that GalNAc was added to G-CSF by the refolded GalNAcT2 protein and confirmed what was reported by the radioactive assay and the IF α -2b assay as reported elsewhere herein.

[0239] In summary, the data presented herein illustrates that E.coli-expressed MBP-GalNAcT2 can be refolded into an active enzyme. Under refold conditions 8 and 15, found in Hampton Research's Foldit kit (Hampton Research, Aliso Viejo, CA), active conformations of MBP-GalNAcT2 construct 1 and 2 were obtained. The generation of a functional refolded protein was shown using radioactive, IF α -2b and G-CSF assays, which demonstrated the transfer of GalNAc to a polypeptide by GalNAcT2 truncation mutants of the present invention.

[0240] As discussed elsewhere herein, GalNAcT2 truncation mutants of the present invention are also useful for the transfer of a glycosyl-polyethyleneglycol ("glycosyl-PEG") conjugate to a polypeptide, also known as "glycoPEGylation" of a polypeptide. Using a purified, refolded Δ 51 GalNAcT2-MBP fusion made according to the present invention, it was shown that Δ 51 GalNAcT2-MBP is capable of transferring a GalNAc-sialic acid (SA)-PEG conjugate to G-CSF.

[0241] A glycoPEGylation reaction mixture was prepared in order to glycoPEGylate G-CSF. The reaction mixture contained 5 μ l of Δ 51 GalNAcT2-MBP (20 μ U), 2 μ l of GalNAc-

α 2,6-sialyltransferase (ST6GalNAcI), 6.25 mM MnCl₂, 15 mM UDP-GalNAc, 0.75 mM CMP-SA-PEG (20K), and between 2 μ l and 10 μ l of 2 mg/ml G-CSF. Gel electrophoresis of the reaction products demonstrated that Δ 51 GalNAcT2-MBP transferred a GalNAc-sialic acid (SA)-PEG conjugate to G-CSF (Figure 9).

5 Example 3: Optimization of Purification and Refolding of Δ 51 GalNAcT2-MBP

[0242] Δ 51 GalNAcT2 refolding and purification development as set forth herein demonstrates the utility of a two column purification procedure for purification of GalNAcT2 mutants. The use of Q Sepharose Fast Flow in binding mode and Q Sepharose XL in binding and flow through mode as an initial purification step has been explored. Q Sepharose XL in flow through mode using a NaCl concentration of 100mM in the load led to best recovery and purity of active Δ 51 GalNAcT2-MBP. The use of Hydroxyapatite Type I has been considered as a second column step. Initial data indicate Δ 51 GalNAcT2-MBP binds to this resin and can be eluted as an active enzyme with a phosphate gradient.

[0243] Δ 51 GalNAcT2-MBP was cloned and expressed as set forth elsewhere herein. To produce double-washed inclusion bodies (DWIBs) containing the expressed Δ 51 GalNAcT2-MBP, harvested cell pellet was resuspended in 10mM Tris/ 5mM EDTA pH 7.5 (5mL/g cells) and lysed in two passes using a microfluidizer at 12,000psi. Inclusion bodies were harvested by centrifugation at 6,000 rpm for 20 min in a Sorvall RC-3B. The pellet was washed twice by resuspension in above buffer at 5mL/g pellet followed by centrifugation at 6,000 RPM for 20min. DWIBs were aliquoted and stored at -20°C.

[0244] Initial studies indicated that urea solubilization leads to higher Δ 51 GalNAcT2-MBP activities of refolded material than does guanidine hydrochloride solubilization. Therefore, Δ 51 GalNAcT2-MBP was solubilized in 7M urea/ 50mM Tris/ 10mM DTT/ 5mM EDTA pH 8.0 for all subsequent experiments.

25 *1. Refolding experiments – pH scout*

[0245] A pH scout was performed to identify the best pH for Δ 51 GalNAcT2-MBP refolding.

Table 11: Reaction parameters for pH scouting of Δ 51 GalNAcT2-MBP refolding conditions

| Sample ref. no.: | 1b | 1a | 2a | 2b | 3 |
|----------------------------------|------|------|------|------|------|
| MES (mM) | 50 | 50 | | | |
| Tris (mM) | | | 50 | 50 | 50 |
| L-Arginine (mM) | 550 | 550 | 550 | 550 | 550 |
| NaCl (mM) | 250 | 250 | 250 | 250 | 10 |
| KCl (mM) | 10 | 10 | 10 | 10 | |
| PEG 3350 (%) | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| L-cysteine (mM) | 4 | 4 | 4 | 4 | 4 |
| L-cystamine dihydrochloride (mM) | 1 | 1 | 1 | 1 | 1 |
| MnCl ₂ (mM) | | | | | 1 |
| pH | 5.5 | 6.5 | 8.0 | 8.5 | 8.0 |

[0246] Δ 51 GalNAcT2-MBP refolds were performed by solubilizing 2.5g of DWIB's in

5 250 mL of 7M urea/ 50mM Tris/ 10mM DTT/ 5mM EDTA pH 8.0 at 4°C. 50mL solubilized Δ 51 GalNAcT2-MBP DWIB's were added to 1L of refold buffer at 4°C while stirring (21-fold dilution – 0.5mg/mL). Refolding was allowed to proceed for 20.5h at 4°C with stirring.

[0247] Refolds were filtered using a Cuno Zeta Plus BioCap (Cuno, Meriden, CT),

concentrated 4-fold and diafiltered on a 1 ft² 30kDa MWCO TFF (regenerated cellulose)

10 filter at constant volume with 5 diavolumes of 10mM Tris/ 5mM NaCl pH 8.

[0248] Concentrated and diafiltered refolds were loaded onto a pre-equilibrated 48mL Q

Sepharose Fast Flow column (Amersham Biosciences, Piscataway, NJ) and washed with 2

column volumes (CVs) of low salt buffer (10mM Tris/5mM NaCl pH 8.0). Protein was eluted

15 with a 15CV gradient from 0 to 50% high salt buffer (10mM Tris/1M NaCl pH 8.0) followed

by a 1CV gradient to 100% high salt buffer. The column was regenerated with 0.5M NaOH.

[0249] The highest Δ 51 GalNAcT2-MBP activity was achieved using refold 2a conditions (pH 8.0) in combination with urea solubilization. Active Δ 51 GalNAcT2-MBP eluted early during QSFF elution. The 1L refold yielded a total of 420mU Δ 51 GalNAcT2-MBP.

[0250] Additional refolding conditions for Δ 51 GalNAcT2-MBP were screened. Refolding

20 buffer containing 55 mM MES pH 6.5, 264 mM NaCl, 11 mM KCl, 0.055% PEG 3350 and

550 mM L-Arginine and refolding buffer containing 55 mM Tris-HCl pH 8.0, 10.56 mM

NaCl, 0.44 mM KCl, 0.055% PEG 3350 and 550 mM L-arginine were screened. Four

conditions were screened using the two buffers, namely, solubilization at pH 6.5 followed by

refolding at pH 6.5, solubilization at pH 6.5 followed by refolding at pH 8.0, solubilization at

pH 8.0 followed by refolding at pH 6.5, and solubilization at pH 8.0 followed by refolding at pH 8.0. Assays of Δ 51 GalNAcT2-MBP refolded under all four conditions demonstrated enzymatic activity, the ability to transfer GalNAc to GCSF.

2. Δ 51 GalNAcT2-MBP Purification

5 [0251] The use of Q Sepharose Fast Flow (QSFF) and Q Sepharose XL (QXL) (Amersham Biosciences, Piscataway, NJ) in Δ 51 GalNAcT2-MBP purification was examined. QSFF was used in binding mode. For this purpose, concentrated diafiltered Δ 51 GalNAcT2-MBP refolds (in 10mM Tris/5mM NaCl pH 8.0 - A) were applied onto a pre-equilibrated 50mL QSFF column and eluted using a gradient from 10mM Tris/ 5mM NaCl pH 8.0 to 50% 10mM Tris/ 1M NaCl pH 8.0 (B) over 15 CV, followed by a second gradient from 50 to 100% B over 1CV.

10 [0252] QXL was used in binding and in flow through mode. The NaCl concentration in the concentrated diafiltered Δ 51 GalNAcT2-MBP refold material (40mL each = 160mL refold volume) was adjusted to 5, 50, 100, and 200mM NaCl prior to application onto a 3.9mL QXL 15 column. The column was washed with 2CV and bound protein was eluted with a 30CV gradient from A to B.

20 [0253] Δ 51 GalNAcT2-MBP bound tightly to QSFF resin under above conditions with 5mM NaCl in load and equilibration buffers. Active Δ 51 GalNAcT2-MBP eluted at the beginning of the major peak and appears as a doublet on a nonreduced 4-20% Tris-glycine gel. The major contaminant is a currently unidentified band running at a slightly lower molecular weight close to the 98kDa marker band. A variety of other contaminants elute with inactive Δ 51 GalNAcT2-MBP in the remainder of the major peak.

25 [0254] Δ 51 GalNAcT2-MBP bound tightly to QXL resin if the same conditions as for QSFF binding were applied (i.e. 5mM NaCl). Increasing Δ 51 GalNAcT2-MBP activity was observed in flow through and wash at higher NaCl concentrations in the load. Interestingly, the major contaminating band observed in QSFF purification was not visible in the flow through if the load contained 50 and 100mM NaCl. At both NaCl concentrations the majority of active Δ 51 GalNAcT2-MBP could be found in flow through and wash; only some residual Δ 51 GalNAcT2-MBP activity was detected in the left shoulder of the elution peak. As 30 observed with QSFF resin, the bulk of contaminating bands was observed in the major elution peak. Although the majority of active Δ 51 GalNAcT2-MBP was located in the flow through if the salt concentration of the load was adjusted to 200mM, no significant

purification was achieved under this condition. In conclusion, optimum NaCl concentration for the use of QXL in FT mode would be higher than 50mM NaCl, but below 200mM NaCl. On the basis of these data, 100mM NaCl is a suitable concentration in the load and in the equilibration buffer in order to use the anion exchange resin in flowthrough mode.

5 [0255] Hydroxyapatite Type I (80 μ m) (BioRad, Hercules, CA) was examined as a second column step. Active Δ 51 GalNAcT2-MBP partially purified over QSFF (using bind and elute mode) was used to investigate if active Δ 51 GalNAcT2-MBP would bind to an HA Type I resin and would be useful to further purify the protein. For this purpose, a 2.25 mL HA Type I column was pre-equilibrated with 5mM NaPO₄/ 5mM NaCl pH 7.0 (C). Active Δ 51

10 GalNAcT2-MBP eluted from QSFF was adjusted to pH 7.0 with 1M HCl and applied onto the HA Type I column. The protein was eluted using a 20 CV gradient from 0-50% 300mM NaPO₄/ 5mM NaCl pH 7.0 (D), followed by a 5 CV gradient from 50-100% D. The column was regenerated using 0.5M NaOH. The data obtained indicate that Δ 51 GalNAcT2-MBP binds to hydroxyapatite type I resin and can be eluted as an active enzyme.

15 [0256] The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

[0257] While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The 20 appended claims are intended to be construed to include all such embodiments and equivalent variations.

SEQUENCE LISTING

5 <110> Neose Technologies, Inc.
 Johnson, Karl
 Chen, Xi

10 <120> Truncated GalNAcT2 Polypeptides and Nucleic Acids

15 <130> 040853-01-5149PR

20 <160> 16

25 <170> PatentIn version 3.2

30 <210> 1

35 <211> 1713

40 <212> DNA

45 <213> human

50 <220>

55 <221> misc_feature

60 <223> wild-type GalNAcT2

65 <400> 1
25 atgcggcggc gctcgccggat gctgctctgc ttgcgccttcc tgtgggtgat gggcatcgcc 60

30 tactacatgt actcgggggg cggctctgcg ctggccgggg gcgcggggcgg cggcgccggc 120

35 aggaaggagg actggaatga aattgacccc attaaaaaga aagaccttca tcacagcaat 180

40 ggagaagaga aagcacaaag catggagacc ctccctccag ggaaagtacg gtggccagac 240

45 tttaaccagg aagcttatgt tggagggacg atggtccgct ccgggcagga cccttacgcc 300

50 cgcaacaagt tcaaccagggt ggagagtgtat aagcttcgaa tggacagagc catccctgac 360

55 acccggcatg accagtgtca gcggaagcag tggcggtgg atctgccggc caccagcgtg 420

60 gtgatcacgt ttcacaatga agccaggtcg gccctactca ggaccgtgg cagcgtgctt 480

65 aagaaaagcc cgccccatct cataaaagaa atcatcttgg tggatgacta cagcaatgat 540

70 cctgaggacg gggctctctt gggaaaatt gagaaagtgc gagttcttag aatgatcga 600

75 cgagaaggcc tcatgcgctc acgggttcgg gggccgatg ctgccaagc caaggctctg 660

80 accttcttgg acagtcactg cgagtgtat gagcactggc tggagccctt cctggaaagg 720

85 gtggcggagg acaggactcg ggttgtgtca cccatcatcg atgtcattaa tatggacaac 780

90 tttcagttatg tgggggcatac tgctgacttg aaggcggtt ttgatggaa cttggatttc 840

95 aagtggatt acatgacgac tgagcagaga aggtcccgac agggaaaccc agtcgcccct 900

100 ataaaaaccc ccatgattgc tgggtggctg tttgtatgg ataagttcta ttttgaagaa 960

105 ctggggaaagt acgacatgtat gatggatgtg tggggaggag agaacatcaga gatctcgatc 1020

110 cgcgtgtggc agtgtgggtgg cagcctggag atcatcccgt gcagccgtgt gggacacgtg 1080

115 ttccggaaagc agcaccccta cacgttccccg ggtggcagtg gcactgtctt tgccccgaaac 1140

acccgccggg cagcagaggt ctggatggat gaatacAAAAA atttcttatta tgcagcagtG 1200
 ccttctgcta gaaacgttcc ttatggAAat attcagagca gattggagct taggaagAAA 1260
 5 ctcagctgca agcctttcaa atgg tacctt gaaaatgtct atccagagtt aagggttcca 1320
 gaccatcagg atata gcttt tggggccttG cagcaggaa ctaactgcct cgacactttG 1380
 10 ggacactttG ctgatgggtG ggttggagtt tatgaatgtc acaatgctgg gggaaaccag 1440
 gaatgggcct tgacgaagga gaagtcggtg aagcacatgg atttgtgcct tactgtggtg 1500
 gaccgggcac cgggctcttG tataaagctG cagggctgccc gagaaaaatga cagcagacag 1560
 15 aaatgggaac agatcgaggg caactccaag ctgaggcacG tgggcagcaa cctgtgcctG 1620
 gacagtgcac cggccaagag cgggggccta agcgtggagg tgtgtggccc gcccctttG 1680
 cagcagtggG agttcacGct caacctgcag cag 1713
 20

<210> 2
 <211> 571
 <212> PRT
 25 <213> human
 <220>
 <221> MISC_FEATURE
 <223> wild-type GalNAcT2

30 <400> 2

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Arg | Arg | Arg | Ser | Arg | Met | Leu | Leu | Cys | Phe | Ala | Phe | Leu | Trp | Val |
| 1 | | | | | | 5 | | | 10 | | | | 15 | | |

35 Leu Gly Ile Ala Tyr Tyr Met Tyr Ser Gly Gly Gly Ser Ala Leu Ala
 20 25 30

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Gly | Ala | Gly | Gly | Ala | Gly | Arg | Lys | Glu | Asp | Trp | Asn | Glu | Ile |
| 35 | | | | | | 40 | | | | | 45 | | | |

40 Asp Pro Ile Lys Lys Asp Leu His His Ser Asn Gly Glu Glu Lys
 50 55 60

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Gln | Ser | Met | Glu | Thr | Leu | Pro | Pro | Gly | Lys | Val | Arg | Trp | Pro | Asp |
| 65 | | | | | | 70 | | | 75 | | | 80 | | | |

45 Phe Asn Gln Glu Ala Tyr Val Gly Gly Thr Met Val Arg Ser Gly Gln
 85 90 95

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Pro | Tyr | Ala | Arg | Asn | Lys | Phe | Asn | Gln | Val | Glu | Ser | Asp | Lys | Leu |
| 100 | | | | | | | 105 | | | | 110 | | | | |

50 Arg Met Asp Arg Ala Ile Pro Asp Thr Arg His Asp Gln Cys Gln Arg
 115 120 125

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Gln | Trp | Arg | Val | Asp | Leu | Pro | Ala | Thr | Ser | Val | Val | Ile | Thr | Phe |
| 130 | | | | | | 135 | | | | 140 | | | | | |

55 His Asn Glu Ala Arg Ser Ala Leu Leu Arg Thr Val Val Ser Val Leu
 145 150 155 160

Lys Lys Ser Pro Pro His Leu Ile Lys Glu Ile Ile Leu Val Asp Asp
 165 170 175
 5 Tyr Ser Asn Asp Pro Glu Asp Gly Ala Leu Leu Gly Lys Ile Glu Lys
 180 185 190
 Val Arg Val Leu Arg Asn Asp Arg Arg Glu Gly Leu Met Arg Ser Arg
 195 200 205
 10 Val Arg Gly Ala Asp Ala Ala Gln Ala Lys Val Leu Thr Phe Leu Asp
 210 215 220
 Ser His Cys Glu Cys Asn Glu His Trp Leu Glu Pro Leu Leu Glu Arg
 225 230 235 240
 15 Val Ala Glu Asp Arg Thr Arg Val Val Ser Pro Ile Ile Asp Val Ile
 245 250 255
 20 Asn Met Asp Asn Phe Gln Tyr Val Gly Ala Ser Ala Asp Leu Lys Gly
 260 265 270
 Gly Phe Asp Trp Asn Leu Val Phe Lys Trp Asp Tyr Met Thr Pro Glu
 275 280 285
 25 Gln Arg Arg Ser Arg Gln Gly Asn Pro Val Ala Pro Ile Lys Thr Pro
 290 295 300
 Met Ile Ala Gly Gly Leu Phe Val Met Asp Lys Phe Tyr Phe Glu Glu
 305 310 315 320
 30 Leu Gly Lys Tyr Asp Met Met Asp Val Trp Gly Gly Glu Asn Leu
 325 330 335
 Glu Ile Ser Phe Arg Val Trp Gln Cys Gly Gly Ser Leu Glu Ile Ile
 35 340 345 350
 Pro Cys Ser Arg Val Gly His Val Phe Arg Lys Gln His Pro Tyr Thr
 355 360 365
 40 Phe Pro Gly Gly Ser Gly Thr Val Phe Ala Arg Asn Thr Arg Arg Ala
 370 375 380
 Ala Glu Val Trp Met Asp Glu Tyr Lys Asn Phe Tyr Tyr Ala Ala Val
 385 390 395 400
 45 Pro Ser Ala Arg Asn Val Pro Tyr Gly Asn Ile Gln Ser Arg Leu Glu
 405 410 415
 Leu Arg Lys Lys Leu Ser Cys Lys Pro Phe Lys Trp Tyr Leu Glu Asn
 50 420 425 430
 Val Tyr Pro Glu Leu Arg Val Pro Asp His Gln Asp Ile Ala Phe Gly
 435 440 445
 55 Ala Leu Gln Gln Gly Thr Asn Cys Leu Asp Thr Leu Gly His Phe Ala
 450 455 460
 Asp Gly Val Val Gly Val Tyr Glu Cys His Asn Ala Gly Gly Asn Gln
 465 470 475 480
 60 Glu Trp Ala Leu Thr Lys Glu Lys Ser Val Lys His Met Asp Leu Cys

| | 485 | 490 | 495 |
|----|---|------|-----|
| | Leu Thr Val Val Asp Arg Ala Pro Gly Ser Leu Ile Lys Leu Gln Gly | | |
| | 500 | 505 | 510 |
| 5 | Cys Arg Glu Asn Asp Ser Arg Gln Lys Trp Glu Gln Ile Glu Gly Asn | | |
| | 515 | 520 | 525 |
| 10 | Ser Lys Leu Arg His Val Gly Ser Asn Leu Cys Leu Asp Ser Arg Thr | | |
| | 530 | 535 | 540 |
| | Ala Lys Ser Gly Gly Leu Ser Val Glu Val Cys Gly Pro Ala Leu Ser | | |
| | 545 | 550 | 555 |
| 15 | Gln Gln Trp Lys Phe Thr Leu Asn Leu Gln Gln | | |
| | 565 | 570 | |
| 20 | <210> 3 | | |
| | <211> 1593 | | |
| | <212> DNA | | |
| | <213> human | | |
| | <220> | | |
| | <221> misc_feature | | |
| 25 | <223> delat 40 GalNAcT2 | | |
| | <400> 3 | | |
| | aggaaggagg actggaatga aattgacccc attaaaaaga aagaccttca tcacagcaat | 60 | |
| 30 | ggagaagaga aagcacaaag catggagacc ctccctccag ggaaagtacg gtggccagac | 120 | |
| | tttaaccagg aagcttatgt tggagggacg atggtccgct ccgggcagga cccttacgcc | 180 | |
| 35 | cgcaacaagt tcaaccaggt ggagagtgtat aagcttcgaa tggacagagc catccctgac | 240 | |
| | acccggcatg accagtgtca gcggaagcag tggcgggtgg atctgccggc caccagcgtg | 300 | |
| | gtgatcacgt ttcacaatga agccaggtcg gccctactca ggaccgtgg cagcgtgctt | 360 | |
| 40 | aagaaaagcc cgccccatct cataaaagaa atcatcttgg tggatgacta cagcaatgtat | 420 | |
| | cctgaggacg gggctctt gggaaaatt gagaaagtgc gagttcttag aaatgatcga | 480 | |
| 45 | cgagaaggcc tcatgcgtc acgggttcgg gggccgtatg ctgccaagc caaggcctg | 540 | |
| | accttcctgg acagtcactg cgagtgtat gagcactggc tggagccctt cctggaaagg | 600 | |
| | gtggcggagg acaggactcg ggttgtgtca cccatcatcg atgtcattaa tatggacaac | 660 | |
| 50 | tttcagtatg tggggcatc tgctgacttg aagggcggtt ttgattggaa cttggatattc | 720 | |
| | aagtggatt acatgacgcc tgagcagaga aggtcccgcc agggaaaccc agtcgccc | 780 | |
| 55 | ataaaaaaccc ccatgattgc tggggctg tttgtatgg ataagttcta ttttgaagaa | 840 | |
| | ctggggaaatg acgacatgtat gatggatgtg tggggaggag agaacctaga gatctcgatc | 900 | |
| | cgcgtgtggc agtgtggatgg cagcctggag atcatccgt gcagccgtgt gggacacgtg | 960 | |
| 60 | ttccggaaagc agcaccccta cacgttcccg ggtggcagtg gcactgtctt tgccccaaac | 1020 | |

accccccggg cagcagaggt ctggatggat gaatacaaaaa atttcttatta tgcagcagtg 1080
 ctttctgcta gaaacgttcc ttatggaaat attcagagca gattggagct taggaagaaa 1140
 5 ctcagctgca agccttcaa atggtacctt gaaaatgtct atccagagtt aagggttcca 1200
 gaccatcagg atatagctt tggggccttg cagcagggaa ctaactgcct cgacactttg 1260
 10 ggacactttg ctgatggtgt ggttggagtt tatgaatgtc acaatgtgg gggaaaccag 1320
 gaatgggcct tgacgaagga gaagtcggtg aagcacatgg atttgcct tactgtggtg 1380
 gaccgggcac cgggctctct tataaagctg cagggctgcc gagaaaatga cagcagacag 1440
 15 aaatgggaac agatcgaggg caactccaag ctgaggcacg tgggcagcaa cctgtgcctg 1500
 gacagtgcga cggccaagag cgggggccta agcgtggagg tgtgtggccc ggccctttcg 1560
 20 cagcagtgga agttcacgct caacctgcag cag 1593
 <210> 4
 <211> 531
 <212> PRT
 25 <213> human
 <220>
 <221> MISC_FEATURE
 <223> delta 40 GalNAcT2
 30 <400> 4

 Arg Lys Glu Asp Trp Asn Glu Ile Asp Pro Ile Lys Lys Lys Asp Leu
 1 5 10 15

 35 His His Ser Asn Gly Glu Glu Lys Ala Gln Ser Met Glu Thr Leu Pro
 20 25 30

 Pro Gly Lys Val Arg Trp Pro Asp Phe Asn Gln Glu Ala Tyr Val Gly
 35 40 45
 40 Gly Thr Met Val Arg Ser Gly Gln Asp Pro Tyr Ala Arg Asn Lys Phe
 50 55 60

 45 Asn Gln Val Glu Ser Asp Lys Leu Arg Met Asp Arg Ala Ile Pro Asp
 65 70 75 80

 Thr Arg His Asp Gln Cys Gln Arg Lys Gln Trp Arg Val Asp Leu Pro
 85 90 95

 50 Ala Thr Ser Val Val Ile Thr Phe His Asn Glu Ala Arg Ser Ala Leu
 100 105 110

 Leu Arg Thr Val Val Ser Val Leu Lys Lys Ser Pro Pro His Leu Ile
 115 120 125
 55 Lys Glu Ile Ile Leu Val Asp Asp Tyr Ser Asn Asp Pro Glu Asp Gly
 130 135 140

 60 Ala Leu Leu Gly Lys Ile Glu Lys Val Arg Val Leu Arg Asn Asp Arg
 145 150 155 160

Arg Glu Gly Leu Met Arg Ser Arg Val Arg Gly Ala Asp Ala Ala Gln
 165 170 175
 Ala Lys Val Leu Thr Phe Leu Asp Ser His Cys Glu Cys Asn Glu His
 5 180 185 190
 Trp Leu Glu Pro Leu Leu Glu Arg Val Ala Glu Asp Arg Thr Arg Val
 195 200 205
 10 Val Ser Pro Ile Ile Asp Val Ile Asn Met Asp Asn Phe Gln Tyr Val
 210 215 220
 Gly Ala Ser Ala Asp Leu Lys Gly Gly Phe Asp Trp Asn Leu Val Phe
 225 230 235 240
 15 Lys Trp Asp Tyr Met Thr Pro Glu Gln Arg Arg Ser Arg Gln Gly Asn
 245 250 255
 Pro Val Ala Pro Ile Lys Thr Pro Met Ile Ala Gly Gly Leu Phe Val
 20 260 265 270
 Met Asp Lys Phe Tyr Phe Glu Glu Leu Gly Lys Tyr Asp Met Met Met
 275 280 285
 25 Asp Val Trp Gly Gly Glu Asn Leu Glu Ile Ser Phe Arg Val Trp Gln
 290 295 300
 Cys Gly Gly Ser Leu Glu Ile Ile Pro Cys Ser Arg Val Gly His Val
 30 305 310 315 320
 30 Phe Arg Lys Gln His Pro Tyr Thr Phe Pro Gly Gly Ser Gly Thr Val
 325 330 335
 Phe Ala Arg Asn Thr Arg Arg Ala Ala Glu Val Trp Met Asp Glu Tyr
 35 340 345 350
 Lys Asn Phe Tyr Tyr Ala Ala Val Pro Ser Ala Arg Asn Val Pro Tyr
 355 360 365
 40 Gly Asn Ile Gln Ser Arg Leu Glu Leu Arg Lys Lys Leu Ser Cys Lys
 370 375 380
 Pro Phe Lys Trp Tyr Leu Glu Asn Val Tyr Pro Glu Leu Arg Val Pro
 385 390 395 400
 45 Asp His Gln Asp Ile Ala Phe Gly Ala Leu Gln Gln Gly Thr Asn Cys
 405 410 415
 Leu Asp Thr Leu Gly His Phe Ala Asp Gly Val Val Gly Val Tyr Glu
 50 420 425 430
 Cys His Asn Ala Gly Gly Asn Gln Glu Trp Ala Leu Thr Lys Glu Lys
 435 440 445
 55 Ser Val Lys His Met Asp Leu Cys Leu Thr Val Val Asp Arg Ala Pro
 450 455 460
 Gly Ser Leu Ile Lys Leu Gln Gly Cys Arg Glu Asn Asp Ser Arg Gln
 465 470 475 480
 60 Lys Trp Glu Gln Ile Glu Gly Asn Ser Lys Leu Arg His Val Gly Ser

| | 485 | 490 | 495 |
|----|---|-------------|-----|
| | Asn Leu Cys Leu Asp Ser Arg Thr Ala Lys Ser Gly Gly | Leu Ser Val | |
| | 500 | 505 | 510 |
| 5 | Glu Val Cys Gly Pro Ala Leu Ser Gln Gln Trp Lys Phe Thr Leu Asn | | |
| | 515 | 520 | 525 |
| 10 | Leu Gln Gln | | |
| | 530 | | |
| 15 | <210> 5 <211> 1560 <212> DNA <213> human <220> <221> misc_feature <223> delta 51 GalNAcT2 | | |
| 20 | <400> 5 aaaaagaaaag actttcatca cagcaatgg aagagagaaag cacaaggcat ggagaccctc | 60 | |
| 25 | cctccaggg aagtacggtg gccagactt aaccaggaag cttatgttgg agggacgatg | 120 | |
| | gtccgctccg ggcaggaccc ttacgcccc aacaagttca accaggtgga gagtgataag | 180 | |
| | cttcgaatgg acagagccat ccctgacacc cggcatgacc agtgtcagcg gaagcagtgg | 240 | |
| 30 | cgggtggatc tgccggccac cagcgtggtg atcacgttca acaatgaagc cagtcggcc | 300 | |
| | ctactcagga cctgtggtcag cgtgcttaag aaaagccgc cccatctcat aaaagaaaatc | 360 | |
| 35 | atcttggtgg atgactacag caatgatcct gaggacgggg ctctcttggg gaaaatttag | 420 | |
| | aaagtgcgag ttcttagaaa tgatcgacga gaaggcctca tgcgctcacg gttcgggg | 480 | |
| | gccgatgctg cccaaagccaa ggtcctgacc ttccctggaca gtcactgcga gtgtaatgag | 540 | |
| 40 | cactggctgg agcccccctgg gaaaagggtg gctggaggaca ggactcgggt tgtgtcaccc | 600 | |
| | atcatcgatg tcattaatat ggacaactt cagtagtgg gggcatctgc tgacttgaag | 660 | |
| 45 | ggcggttttg attggaactt ggtattcaag tgggattaca tgacgcctga gcagagaagg | 720 | |
| | tcccgccagg ggaaccctgt cggccctata aaaaccccca tgattgctgg tgggtgttt | 780 | |
| | gtgatggata agttctatgg tgaagaactg gggaaagtacg acatgatgat ggatgtgtgg | 840 | |
| 50 | ggaggagaga acctagagat ctgcgtccgc gtgtggcagt gtgggtggcag cctggagatc | 900 | |
| | atccccgtgca gccgtgtggg acacgtgttc cggaaaggcagc accccctacac gttcccggt | 960 | |
| 55 | ggcagtggca ctgtctttgc ccgaaacacc cggccggcag cagaggctcg gatggatgaa | 1020 | |
| | tacaaaaatt tctattatgc agcagtgcct tctgctagaa acgttccctta tggaaatatt | 1080 | |
| | cagagcagat tggagcttag gaagaaaactc agctgcaagc ctttcaaattg gtaccttgaa | 1140 | |
| 60 | aatgtctatc cagagttaaag gttccagac catcaggata tagctttgg ggccttgca | 1200 | |

cagggaaacta actgcctcga cactttggga cactttgctg atggtgtggc tggagtttat 1260
 gaatgtcaca atgctgggg aaaccaggaa tgggccttga cgaaggagaa gtcgggtgaag 1320
 5 cacatggatt tgtgccttac tgtggtggac cgggcaccgg gctctcttat aaagctgcag 1380
 ggctgccgag aaaatgacag cagacagaaa tgggaacaga tcgagggcaa ctccaagctg 1440
 10 aggcacgtgg gcagcaacct gtgcctggac agtcgcacgg ccaagagcgg gggcctaagc 1500
 gtggaggtgt gtggcccgcc cctttcgac cagtggaaat tcacgctcaa cctgcagcag 1560

 15 <210> 6
 <211> 520
 <212> PRT
 <213> human
 <220>
 20 <221> MISC_FEATURE
 <223> delta 51 GalNAcT2

 <400> 6

 25 Lys Lys Lys Asp Leu His His Ser Asn Gly Glu Glu Lys Ala Gln Ser
 1 5 10 15

 Met Glu Thr Leu Pro Pro Gly Lys Val Arg Trp Pro Asp Phe Asn Gln
 20 25 30

 30 Glu Ala Tyr Val Gly Gly Thr Met Val Arg Ser Gly Gln Asp Pro Tyr
 35 40 45

 Ala Arg Asn Lys Phe Asn Gln Val Glu Ser Asp Lys Leu Arg Met Asp
 50 55 60
 35 Arg Ala Ile Pro Asp Thr Arg His Asp Gln Cys Gln Arg Lys Gln Trp
 65 70 75 80

 40 Arg Val Asp Leu Pro Ala Thr Ser Val Val Ile Thr Phe His Asn Glu
 85 90 95

 Ala Arg Ser Ala Leu Leu Arg Thr Val Val Ser Val Leu Lys Lys Ser
 100 105 110

 45 Pro Pro His Leu Ile Lys Glu Ile Ile Leu Val Asp Asp Tyr Ser Asn
 115 120 125

 Asp Pro Glu Asp Gly Ala Leu Leu Gly Lys Ile Glu Lys Val Arg Val
 130 135 140
 50 Leu Arg Asn Asp Arg Arg Glu Gly Leu Met Arg Ser Arg Val Arg Gly
 145 150 155 160

 55 Ala Asp Ala Ala Gln Ala Lys Val Leu Thr Phe Leu Asp Ser His Cys
 165 170 175

 Glu Cys Asn Glu His Trp Leu Glu Pro Leu Leu Glu Arg Val Ala Glu
 180 185 190

 60 Asp Arg Thr Arg Val Val Ser Pro Ile Ile Asp Val Ile Asn Met Asp
 195 200 205

| | | | | |
|----|---|-----|-----|-----|
| | Asn Phe Gln Tyr Val Gly Ala Ser Ala Asp Leu Lys Gly Gly Phe Asp | | | |
| | 210 | 215 | 220 | |
| 5 | Trp Asn Leu Val Phe Lys Trp Asp Tyr Met Thr Pro Glu Gln Arg Arg | | | |
| | 225 | 230 | 235 | 240 |
| | Ser Arg Gln Gly Asn Pro Val Ala Pro Ile Lys Thr Pro Met Ile Ala | | | |
| | 245 | 250 | 255 | |
| 10 | Gly Gly Leu Phe Val Met Asp Lys Phe Tyr Phe Glu Glu Leu Gly Lys | | | |
| | 260 | 265 | 270 | |
| 15 | Tyr Asp Met Met Asp Val Trp Gly Gly Glu Asn Leu Glu Ile Ser | | | |
| | 275 | 280 | 285 | |
| | Phe Arg Val Trp Gln Cys Gly Gly Ser Leu Glu Ile Ile Pro Cys Ser | | | |
| | 290 | 295 | 300 | |
| 20 | Arg Val Gly His Val Phe Arg Lys Gln His Pro Tyr Thr Phe Pro Gly | | | |
| | 305 | 310 | 315 | 320 |
| | Gly Ser Gly Thr Val Phe Ala Arg Asn Thr Arg Arg Ala Ala Glu Val | | | |
| | 325 | 330 | 335 | |
| 25 | Trp Met Asp Glu Tyr Lys Asn Phe Tyr Tyr Ala Ala Val Pro Ser Ala | | | |
| | 340 | 345 | 350 | |
| | Arg Asn Val Pro Tyr Gly Asn Ile Gln Ser Arg Leu Glu Leu Arg Lys | | | |
| 30 | 355 | 360 | 365 | |
| | Lys Leu Ser Cys Lys Pro Phe Lys Trp Tyr Leu Glu Asn Val Tyr Pro | | | |
| | 370 | 375 | 380 | |
| 35 | Glu Leu Arg Val Pro Asp His Gln Asp Ile Ala Phe Gly Ala Leu Gln | | | |
| | 385 | 390 | 395 | 400 |
| | Gln Gly Thr Asn Cys Leu Asp Thr Leu Gly His Phe Ala Asp Gly Val | | | |
| | 405 | 410 | 415 | |
| 40 | Val Gly Val Tyr Glu Cys His Asn Ala Gly Gly Asn Gln Glu Trp Ala | | | |
| | 420 | 425 | 430 | |
| | Leu Thr Lys Glu Lys Ser Val Lys His Met Asp Leu Cys Leu Thr Val | | | |
| 45 | 435 | 440 | 445 | |
| | Val Asp Arg Ala Pro Gly Ser Leu Ile Lys Leu Gln Gly Cys Arg Glu | | | |
| | 450 | 455 | 460 | |
| 50 | Asn Asp Ser Arg Gln Lys Trp Glu Gln Ile Glu Gly Asn Ser Lys Leu | | | |
| | 465 | 470 | 475 | 480 |
| | Arg His Val Gly Ser Asn Leu Cys Leu Asp Ser Arg Thr Ala Lys Ser | | | |
| | 485 | 490 | 495 | |
| 55 | Gly Gly Leu Ser Val Glu Val Cys Gly Pro Ala Leu Ser Gln Gln Trp | | | |
| | 500 | 505 | 510 | |
| 60 | Lys Phe Thr Leu Asn Leu Gln Gln | | | |
| | 515 | 520 | | |

5 <210> 7
 <211> 1494
 <212> DNA
 <213> human
 <220>
 <221> misc_feature
 <223> delta 73 GalNAcT2

10 <400> 7
 gggaaagtac ggtggccaga ctttaaccag gaagcttatg ttggagggac gatggtccgc 60
 tccgggcagg acccttacgc ccgcaacaag ttcaaccagg tggagagtga taagcttcga
 15 atggacagag ccatccctga caccggcat gaccagtgtc agcggaaagca gtggcgggtg
 gatctgccgg ccaccagcgt ggtgatcacg tttcacaatg aagccaggtc ggccctactc
 20 aggaccgtgg tcagcgtgct taagaaaagc ccgccccatc tcataaaaaga aatcatcttg
 gtggatgact acagcaatga tcctgaggac ggggctctct tggggaaaat tgagaaagtg
 cgagttctta gaaatgatcg acgagaaggc ctcatgcgct cacgggttcg gggggccgat
 25 gctgccaag ccaaggtctt gaccttcctg gacagtcact gcgagtgtaa tgagcactgg
 ctggagcccc tcctggaaag ggtggcggag gacaggactc gggttgtgtc acccatcatc
 30 gatgtcatta atatggacaa ctttcagtat gtggggcat ctgctgactt gaagggcggt
 tttgatttggaa acttggattt caagtggat tacatgacgc ctgagcagag aaggtcccg
 caggggaacc cagtcgcccc tataaaaacc cccatgattt ctggggctt gtttgtatg
 35 gataagttct attttgaaga actggggaaag tacgacatga tggatgtgt gtggggagga
 gagaacctag agatctcggtt ccgcgtgtgg cagtgtggtg gcagcctgga gatcatcccg
 40 tgcagccgtg tgggacacgt gttccggaag cagcacccct acacgttccc ggggtggcagt
 ggcactgtct ttgcccggaa caccggccgg gcagcagagg tctggatgga tgaataaaaa
 aatttctatt atgcagcagt gccttctgct agaaacgttc cttatggaaa tattcagagc
 45 agattggagc tttaggaagaa actcagctgc aagccttca aatggtacct tggaaaatgtc
 tatccagagt taagggttcc agaccatcag gatatacgat ttggggcctt gcagcaggaa
 50 actaactgcc tcgacacttt gggacacttt gctgtggtg tggttggagt ttatgaatgt
 cacaatgctg gggaaaacca ggaatgggca ttgacgaagg agaagtccgtt gaagcacatg
 gatttggcc ttactgtggt ggaccgggca ccgggctctc ttataaagct gcagggctgc
 55 cgagaaaatg acagcagaca gaaatgggaa cagatcgagg gcaactccaa gctgaggcac
 gtggggcagca acctgtgcct ggacagtcgc acggccaaga gcggggccct aagcgtggag
 60 gtgtgtggcc cggcccttgc gcagcagtgg aagttcacgc tcaacctgca gcag 1494

<210> 8
 <211> 498
 <212> PRT
 <213> human
 5 <220>
 <221> MISC_FEATURE
 <223> delta 73 GalNAcT2

10 <400> 8
 Gly Lys Val Arg Trp Pro Asp Phe Asn Gln Glu Ala Tyr Val Gly Gly
 1 5 10 15

15 Thr Met Val Arg Ser Gly Gln Asp Pro Tyr Ala Arg Asn Lys Phe Asn
 20 25 30

Gln Val Glu Ser Asp Lys Leu Arg Met Asp Arg Ala Ile Pro Asp Thr
 35 40 45

20 Arg His Asp Gln Cys Gln Arg Lys Gln Trp Arg Val Asp Leu Pro Ala
 50 55 60

Thr Ser Val Val Ile Thr Phe His Asn Glu Ala Arg Ser Ala Leu Leu
 65 70 75 80

25 Arg Thr Val Val Ser Val Leu Lys Lys Ser Pro Pro His Leu Ile Lys
 85 90 95

Glu Ile Ile Leu Val Asp Asp Tyr Ser Asn Asp Pro Glu Asp Gly Ala
 30 100 105 110

Leu Leu Gly Lys Ile Glu Lys Val Arg Val Leu Arg Asn Asp Arg Arg
 115 120 125

35 Glu Gly Leu Met Arg Ser Arg Val Arg Gly Ala Asp Ala Ala Gln Ala
 130 135 140

Lys Val Leu Thr Phe Leu Asp Ser His Cys Glu Cys Asn Glu His Trp
 40 145 150 155 160

Leu Glu Pro Leu Leu Glu Arg Val Ala Glu Asp Arg Thr Arg Val Val
 165 170 175

Ser Pro Ile Ile Asp Val Ile Asn Met Asp Asn Phe Gln Tyr Val Gly
 45 180 185 190

Ala Ser Ala Asp Leu Lys Gly Gly Phe Asp Trp Asn Leu Val Phe Lys
 195 200 205

50 Trp Asp Tyr Met Thr Pro Glu Gln Arg Arg Ser Arg Gln Gly Asn Pro
 210 215 220

Val Ala Pro Ile Lys Thr Pro Met Ile Ala Gly Gly Leu Phe Val Met
 55 225 230 235 240

Asp Lys Phe Tyr Phe Glu Glu Leu Gly Lys Tyr Asp Met Met Met Asp
 245 250 255

Val Trp Gly Gly Glu Asn Leu Glu Ile Ser Phe Arg Val Trp Gln Cys
 60 260 265 270

Gly Gly Ser Leu Glu Ile Ile Pro Cys Ser Arg Val Gly His Val Phe
 275 280 285

5 Arg Lys Gln His Pro Tyr Thr Phe Pro Gly Gly Ser Gly Thr Val Phe
 290 295 300

Ala Arg Asn Thr Arg Arg Ala Ala Glu Val Trp Met Asp Glu Tyr Lys
 305 310 315 320

10 Asn Phe Tyr Tyr Ala Ala Val Pro Ser Ala Arg Asn Val Pro Tyr Gly
 325 330 335

Asn Ile Gln Ser Arg Leu Glu Leu Arg Lys Lys Leu Ser Cys Lys Pro
 340 345 350

15 Phe Lys Trp Tyr Leu Glu Asn Val Tyr Pro Glu Leu Arg Val Pro Asp
 355 360 365

His Gln Asp Ile Ala Phe Gly Ala Leu Gln Gln Gly Thr Asn Cys Leu
 20 370 375 380

Asp Thr Leu Gly His Phe Ala Asp Gly Val Val Gly Val Tyr Glu Cys
 385 390 395 400

25 His Asn Ala Gly Gly Asn Gln Glu Trp Ala Leu Thr Lys Glu Lys Ser
 405 410 415

Val Lys His Met Asp Leu Cys Leu Thr Val Val Asp Arg Ala Pro Gly
 30 420 425 430

Ser Leu Ile Lys Leu Gln Gly Cys Arg Glu Asn Asp Ser Arg Gln Lys
 435 440 445

35 Trp Glu Gln Ile Glu Gly Asn Ser Lys Leu Arg His Val Gly Ser Asn
 450 455 460

Leu Cys Leu Asp Ser Arg Thr Ala Lys Ser Gly Gly Leu Ser Val Glu
 465 470 475 480

40 Val Cys Gly Pro Ala Leu Ser Gln Gln Trp Lys Phe Thr Leu Asn Leu
 485 490 495

Gln Gln

45

<210> 9
 <211> 1431
 <212> DNA
 50 <213> human
 <220>
 <221> misc_feature
 <223> delta 94 GalNACT2

55 <400> 9
 gggcaggacc cttacgcccc caacaaggttc aaccagggtgg agagtgataa gcttcgaatg 60
 gacagagcca tccctgacac ccggcatgac cagtgtcagc ggaagcagtg gcgggtggat 120
 60 ctgccggcca ccagcgtggt gatcacgttt cacaatgaag ccaggtcggc cctactcagg 180

accgtggtca gcgtgcttaa gaaaagcccg ccccatctca taaaagaaaat catcttggtg 240
 gatgactaca gcaatgatcc tgaggacggg gctctttgg ggaaaattga gaaagtgcga 300
 5 gttcttagaa atgatcgacg agaaggcctc atgcgctcac gggttcgggg ggccgatgct 360
 gcccaagcca aggtcctgac cttcctggac agtcaactgctg agtgtaatga gcactggctg 420
 10 gagccccctcc tggaaagggt ggcggaggac aggactcggg ttgtgtcacc catcatcgat 480
 gtcattaata tggacaactt tcagtatgtg gggcatctg ctgacttgaa gggcggttt 540
 gattggaact tggattcaa gtgggattac atgacgcctg agcagagaag gtcccgccag 600
 15 gggAACCCAG tcgcccctat aaaaACCCCC atgattgctg gtgggctgtt tgtgtatggat 660
 aagttctatt ttgaagaact ggggaagtac gacatgtatgtg tggatgtgtg gggaggagag 720
 20 aacctagaga tctcggtccg cgtgtggcag tgtggtggca gcctggagat catcccgtgc 780
 agccgtgtgg gacacgtgtt ccggaaagcag cacccttaca cgttcccggg tggcagtggc 840
 actgtcttg cccgaaacac ccggccggca gcagaggctt ggtatggatga atacaAAAAT 900
 25 ttctattatg cagcagtgcc ttctgctaga aacgttcattt atggaaatat tcagagcaga 960
 ttggagctta ggaagaaact cagctgcaag ccttcaaattt ggtaccttga aaatgtctat 1020
 30 ccagagttaa gggttccaga ccatcaggat atagcttttgg gggccttgcgc gcaggaaact 1080
 aactgcctcg acactttggg acactttgtt gatggtgtgg ttggagttta tgaatgtcac 1140
 aatgctgggg gaaaccagga atgggccttg acgaaggaga agtcggtgaa gcacatggat 1200
 35 ttgtgcctta ctgtggtgga ccgggcacccg ggctctctta taaagctgca gggctgcccga 1260
 gaaaatgaca gcagacagaa atgggaacacg atcgaggggca actccaagct gaggcacgtg 1320
 40 ggcagcaacc tgtgcctgga cagtcgcacg gccaaagagcg gggccttaag cgtggaggtg 1380
 tgtggcccccgg cccttcgca gcagtggaaat ttcacgctca acctgcagca g 1431

45 <210> 10
 <211> 477
 <212> PRT
 <213> human
 <220>
 50 <221> MISC_FEATURE
 <223> delta 94 GalNAcT2

 <400> 10

55 Gly Gln Asp Pro Tyr Ala Arg Asn Lys Phe Asn Gln Val Glu Ser Asp
 1 5 10 15
 Lys Leu Arg Met Asp Arg Ala Ile Pro Asp Thr Arg His Asp Gln Cys
 20 25 30
 60 Gln Arg Lys Gln Trp Arg Val Asp Leu Pro Ala Thr Ser Val Val Ile
 35 40 45

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Phe | His | Asn | Glu | Ala | Arg | Ser | Ala | Leu | Leu | Arg | Thr | Val | Val | Ser | |
| 50 | | | | 55 | | | | | | 60 | | | | | | |
| 5 | Val | Leu | Lys | Lys | Ser | Pro | Pro | His | Leu | Ile | Lys | Glu | Ile | Ile | Leu | Val |
| | 65 | | | | 70 | | | | | 75 | | | | | 80 | |
| 10 | Asp | Asp | Tyr | Ser | Asn | Asp | Pro | Glu | Asp | Gly | Ala | Leu | Leu | Gly | Lys | Ile |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| 15 | Glu | Lys | Val | Arg | Val | Leu | Arg | Asn | Asp | Arg | Arg | Glu | Gly | Leu | Met | Arg |
| | | | | 100 | | | | | 105 | | | | | 110 | | |
| 20 | Ser | Arg | Val | Arg | Gly | Ala | Asp | Ala | Ala | Gln | Ala | Lys | Val | Leu | Thr | Phe |
| | | | | 115 | | | | | 120 | | | | 125 | | | |
| 25 | Leu | Asp | Ser | His | Cys | Glu | Cys | Asn | Glu | His | Trp | Leu | Glu | Pro | Leu | Leu |
| | | | | 130 | | | | | 135 | | | | 140 | | | |
| 30 | Glu | Arg | Val | Ala | Glu | Asp | Arg | Thr | Arg | Val | Val | Ser | Pro | Ile | Ile | Asp |
| | | | | 145 | | | | | 150 | | | 155 | | 160 | | |
| 35 | Val | Ile | Asn | Met | Asp | Asn | Phe | Gln | Tyr | Val | Gly | Ala | Ser | Ala | Asp | Leu |
| | | | | 165 | | | | | 170 | | | | 175 | | | |
| 40 | Lys | Gly | Gly | Phe | Asp | Trp | Asn | Leu | Val | Phe | Lys | Trp | Asp | Tyr | Met | Thr |
| | | | | 180 | | | | | 185 | | | | 190 | | | |
| 45 | Pro | Glu | Gln | Arg | Arg | Ser | Arg | Gln | Gly | Asn | Pro | Val | Ala | Pro | Ile | Lys |
| | | | | 195 | | | | | 200 | | | | 205 | | | |
| 50 | Thr | Pro | Met | Ile | Ala | Gly | Gly | Leu | Phe | Val | Met | Asp | Lys | Phe | Tyr | Phe |
| | | | | 210 | | | | | 215 | | | | 220 | | | |
| 55 | Glu | Glu | Leu | Gly | Lys | Tyr | Asp | Met | Met | Asp | Val | Trp | Gly | Gly | Glu | |
| | | | | 225 | | | | | 230 | | | 235 | | 240 | | |
| 60 | Asn | Leu | Glu | Ile | Ser | Phe | Arg | Val | Trp | Gln | Cys | Gly | Gly | Ser | Leu | Glu |
| | | | | 245 | | | | | 250 | | | | 255 | | | |
| 65 | Ile | Ile | Pro | Cys | Ser | Arg | Val | Gly | His | Val | Phe | Arg | Lys | Gln | His | Pro |
| | | | | 260 | | | | | 265 | | | | 270 | | | |
| 70 | Tyr | Thr | Phe | Pro | Gly | Gly | Ser | Gly | Thr | Val | Phe | Ala | Arg | Asn | Thr | Arg |
| | | | | 275 | | | | | 280 | | | | 285 | | | |
| 75 | Arg | Ala | Ala | Glu | Val | Trp | Met | Asp | Glu | Tyr | Lys | Asn | Phe | Tyr | Tyr | Ala |
| | | | | 290 | | | | | 295 | | | | 300 | | | |
| 80 | Ala | Val | Pro | Ser | Ala | Arg | Asn | Val | Pro | Tyr | Gly | Asn | Ile | Gln | Ser | Arg |
| | | | | 305 | | | | | 310 | | | 315 | | 320 | | |
| 85 | Leu | Glu | Leu | Arg | Lys | Lys | Leu | Ser | Cys | Lys | Pro | Phe | Lys | Trp | Tyr | Leu |
| | | | | 325 | | | | | 330 | | | | 335 | | | |
| 90 | Glu | Asn | Val | Tyr | Pro | Glu | Leu | Arg | Val | Pro | Asp | His | Gln | Asp | Ile | Ala |
| | | | | 340 | | | | | 345 | | | | 350 | | | |
| 95 | Phe | Gly | Ala | Leu | Gln | Gln | Gly | Thr | Asn | Cys | Leu | Asp | Thr | Leu | Gly | His |
| | | | | 355 | | | | | 360 | | | | 365 | | | |

Phe Ala Asp Gly Val Val Gly Val Tyr Glu Cys His Asn Ala Gly Gly
 370 375 380 385 390 395 400
 Asn Gln Glu Trp Ala Leu Thr Lys Glu Lys Ser Val Lys His Met Asp
 5
 Leu Cys Leu Thr Val Val Asp Arg Ala Pro Gly Ser Leu Ile Lys Leu
 405 410 415
 10 Gln Gly Cys Arg Glu Asn Asp Ser Arg Gln Lys Trp Glu Gln Ile Glu
 420 425 430
 Gly Asn Ser Lys Leu Arg His Val Gly Ser Asn Leu Cys Leu Asp Ser
 435 440 445
 15 Arg Thr Ala Lys Ser Gly Gly Leu Ser Val Glu Val Cys Gly Pro Ala
 450 455 460
 Leu Ser Gln Gln Trp Lys Phe Thr Leu Asn Leu Gln Gln
 20 465 470 475

 <210> 11
 <211> 28
 25 <212> DNA
 <213> artificial sequence
 <220>
 <223> N41R primer

 30 <400> 11
 cgccggatccca ggaaggagga ctggaaatg 28

 <210> 12
 <211> 33
 35 <212> DNA
 <213> artificial sequence
 <220>
 <223> N52K primer

 40 <400> 12
 cgccggatccca aaaagaaaaga ctttcatcac agc 33

 45 <210> 13
 <211> 30
 <212> DNA
 <213> artificial sequence
 <220>
 50 <223> N74G primer

 <400> 13
 cgccggatccg gaaaagtacg gtggccagac 30

 55 <210> 14
 <211> 27
 <212> DNA
 <213> artificial sequence
 <220>
 60 <223> N95G primer

<400> 14
cgcgatccg ggcaggaccc ttacgcc

27

5
<210> 15
<211> 29
<212> DNA
<213> artificial sequence
10 <220>
<223> Antisense Primer with STOP codon

<400> 15
ctgctcgagc tactgctgca ggttgagcg

29

15
<210> 16
<211> 10
<212> PRT
20 <213> artificial sequence
<220>
<223> MuC-2 - like peptide

<400> 16

25 Met Val Thr Pro Thr Pro Thr Pro Thr Cys
1 5 10

30

WHAT IS CLAIMED IS:

1 1. An isolated nucleic acid comprising a nucleic acid sequence encoding
2 a truncated human GalNAcT2 polypeptide, wherein said truncated human GalNAcT2
3 polypeptide is lacking all or a portion of the GalNAcT2 signal domain, with the proviso that
4 the encoded polypeptide is not a human GalNAcT2 truncation mutant polypeptide lacking
5 amino acid residues 1-51.

1 2. The isolated nucleic acid of claim 1, wherein said truncated human
2 GalNAcT2 polypeptide is further lacking all or a portion the GalNAcT2 transmembrane
3 domain, with the proviso that the encoded polypeptide is not a human GalNAcT2 truncation
4 mutant polypeptide lacking amino acid residues 1-51.

1 3. The isolated nucleic of claim 2, wherein said truncated human
2 GalNAcT2 polypeptide is further lacking all or a portion the GalNAcT2 stem domain, with
3 the proviso that the encoded polypeptide is not a human GalNAcT2 truncation mutant
4 polypeptide lacking amino acid residues 1-51.

1 4. The isolated nucleic acid of claim 1, comprising a nucleic acid
2 sequence encoding a truncated human GalNAcT2 polypeptide, said nucleic acid sequence
3 having at least 90% identity with a nucleic acid selected from the group consisting of SEQ ID
4 NO:3, SEQ ID NO:7 and SEQ ID NO:9

1 5. The isolated nucleic acid of claim 4, said isolated nucleic acid
2 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:3,
3 SEQ ID NO:7 and SEQ ID NO:9.

1 6. An isolated nucleic acid of claim 4, e said isolated nucleic acid
2 consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NO:3,
3 SEQ ID NO:7 and SEQ ID NO:9.

1 7. An isolated chimeric nucleic acid encoding a fusion polypeptide, said
2 fusion polypeptide comprising a tag polypeptide covalently linked to a second polypeptide
3 encoded by the isolated nucleic acid of claim 1.

1 8. The isolated chimeric nucleic acid of claim 7, wherein said tag
2 polypeptide is selected from the group consisting of a maltose binding protein, a histidine tag,

3 a Factor IX tag, a glutathione-S-transferase tag, a FLAG-tag, and a starch binding domain
4 tag.

1 9. An isolated truncated human GalNAcT2 polypeptide, wherein said
2 truncated human GalNAcT2 polypeptide is lacking all or a portion of the GalNAcT2 signal
3 domain, with the proviso that said polypeptide is not a human GalNAcT2 polypeptide
4 truncation mutant lacking amino acid residues 1-51.

1 10. The isolated truncated human GalNAcT2 polypeptide of claim 9,
2 wherein said truncated human GalNAcT2 polypeptide is further lacking all or a portion the
3 GalNAcT2 transmembrane domain, with the proviso that said polypeptide is not a human
4 GalNAcT2 polypeptide truncation mutant lacking amino acid residues 1-51.

1 11. The isolated truncated human GalNAcT2 polypeptide of claim 10,
2 wherein said truncated human GalNAcT2 polypeptide is further lacking all or a portion the
3 GalNAcT2 stem domain, with the proviso that said polypeptide is not a human GalNAcT2
4 polypeptide truncation mutant lacking amino acid residues 1-51.

1 12. The isolated truncated human GalNAcT2 polypeptide of claim 9,
2 having at least 90% identity with a polypeptide selected from the group consisting of SEQ
3 ID NO:4, SEQ ID NO:8 and SEQ ID NO:10.

1 13. The isolated truncated human GalNAcT2 polypeptide of claim 9,
2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:4,
3 SEQ ID NO:8 and SEQ ID NO:10.

1 14. The isolated truncated human GalNAcT2 polypeptide of claim 9,
2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:4,
3 SEQ ID NO:8 and SEQ ID NO:10.

1 15. An isolated chimeric polypeptide comprising a tag polypeptide
2 covalently linked to the isolated truncated GalNAcT2 polypeptide of claim 9.

1 16. The isolated chimeric polypeptide of claim 15, wherein said tag
2 polypeptide is selected from the group consisting of a maltose binding protein, a histidine tag,
3 a Factor IX tag, a glutathione-S-transferase tag, a FLAG-tag, and a starch binding domain
4 tag.

1 17. The isolated nucleic acid of any one of claim 1, said nucleic acid
2 further comprising a promoter/regulatory sequence operably linked thereto.

1 18. An expression vector comprising the isolated nucleic acid of claim 1.

1 19. A recombinant cell comprising the isolated expression vector of claim
2 18.

1 20. A recombinant cell of claim 19, wherein said recombinant cell is a
2 eukaryotic cell or a prokaryotic cell.

1 21. The recombinant cell of claim 20, wherein said eukaryotic cell is
2 selected from the group consisting of a mammalian cell, an insect cell, and a fungal cell.

1 22. The recombinant cell of claim 21, wherein said insect cell is selected
2 from the group consisting of an SF9 cell, an SF9+ cell, an Sf21 cell, a HIGH FIVE cell or
3 Drosophila Schneider S2 cell.

1 23. The recombinant cell of claim 20, wherein said prokaryotic cell is
2 selected from the group consisting of an E. coli cell and a B. subtilis cell.

1 24. A method of producing a truncated human GalNAcT2 polypeptide, the
2 method comprising growing the recombinant cell of claim 20 under conditions suitable for
3 expression of the truncated human GalNAcT2 polypeptide.

1 25. A method of catalyzing the transfer of a GalNAc moiety to an acceptor
2 moiety comprising incubating the polypeptide of claim 9 with a GalNAc moiety and an
3 acceptor moiety, wherein said polypeptide mediates the covalent linkage of said GalNAc
4 moiety to said acceptor moiety, thereby catalyzing the transfer of a GalNAc moiety to an
5 acceptor moiety to produce a product saccharide, or a product glycoprotein, or a product
6 glycopeptide.

1 26. The method of claim 25, wherein said acceptor moiety is a granulocyte
2 colony stimulating factor (G-CSF) protein.

1 27. The method of claim 25, wherein said acceptor moiety is selected from
2 the group consisting of erythropoietin, human growth hormone, granulocyte colony


3 stimulating factor, interferons alpha, -beta, and -gamma, Factor IX, follicle stimulating
4 hormone, interleukin-2, erythropoietin, anti-TNF-alpha, and a lysosomal hydrolase.

1 28. The method of claim 25, wherein said polypeptide acceptor is a
2 glycopeptide.


1 29. The method of claim 25, further wherein said GalNAc moiety
2 comprises a polyethylene glycol moiety.

1 30. The method of claim 25, wherein the product saccharide, product
2 glycoprotein, or product glycopeptide is produced on a commercial scale.


1/42

**FIG. 1**


2/42




3/42

**FIG. 3**


4/42

**FIG. 4**


5/42

**FIG. 5**


6/42

**FIG. 6**


7/42

**FIG. 7**

8/42

**FIG. 8**

9/42

**FIG. 9**

10/42

T2-41R

BamHi

EcoRi ~~~~~

1 GAATTCCGGAT CCAGGAAGGA GGACTGGAAT GAAATTGACC CCATTAAAAA GAAAGACCTT
CTTAAGCCTA GGTCTTCCT CCTGACCTA CTTTAACCTGG GGTAATTCTT CTTTCTGGAA

61 CATCACAGCA ATGGAGAAGA GAAAGCACAA AGCATGGAGA CCCTCCCTCC AGGGAAAGTA
GTAGTGTGCT TACCTCTCT CTTCTGTGTT TCGTACCTCT GGGAGGGAGG TCCCTTCAT

HindIII

121 CGGTGGCCAG ACTTTAACCA GGAAGCTTAT GTTGGAGGGAGA CGATGGTCG CTCCGGGCAG
GCCACCGGTC TGAAATTGGT CCTTCGAATA CAACCTCCCT GCTACCAGGC GAGGCCCGTC

181 GACCGTTACG CCCGCAACAA GTTCAACCAG GTGGAGAGTG ATAAGCTTCG AATGGACAGA
CTGGGAATGC GGGCGTTGTT CAAGTTGGTC CACCTCTCAC TATTGAGAC TTACCTGTCT

241 GCCATCCCTG ACACCCGGCA TGACCAAGTG CAGCGGAAGC AGTGGCGGGT GGATCTGCG
CGGTAGGGAC TGTGGGCCGT ACTGGTCACA GTCGCCTTCG TCACCGCCCA CCTAGACGGC

301 GCCACCAAGCG TGTTGATCAC GTTCAACAAT GAAGCCAGGT CGGCCCTACT CAGGACCGTG
CGGTGGTCGC ACCACTAGTG CAAAGTGTAA CCTCGGTCCA GCCGGGATGA GTCCCTGGCAC

361 GTCAGGGTGC TTAAGAAAAG CCCGCCCCAT CTCATAAAAG AAATCATCTT GTTGGATGAC
CAGTCGCACG AATTCTTTG GGGCGGGGTA GAGTATTTC TTTAGTAGAA CCACCTACTG

421 TACAGCAATG ATCCTGAGGA CGGGGCTCTC TTGGGGAAAAA TTGAGAAAGT GCGAGTTCTT
ATGTCGTTAC TAGGACTCCT GCCCGAGAG AACCCCTTT AACTCTTC ACGCTCAAGAA

481 AGAAATGATC GACGAGAAGG CCTCATGCGC TCACGGGTTG GGGGGGCCGA TGCTGCCAA
TCTTACTAG CTGCTCTTC GGAGTACGCG AGTGCCAAG CCCCCCGGCT ACGACGGGTT

541 GCCAAGGTCC TGACCTTCCT GGACAGTCAC TGCGAGTGTGTA ATGAGCACTG GCTGGAGCCC
CGGTTCCAGG ACTGGAAGGA CCTGTCAGTG ACGCTCACAT TACTCGTGAC CGACCTCGGG

ClaI

601 CTCCTGGAAA GGGTGGCGGA GGACAGGACT CGGGTTGTGT CACCCATCAT CGATGTCATT
GAGGACCTTT CCCACCGCCT CCTGTCCCTGA GCCAACACA GTGGGTAGTA GCTACAGTAA

661 AATATGGACA ACTTTCACTA TGTGGGGCA TCTGCTGACT TGAAGGGCGG TTTTGATTGG
TTATACCTGT TGAAAGTCAT ACACCCCGT AGACGACTGA ACTTCCCGCC AAAACTAAC

721 AACTGGTAT TCAAGTGGGA TTACATGACG CCTGAGCAGA GAAGGTCCCC GCAGGGGAAC
TTGAACCATA AGTTCACCCCT AATGACTTGC GGACTCGTCT CTTCCAGGGC CGTCCCTTG

781 CCAGTCGCCCT ATAAAAAAC CCCCATGATT GCTGGTGGGC TGTTGTGAT GGATAAGTTC
GGTCAGCGGG GATATTGGT GGGGTACTAA CGACCACCCG ACAAACACTA CCTATTCAAG

841 TATTTGAAG AACTGGGGAA GTACGACATG ATGATGGATG TGTGGGGAGG AGAGAACCTA
ATAAAACTTC TTGACCCCTT CATGCTGTAC TACTACCTAC ACACCCCTCC TCTCTGGAT

901 GAGATCTCGT TCCCGGTGTG GCAGTGTGGT GGCAGCCTGG AGATCATCCC GTGCAGCCGT
CTCTAGAGCA AGGCGCACAC CGTCACACCA CGTCCGGACC TCTAGTAGGG CACGTCCGCA

961 GTGGGACACG TGTTCGGAA GCAGCACCC TACACGTTCC CGGGTGGGAG TGGCACTGTC
CACCCCTGTGC ACAAGGCCTT CGTCGTGGGG ATGTGCAAGG GCCCACCGTC ACCGTGACAG

1021 TTTGCCGAA ACACCCGCCG GGCAAGCAGAG GTCTGGATGG ATGAATACAA AAATTCTAT
AAACGGGCTT TGTGGCGGC CGTCGTCTC CAGACCTACC TACTTATGTT TTTAAAGATA

1081 TATGCAGCAG TGCCTCTGC TAGAAACGTT CCTTATGGAA ATATTCAAGAG CAGATTGGAG
ATACGTGTC ACAGGAAGACG ATCTTGCAA GGAATACCTT TATAAGTCTC GTCTAACCTC

FIG. 10A

11/42

T2-41R

KpnI

| | |
|------|--|
| 1141 | CTTAGGAAGA AACTCAGCTG CAAGCCTTC AAATGGTACC TTGAAAATGT CTATCCAGAG GAATCCTTCT TTGAGTCGAC GTTCGAAAG TTTACCATGG AACTTTACA GATAGGTCTC |
| 1201 | TTAAGGGTTC CAGACCATCA GGATATAGCT TTTGGGCCT TGCAGCAGGG AACTAACTGC AATTCCAAG GTCTGGTAGT CCTATATCGA AAACCCCGGA ACGTGTCCC TTGATTGACG |
| 1261 | CTCGACACTT TGGGACACTT TGCTGATGGT GTGGTTGGAG TTTATGAATG TCACAAATGCT GAGCTGTGAA ACCCTGTGAA ACGACTACCA CACCAACCTC AAATACTTAC AGTGTACGA |
| 1321 | GGGGGAAACC AGGAATGGGC CTTGACGAAG GAGAAGTCGG TGAAGCACAT GGATTGTGC CCCCCTTGG TCCTTACCCG GAACTGCTTC CTCTTCAGCC ACTCGTGTA CCTAAACACG |
| 1381 | CTTACTGTGG TGGACCGGGC ACCGGGCTCT CTTATAAAAGC TGCAGGGCTG CCGAGAAAAT GAATGACACC ACCTGGCCCG TGGCCCGAGA GAATATTTCG ACGTCCCAC GGCCTTTTA |
| 1441 | GACAGCAGAC AGAAATGGGA ACAGATCGAG GGCAACTCCA AGCTGAGGCA CGTGGGCAGC CTGTCGTCTG TCTTACCCCT TGTCTAGCTC CCGTTGAGGT TCGACTCCGT GCACCCGTG |
| 1501 | AACCTGTGCC TGGACAGTCG CACGGCCAAG AGCGGGGGCC TAAGCGTGGA GGTGTGTGGC TTGGACACGG ACCTGTCAAGC GTGCCGGTTC TCGCCCCCGG ATTTCGCACCT CCACACACCG |
| 1561 | CCGGCCCTTT CGCAGCAGTG GAAGTTCACG CTCAACCTGC AGCAGTAGCT CGAGGAATTC GGCCGGAAA GCGTCGTAC CTTCAAGTGC GAGTTGGACG TCGTCATCGA GCTCCTTAAG |

XbaIEcoRI**FIG. 10B**

12/42

EooRi BamHi

T2-52K

1 GAATTCCGGAT CCAAAAAGAA AGACCTTCAT CACAGCAATG GAGAAGAGAA AGCACAAAGC
CTTAAGCCTA GGTTTTCTT TCTGGAAGTA GTGTCGTTAC CTCTTCCTT TCGTGTTCG

61 ATGGAGACCC TCCCTCCAGG GAAAGTACGG TGGCCAGACT TTAACCAGGA AGCTTATGTT
TACCTCTGGG AGGGAGGTCC CTTTCATGCC ACCGGTCTGA AATTGGCCTT TCGAATACAA

121 GGAGGGACGA TGGTCGCTC CGGGCAGGAC CCTTACGCC GCAACAAGTT CAACCAGGTG
CCTCCCTGCT ACCAGGCCAG GCCCCGTCTG GGAATGCGGG CGTTGTCAA GTGGTCCAC

181 GAGAGTGATA AGCTTCGAAT GGACAGAGCC ATCCCTGACA CCCGGCATGA CCAGTGTCA
CTCTCACTAT TCGAAGCTTA CCTGTCCTGG TAGGGACTGT GGGCCGTACT GGTACAGTC

241 CGGAAGCAGT GGCGGGTGGGA TCTGCGGCC ACCAGCGTGG TGATCACGTT TCACAATGAA
GCCTTCGTCA CCGCCCACCT CTGGCACCAAG TGTCGCAAC ACTAGTGCAA AGTGTACTT

301 GCCAGGTCTGG CCCTACTCAG GACCGTGGTC AGCGTGCTTA AGAAAAGCCC GCCCCATCTC
CGGTCCAGCC GGGATGAGTC CTGGCACCAAG TCGCACGAAT TCTTTCTGGG CGGGTAGAG

361 ATAAAAGAAA TCATCTTGGT GGATGACTAC AGCAATGATC CTGAGGACGG GGCTCTCTTG
TATTTCTTT AGTAGAACCA CCTACTGATG TCGTTACTAG GACTCCTGCC CGAGAGAAC

421 GGGAAAATTG ATCCTGAGGA AGTTCTAGA AATGATCGAC GAGAAGGCCT CATGCGCTCA
CCCTTTAAC TCTTCACGC TCAAGAATCT TTACTAGCTG CTCTCCGGA GTACCGAGT

481 CGGGTTCGGG GGGCGATGC TGCCCAAGCC AAGGTCTGAA CCTTCTGGG CAGTCACTGC
GCCCAAGCCC CCCGGCTACG CCTCGGGGAG TTCCAGGACT GGAAGGACCT GTCAGTGACG

541 GAGGTAAATG AGCACTGGCT GGAGCCCTC CTGGAAAGGG TGGCGGAGGA CAGGACTCGG
CTCACATTAC TCGTACCGA CCTCGGGGAG GACCTTCCC ACCGCTCCT GTCTGAGCC

601 GTTGTGTCAC CCATCATCGA TGTCATTAAT ATGGACAATC TTCAGTATGT GGGGGCATCT
CAACACAGT GGTAGTAGCT ACAGTAATTAA TACCTGTTGA AAGTCATACA CCCCCGTAGA

661 GCTGACTTGA AGGGCGGTT TGATTGGAAC TTGGTATTCA AGTGGGATTA CATGACGCCT
CGACTGAAC TCCCGCCAAA ACTAACCTTG AACCATAAAGT TCACCTTAAT GTACTGCGGA

721 GAGCAGAGAA GGTCCCGGCA GGGGAACCCA GTCGCCCCCTA TAAAAACCCC CATGATTGCT
CTCGTCTCTT CCAGGGCCGT CCCCTTGGGT CAGCGGGGAG ATTTTGGGG GTACTAACGA

781 GGTGGGCTGT TTGATGAGGA TAAGTTCTAT TTGAGAAAC TGGGAAAGTA CGACATGATG
CCACCCGACA AACACTACCT ATTCAAGATA AAACCTCTTG ACCCCTTCAT GCTGTACTAC

841 ATGGATGTGT GGGGAGGAGA GAACCTAGAG ATCTCGTTC GCGTGTGGCA GTGTGGTGGC
TACCTACACA CCCCTCCCTC CTTGGATCTC TAGAGCAAGG CGCACACCGT CACACCACCG

901 AGCCTGGAGA TCATCCCGTG CAGCCGTGT GGACACGTGT TCCGGAAGCA GCACCCCTAC
TGCAAGGGCC CACCGTCACC GTCGGCACAC CCTGTGCACA AGGCCTTCGT CGTGGGGAGT

961 ACGTTCCCGG GTGGCAGTGG CACTGTCTT GCCCCAAACA CCCGCCGGGC AGCAGAGGTG
TGCAAGGGCC CACCGTCACC GTCGGCACAC CGGGCTTGT GGGCGGGCCCG TCGTCTCCAG

1021 TGGATGGATG AATACAAAAAA TTTCTATTAT GCAGCAGTGC CTTCTGCTAG AACGTTCTT
ACCTACCTAC TTATGTTTT AAAGATAATA CGTCGTACAG GAAGACGATC TTTGCAAGGA

1081 TATGGAAATA TTCAGAGCAG ATTGGAGCTT AGGAAGAAC TCAGCTGCAA GCCTTTCAA
ATACCTTAT AAGTCTCGTC TAACCTCGAA TCCTTCTTT AGTCGACGTT CGGAAAGTT

FIG. 11A

13/42

T2-52K

KpnI

| | |
|------|--|
| 1141 | TGGTACCTTG AAAATGTCTA TCCAGAGTTA AGGGTTCCAG ACCATCAGGA TATAGCTTT ACCATGGAAC TTTTACAGAT AGGTCTCAAT TCCCAAGGTC TGGTAGTCCT ATATCGAAAA |
| 1201 | GGGCCTTGC AGCAGGGAAC TAACTGCCTC GACACTTGG GACACTTGC TGATGGTGTG CCCCGGAACG TCGTCCCTTG ATTGACGGAG CTGTGAAACG ACTACCACAC |
| 1261 | GTTGGAGTTT ATGAATGTCA CAATGCTGGG GCAAACCAGG AATGGGCCTT GACGAAGGAG CAACCTCAAA TACTTACAGT GTTACGACCC CCTTTGGTCC TTACCCGGAA CTGCTTCCTC |
| 1321 | AAGTCGGTGA AGCACATGGA TTTGTGCCTT ACTGTGGTGG ACCGGGCACC GGGCTCTCTT TTCAGCCACT TCGTGTACCT AAACACGGAA TGACACCACC TGGCCCGTGG CCCGAGAGAA |
| 1381 | ATAAAGCTGC AGGGCTGCCG AGAAAATGAC AGCAGACAGA AATGGGAACA GATCGAGGGC TATTCGACG TCCCGACGGC TCTTTACTG TCGTCTGTCT TTACCCTTGT CTAGCTCCG |
| 1441 | AACTCCAAGC TGAGGCACGT GGGCAGCAAC CTGTGCCTGG ACAGTCGCAC GGCCAAGAGC TTGAGGTTCG ACTCCGTGCA CCCGTCGTTG GACACGGACC TGTCAGCGTG CCGGTTCTCG |
| 1501 | GGGGGCCTAA GCGTGGAGGT GTGTGGCCCG GCCCTTCGC AGCAGTGGAA GTTCACGCTC CCCCCGGATT CGCACCTCCA CACACCGGGC CGGGAAAGCG TCGTCACCTT CAAGTGCGAG |

XholKpnI

| | |
|------|--|
| 1561 | AACCTGCAGC AGTAGCTCGA GGAATTG TTGGACGTCG TCATCGAGCT CCTTAAG |
|------|--|

FIG. 11B

14/42

T2-74G

Bam Hi

Eco RI

Hind III

1 GAATTCCGGAT CCGGGAAAGT ACGGTGGCCA GACTTTAACCC AGGAAGCTTA TGTTGGAGGG
 TGCTACCAAGG GGCCCTTCA TGCCACCGGT CTGAAATTGG TCCTTCGAAT ACCACCTCCC
 61 ACGATGGTCC GCTCCGGGCA GGACCCCTAC GCCCGCAACA AGTTCAACCA GGTGGAGAGT
 TGCTACCAAGG CGAGGCCCGT CCTGGGAATG CGGGCGTTGT TCAAGTTGGT CCACCTCTCA

Hind III

121 GATAAGCTTC GAATGGACAG AGCCATCCCT GACACCCGGC ATGACCAGTG TCAGCGGAAG
 CTATTGAGA CTTACCTGTC TCGGTAGGG A CTGTGGGCCG TACTGGTCAC AGTCGCCTTC
 181 CAGTGGCGGG TGGATCTGCC GGCCACCAGC GTGGTGTAC CGTTTCACAA TGAAGCCAGG
 GTCAACCGCCC ACCTAGACGG CGGGTGGTCG CACCACTAGT GCAAAGTGT T ACTTCGGTCC
 241 TCGGCCCTAC TCAGGACCGT TCTGCCGGCC CTTAAGAAAA GCCCGCCCCA TCTCATAAAA
 AGCCGGGATG AGTCCTGGCA CTGGCACCAAG GAATTCTTT CGGGCGGGGT AGAGTATTT
 301 GAAATCATCT TGGTGGATGA CTACAGCAAT GATCCTGAGG ACGGGGCTCT CTTGGGAAA
 CTTTAGTAGA ACCACCTACT GATGTCGTTA CTAGGACTCC TGGCCCGAGA GAACCCCTT
 361 ATTGAGAAAG TCGGAGTTCT AGCCAAGGTC CGACGACAAG GCCTCATGCG CTCACGGGTT
 TAACTCTTTC ACGCTCAAGA ATCTTTACTA GCTGCTCTTC CGGAGTACGC GAGTGCCAA
 421 CGGGGGGCCG ATGCTGCCA AGCCAAGGTC CTGACCTCC TGGACAGTCA CTGCGAGTGT
 GCCCCCCCGGC TACGACGGGT TCGGTTCCAG GACTGGAAGG ACCTGTCAGT GACGCTCAC
 481 AATGAGCACT GGCTGGAGCC CCTCCTGGAA AGGGTGGCGG AGGACAGGAC TCAGGGTTGTG
 TTACTCGTGA CCGACCTCGG GGAGGACCTT TCCCACCGCC TCCTGTCCTG AGCCCAACAC

Cla

541 TCACCCATCA TCGATGTCAT TAATATGGAC AACTTCAGT ATGTGGGGC ATCTGCTGAC
 AGTGGGTAGT AGCTACAGTA ATTATACCTG TTGAAAGTCA TACACCCCCG TAGACGACTG
 601 TTGAAGGGCG GTTTGATTG GAACTGGTA TTCAAGTGGG ATTACATGAC GCCTGAGCAG
 AACTTCCCGC CAAAACTAAC CTTGAACCAT AAGTTCACCC TAATGTAATG CGGACTCGTC
 661 AGAAGGTCCC GGCAGGGAA CCCAGTCGCC CCTATAAAA CCCCCATGAT TGCTGGTGGG
 TCTTCCAGGG CCGTCCCCTT GGGTCAGCGG GGATATTTT GGGGGTACTA ACGACCACCC
 721 CTGTTGTGA TGGATAAGTT CTATTTGAA GAACTGGGA AGTACGACAT GATGATGGAT
 GACAAACACT ACCTATTCAA GATAAAACTT CTTGACCCCT TCATGCTGTA CTACTACCTA
 781 GTGTGGGAG GAGAGAACCT AGAGATCTCG TTCCGCGTGT GGCAGTGTGG TGGCAGCCTG
 CACACCCCTC CTCTCTTGA TCTCTAGAGC AAGGCGCACA CCGTCACACC ACCGTCGGAC
 841 GAGATCATCC CGTGCAGCCG TGTGGGACAC GTGTTCCGGA AGCAGCACCC CTACACGTT
 CTCTAGTAGG GCACGTCGGC ACACCCCTGTG CACAAGGCCT TCGTCGTGG GATGTGCAAG
 901 CCGGGTGGCA GTGGCACTGT CTTGCCGAA AACACCCGCC GGGCAGCAGA GGTCTGGATG
 GGCCCACCGT CACCGTGACA GAAACGGGCT TTGTGGCGG CCCGTCGTCT CCAGACCTAC
 961 GATGAATACA AAAATTCTA TTATGCAGCA GTGCCTCTG CTAGAAAGCT AGCAGAGGTC
 CTACTTATGT TTTAAAGAT AATACGTCGT CACGGAAGAC GGGCGGCCCG AGGAATACCT

Kpn

1021 AATATTCA GAAGATTGGA GCTTAGGAAG AAACTCAGCT GCAAGCCCT CAAATGGTAC
 TTATAAGTCT CGTGTACCT CGAATCCTTC TTTGAGTCGA CGTCGGAAA GTTTACCATG

Kpn

1081 CTTGAAAATG TCTATCCAGA GTTAAGGGTT CCAGACCATC AGGATATAGC TTTGGGGCC
 GAACTTTAC AGATAGGTCT CAATTCCAA GGTCTGGTAG TCCTATATCG AAAACCCCGG

FIG. 12A

15/42

T2-74G

1141 TTGCAGGAGG GAACTAACTG CCTCGACACT TTGGGACACT TTGCTGATGG TGTGGTTGGA
 AACGTCGTCC CTTGATTGAC GGAGCTGTGA AACCCGTGAA AACGACTACC ACACCAACCT

1201 GTTTATGAAT GTCACAATGC TGGGGAAAC CAGGAATGGG CCTTGACGAA GGAGAAAGTCG
 CAAATACTTA CAGTGTACG ACCCCCTTG GTCCCTTACCC GGAAGTGCTT CCTCTTCAGC

1261 GTGAAGCACA TGGATTTGTG CCTTAUTGTG GTGGACCGGG CACCGGGCTC TCTTATAAAG
 CACTTCGTGT ACCTAAACAC GGAATGACAC CACCTGGCCG GTGGCCCGAG CCCGTTGAGG

1321 CTGCAGGGCT TGGATTTGTG TGACAGCAGA CAGAAATGGG AACAGATCGA GGGCAACTCC
 GACGTCCCCGA ACCTAAACAC ACTGTGTCT GTCTTACCC TTGTCTAGCT CCCGTTGAGG

1381 AAGCTGAGGC ACGTGGGAG CAACCTGTGC CTGGACAGTC GCACGGCCAA GAGCGGGGGC
 TTGCACTCCG TGCAACCGTC GTGGACACG GACCTGTCA CGTGCCGGTT CTCGCCCCCG

1441 CTAAGCGTGG AGGTGTGTGG CCCGGCCCTT TCGCAGCAGT GGAAGTTCAC GCTCAACCTG
 GATTGCAACC TCCACACACC GGGCCGGAA ACGCTGTCA CCTTCAAGTG CGAGTTGGAC

XholEccRI

1501 CAGCAGTAGC TCGAGGAATT C
 GTCGTCACTCG AGCTCCTTAA G

FIG. 12B

16/42

| | Bam HI | T2-94 |
|------|----------------|-------|
| 1 | <u>EcoRI</u> | |
| 61 | <u>HindIII</u> | |
| 121 | | |
| 181 | | |
| 241 | | |
| 301 | | |
| 361 | | |
| 421 | | |
| 481 | <u>Clal</u> | |
| 541 | | |
| 601 | | |
| 661 | | |
| 721 | | |
| 781 | | |
| 841 | | |
| 901 | | |
| 961 | <u>KpnI</u> | |
| 1021 | | |
| 1081 | | |

FIG. 13A

17/42

T2-94

1141 TAGAATGTC ACAATGCTGG GGGAAACCAG GAATGGGCCT TGACGAAGGA GAAGTCGGTG
 ATACTTACAG TGTTACGACC CCCTTGGTC CTTAACCGGA ACTGCTTCCT CTTCAGCCAC

1201 AAGCACATGG ATTTGTGCCT TACTGTGGTG GACCGGGCAC CGGGCTCTCT TATAAAGCTG
 TTCGTGTACC TAAACACGGGA ATGACACCCAC CTGGCCCGTG GCCCGAGAGA ATATTCGAC

1261 CAGGGCTGCC GAGAAAATGA CAGCAGACAG AAATGGGAAC AGATCGAGGG CAAGTCCAG
 GTCCCGACGG CTCTTTACT TTTACCCCTTG TTTACCCCTTG TCTAGCTCCC GTTGAGTTC

1321 CTGAGGCACG TGGGCAGCAA CCTGTGCCTG GACAGTCGCA CGGCCAAGAG CGGGGGCCTA
 GACTCCGTGC ACCCGTCGTT GGACACGGAC CTGTCAGGGT GCCGGTTCTC GCCCCCCGGAT


1381 AGCGTGGAGG TGTGTGGCCC GGCCCTTCG CAGCAGTGGGA AGTCACGCT CAACCTGCAG
 TCGCACCTCC ACACACCGGG CCGGAAAGC GTCGTACACCT TCAAGTGCAG GTTGGACGTC

*Xhol**~~~~~*
EccRI
~~~~~

1441 CAGTAGCTCG AGGAATTG
 GTCATCGAGC TCCTTAAG

FIG. 13B

18/42

**FIG. 14A****FIG. 14B**

19/42


| AC# | Sample Description | Activity (U/L) | %RSD | Volume (ml) | Activity (U) |
|------------|--------------------|----------------|------|-------------|--------------|
| AC04-08477 | 040603 1b A6 | 0.10 | 22.3 | 45 | 0.00 |
| AC04-08478 | 040603 1b B7 | 0.20 | 42.4 | 45 | 0.01 |
| AC04-08479 | 040603 1b B6 | 0.15 | 10.7 | 45 | 0.01 |
| AC04-08480 | 040603 1b B5 | 0.19 | 78.4 | 45 | 0.01 |
| AC04-08481 | 040603 1b B4 | 0.06 | 0.0 | 45 | 0.00 |
| AC04-08482 | 040603 1b B3 | 0.10 | 4.9 | 45 | 0.00 |
| AC04-08483 | 040603 1b B2 | 0.39 | 76.4 | 45 | 0.02 |
| AC04-08484 | 040603 1b C6 | 0.02 | 35.1 | | 0.00 |
| AC04-08485 | 040603 1b FR | 0.04 | 2.2 | 1000 | 0.04 |
| AC04-08486 | 040603 1b cFR | 0.09 | 2.3 | 250 | 0.02 |
| AC04-08487 | 040603 1b CP | -0.01 | 8.4 | 750 | 0.00 |
| AC04-08488 | 040603 1b DP | -0.02 | 9.0 | 1000 | -0.02 |
| AC04-08489 | 040603 1b QL | 0.03 | 0.6 | 245 | 0.01 |
| AC04-08490 | 040603 1b QFT | -0.04 | 8.3 | 245 | -0.01 |
| AC04-08491 | 040603 1b QW | -0.02 | 19.8 | 48 | 0.00 |

FIG. 14C

20/42

Refold 1b - pH 6.5

— 040603GaiNaCT2pH55001:1 UV
 040603GaiNaCT2pH55001:1 Logbook
 040603GaiNaCT2pH55001:1 Q300
 040603GaiNaCT2pH55001:1 Q300C
 040603GaiNaCT2pH55001:1 Logbook


**FIG. 15B**

21/42

| AC# | Sample Description | Activity (U/L) | %RSD | Volume (ml) | Activity (U) |
|---------------------------------|--------------------|----------------|------|-------------|--------------|
| Negative Control (No Enzyme) | | 0.00 | 14.6 | | |
| AC04-08462 | 040603 1a FR | 1.08 | 24.0 | 1000 | 1.08 |
| AC04-08463 | 040603 1a cFR | 1.03 | 4.4 | 250 | 0.26 |
| AC04-08464 | 040603 1a CP | 0.13 | 17.8 | 750 | 0.09 |
| AC04-08465 | 040603 1a DP | 0.08 | 5.7 | 1000 | 0.08 |
| AC04-08466 | 040603 1a QFT | 0.07 | 34.0 | 270 | 0.02 |
| AC04-08467 | 040603 1a QW | 0.05 | 24.4 | 48 | 0.00 |
| AC04-08468 | 040603 1a B12-10 | 1.60 | 9.0 | 45 | 0.07 |
| AC04-08469 | 040603 1a B9-7 | 2.21 | 11.7 | 45 | 0.10 |
| AC04-08470 | 040603 1a B6-4 | 0.88 | 17.0 | 45 | 0.04 |
| AC04-08471 | 040603 1a B3-1 | 0.43 | 4.4 | 45 | 0.02 |
| AC04-08472 | 040603 1a C1-3 | 0.36 | 22.2 | 45 | 0.02 |
| AC04-08473 | 040603 1a C4-6 | 0.32 | 4.9 | 45 | 0.01 |
| AC04-08474 | 040603 1a C7-9 | 0.22 | 1.3 | 45 | 0.01 |
| AC04-08475 | 040603 1a C10-12 | 0.27 | 71.8 | 45 | 0.01 |
| AC04-08476 | 040603 1a X1 | 0.04 | 6.3 | 29 | 0.00 |

FIG. 15C

22/42




23/42

| AC# | Sample Description | Activity (U/L) | % RSD | Volume (mL) | Activity (U) | A280 | Conc (mg/mL) | Mass (mg) | Specif. Act. (U/mg) |
|------------|--------------------|----------------|-------|-------------|--------------|-------|--------------|-----------|---------------------|
| AC04-08492 | 040603 2a A6 | 3.23 | 9.6 | 45 | 0.15 | 0.027 | 0.0179 | 0.806 | 0.186 |
| AC04-08493 | 040603 2a B7 | 4.14 | 0.2 | 45 | 0.19 | 0.064 | 0.0424 | 1.908 | 0.099 |
| AC04-08494 | 040603 2a B6 | 1.79 | 3.7 | 45 | 0.08 | 0.096 | 0.0636 | 2.862 | 0.028 |
| AC04-08495 | 040603 2a B5 | 0.52 | 15.0 | 45 | 0.02 | 0.223 | 0.148 | 33.3 | |
| AC04-08496 | 040603 2a B4 | 0.12 | 8.1 | 45 | 0.01 | | | | |
| AC04-08497 | 040603 2a B3 | 0.16 | 18.6 | 45 | 0.01 | | | | |
| AC04-08498 | 040603 2a B2 | 0.03 | 18.4 | 45 | 0.00 | | | | |
| AC04-08499 | 040603 2a B1 | 0.00 | 1.4 | 45 | 0.00 | | | | |
| AC04-08500 | 040603 2a C6 | 0.07 | 24.8 | 45 | 0.00 | | | | |
| AC04-08501 | 040603 2a CP | 0.30 | 73.3 | 750 | 0.22 | | | | |
| AC04-08502 | 040603 2a DP | -0.05 | 1.26 | 1000 | -0.05 | | | | |
| AC04-08503 | 040603 2a QL | 1.24 | 5.0 | 265 | 0.33 | 0.651 | 0.431 | 114.2 | |
| AC04-08504 | 040603 2a QFT1 | -0.24 | 4.3 | 130 | -0.03 | 0.000 | - | - | |
| AC04-08505 | 040603 2a QFT2 | -0.22 | 8.5 | 90 | -0.02 | 0.284 | 0.188 | 16.92 | |
| AC04-08506 | 040603 2a QW | -0.21 | 2.3 | 48 | -0.01 | 0.068 | 0.045 | 2.16 | |

FIG. 16C

24/42


Refold 2b - pH 8.5**FIG. 17A****FIG. 17B**

25/42

| AC# | Sample Description | Activity (U/L) | %RSD | Volume (mL) | Activity (U) | A280 | Conc (mg/mL) | Mass (mg) | Specif. Act. (U/mg) |
|------------|--------------------|----------------|-------|-------------|--------------|-------|--------------|-----------|---------------------|
| AC04-08507 | 040603 2b A6 | 2.40 | 14.76 | 45 | 0.11 | 0.029 | 0.0192 | 0.864 | 0.127 |
| AC04-08508 | 040603 2b B7 | 3.77 | 11.14 | 45 | 0.17 | 0.058 | 0.0384 | 1.728 | 0.098 |
| AC04-08509 | 040603 2b B6 | 1.17 | 3.84 | 45 | 0.05 | | | | |
| AC04-08510 | 040603 2b B5 | 0.10 | 2.06 | 45 | 0.00 | | | | |
| AC04-08511 | 040603 2b B4 | -0.13 | 3.21 | 45 | -0.01 | | | | |
| AC04-08512 | 040603 2b B3 | -0.10 | 33.30 | 45 | 0.00 | | | | |
| AC04-08513 | 040603 2b B2 | -0.18 | 30.69 | 45 | -0.01 | | | | |
| AC04-08514 | 040603 2b B1 | -0.20 | 19.19 | 45 | -0.01 | | | | |
| AC04-08515 | 040603 2b C5 | -0.24 | 7.25 | 45 | -0.01 | | | | |
| AC04-08516 | 040603 2b CP | -0.09 | 1.89 | 750 | -0.07 | | | | |
| AC04-08517 | 040603 2b DP | 0.01 | 3.26 | 1000 | 0.01 | | | | |
| AC04-08518 | 040603 2b QL | 1.43 | 4.13 | 270 | 0.39 | 0.497 | | | |
| AC04-08519 | 040603 2b QFT1 | -0.23 | 46.04 | 133 | -0.03 | | | | |
| AC04-08520 | 040603 2b QFT2 | -0.03 | 28.76 | 78 | 0.00 | | | | |
| AC04-08521 | 040603 2b QW | -0.01 | 9.12 | 48 | 0.00 | | | | |

FIG. 17C

26/42



Refold 3**FIG. 18A****FIG. 18B**

27/42

| AC# | Sample Description | Activity (U/L) | % RSD | Volume (ml) | Activity (U) |
|------------|--------------------|-------------------|-------|-------------|--------------|
| AC04-08522 | 040603 3 A6 | 0.14 | 14.4 | 45 | 0.01 |
| AC04-08523 | 040603 3 B7 | 0.13 | 0.0 | 45 | 0.01 |
| AC04-08524 | 040603 3 B6 | 0.01 | 1.9 | 45 | 0.00 |
| AC04-08525 | 040603 3 B5 | 0.02 | 29.8 | 45 | 0.00 |
| AC04-08526 | 040603 3 B4 | -0.05 | 0.0 | 45 | 0.00 |
| AC04-08527 | 040603 3 B3 | -0.03 | 7.4 | 45 | 0.00 |
| AC04-08528 | 040603 3 B2 | -0.01 | 2.2 | 45 | 0.00 |
| AC04-08529 | 040603 3 B1 | -0.02 | 33.7 | 45 | 0.00 |
| AC04-08530 | 040603 3 C1 | -0.03 | 21.6 | 45 | 0.00 |
| AC04-08531 | 040603 3 CP | -0.02 | 7.0 | 750 | -0.02 |
| AC04-08532 | 040603 3 DP | -0.05 | 8.3 | 1000 | -0.05 |
| AC04-08533 | 040603 3 QL | 0.05 | 19.7 | 250 | 0.01 |
| AC04-08534 | 040603 3 QFT1 | -0.07 | 3.1 | 139 | -0.01 |
| AC04-08535 | 040603 3 QFT2 | -0.07 | 18.4 | 56 | 0.00 |
| AC04-08536 | 040603 3 QW | 0.04 | 47.1 | 48 | 0.00 |

FIG. 18C

28/42

**FIG. 19A****FIG. 19B**

29/42

| | Volume (mL) | Activity (U/L) | A280 | A280/ 1.51 (mg/ mL) | Activity (U) | Mass (mg) | Specific Activity (U/mg) |
|--------|----------------|-------------------|-------|------------------------|-----------------|--------------|--------------------------------|
| Load | 576 | 2.73 | 0.581 | 0.385 | 1.57 | 222 | 0.007 |
| FT | 576 | 0.02 | 0.155 | 0.103 | 0.01 | 59 | |
| Wash | 48 | 0.00 | 0.000 | | 0 | 0 | |
| A5 | 45 | | 0.016 | 0.010 | 0 | 0.5 | |
| A6 | 45 | 7.74 | 0.162 | 0.107 | 0.35 | 4.8 | 0.073 |
| B7 | 45 | 10.90* | 0.218 | 0.144 | 0.49 | 6.5 | 0.075 |
| B6 | 45 | 1.15* | 0.249 | 0.165 | 0.05 | 7.4 | 0.007 |
| B5 -B1 | 225 | 0.00 | 0.482 | 0.319 | 0 | 108 | |

* Adjusted by multiplication with 2.5 necessary due to ³H-label change

FIG. 19C

30/42




FIG. 20A






FIG. 20B

31/42

| | Volume (mL) | Activity (U/L) | A280 | A280/ 1.51 (mg/mL) | Activity (mU) | Mass (mg) | Specific Activity (U/mg) |
|-------|----------------|-------------------|--------|-----------------------|------------------|--------------|--------------------------------|
| Load | 40 | 1.23 | 0.550 | 0.364 | 49.2 | 14.6 | 0.003 |
| FT | 40 | -0.02 | -0.017 | | | | |
| Wash | 7.8 | -0.01 | -0.008 | | | | |
| A3 | 5 | 0.41 | 0.000 | | | | |
| A4 | 5 | 1.82 | 0.048 | 0.032 | 9.1 | 0.16 | 0.057 |
| A5 | 5 | 2.14 | 0.100 | 0.066 | 10.7 | 0.33 | 0.032 |
| A6-A9 | 20 | 1.12 | 0.422 | 0.279 | 22.4 | 5.58 | 0.004 |

FIG. 20C

32/42

Q XL- 50mM NaCl**FIG. 21A****FIG. 21B**

33/42

| | Volume (mL) | Activity (U/L) | A280 | A280/ 1.51 (mg/mL) | Activity (mU) | Mass (mg) | Specific Activity (U/mg) |
|-------|----------------|-------------------|--------|-----------------------|------------------|--------------|--------------------------------|
| Load | 40 | 1.27 | 0.550 | 0.364 | 50.8 | 14.6 | 0.0035 |
| FT | 40 | 0.41 | 0.001 | 0.007 | 16.4 | 0.03 | 0.55 |
| Wash | 7.8 | 0.07 | -0.007 | | | | |
| A2 | 5 | 0.40 | -0.018 | | | | |
| A3 | 5 | 0.50 | 0.004 | 0.003 | 2.5 | 0.02 | 0.125 |
| A4 | 5 | 0.87 | 0.049 | 0.032 | 4.4 | 0.16 | 0.0275 |
| A5 | 5 | | 0.136 | 0.090 | | 0.45 | |
| A6-A9 | 20 | 0.29 | 0.418 | 0.277 | 5.8 | 5.54 | 0.001 |

FIG. 21C

34/42




FIG. 22A




FIG. 22B

35/42

| | Volume (mL) | Activity (U/L) | A280 | A280/ 1.51 (mg/mL) | Activity (mU) | Mass (mg) | Specific Activity (U/mg) |
|--------|----------------|-------------------|-------|-----------------------|------------------|--------------|--------------------------------|
| Load | 40 | 1.25 | 0.561 | 0.372 | 50.0 | 14.9 | 0.0034 |
| FT | 40 | 0.71 | 0.019 | 0.012 | 28.4 | 0.48 | 0.059 |
| Wash | 7.8 | 0.48 | 0.026 | 0.017 | 3.7 | 0.13 | 0.028 |
| A3 | 5 | 0.13 | 0.011 | 0.007 | 0.6 | 0.04 | 0.015 |
| A4 | 5 | 0.11 | 0.062 | 0.041 | 0.6 | 0.21 | 0.003 |
| A5 -A9 | 25 | 0.04 | 0.311 | 0.206 | 1.0 | 5.15 | 0.0002 |

FIG. 22C

36/42




FIG. 23A





FIG. 23B

37/42


| | Volume (mL) | Activity (U/L) | A280 | A280/ 1.51 (mg/ mL) | Activity (mU) | Mass (mg) | Specific Activity (U/mg) |
|------|----------------|-------------------|-------|------------------------|------------------|--------------|--------------------------------|
| Load | 40 | 1.20 | 0.579 | 0.383 | 48.0 | 15.3 | 0.0031 |
| FT | 40 | 0.81 | 0.151 | 0.100 | 32.4 | 4.00 | 0.0081 |
| Wash | 7.8 | 0.01 | 0.128 | 0.085 | 0 | 0.66 | |
| A3 | 5 | 1.65 | 0.158 | 0.105 | 8.25 | 0.53 | 0.0156 |
| A4 | 5 | 3.76 | 0.273 | 0.181 | 18.8 | 0.91 | 0.0206 |
| A5/6 | 10 | 0.01 | 0.093 | 0.062 | 0.1 | 0.62 | 0.0002 |

FIG. 23C

38/42

**FIG. 24A**

| | Volume (mL) | Activity (U/L) | Activity (U) |
|---------|-------------|----------------|--------------|
| Load | 71 | 7.2 | 0.511 |
| FT | 81 | 0.0 | 0 |
| Wash | 6.75 | 0.0 | 0 |
| A8/9 | 6 | 1.0 | 0.006 |
| A10/11 | 6 | 18.3 | 0.110 |
| A12/B12 | 6 | 30.5 | 0.183 |
| B11/10 | 6 | 11.2 | 0.067 |
| B9 | 3 | 0.5 | 0.002 |
| B3 | 3 | 0.1 | 0 |

FIG. 24C**FIG. 24B**

39/42

GalNAcT2 activities of refolded MBP-GalNAcT2(D51)




FIG. 25

40/42

pH effect on the MBP-GalNAcT2(Δ 51) specific activities




FIG. 26

41/42




FIG. 27

42/42

